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Summary
Huntington’s disease (HD) is an autosomal dominant neurodegeneration, 
characterised by a movement disorder, complex cognitive disturbances and 
psychiatric problems. The disease is caused by the expansion of a CAG repeat in 
the HD gene on chromosome 4, giving rise to an expanded glutamine tract in the 
encoded protein, huntingtin.
Microarray studies have already found substantial changes in gene 
expression in HD individuals and in transgenic mouse models of HD. However, it 
was important to determine whether a similar pattern of differential expression 
could be found at the protein level, in order to assess the significance of the 
observed gene expression changes to the disease process. For this, the Surface- 
Enhanced Laser Desorption Ionization - Time Of Flight (SELDI-TOF) system was 
used to analyse brain protein extracts from genetic mouse models of HD, both 
from whole brain and microdissected brain samples. Several brain regions and 
different timepoints of transgenic R6/1 and knock-in Hdh092 and Hdh0150 mouse 
models were analysed. To analyse a wider range of the HD mouse brain 
proteome, Hdh0150 mouse caudate-putamen was analysed using the 2-D 
fluorescence Difference Gel Electrophoresis (DIGE) system.
Differentially expressed proteins have been detected in brain samples from 
HD mice, and sixteen of these have been identified using Tandem Mass 
Spectrometry. Western blot analysis confirmed results for some of the proteins.
The majority of the proteins identified as changed in expression had earlier 
been reported as changed in gene expression in human HD and mouse HD brain. 
In general, there is a high degree of agreement between the protein and the gene 
expression data. Some of the proteins identified in this study have been 
implicated in HD pathogenesis, and many are part of a pathogenic mechanism 
recognised to contribute to HD, such as mitochondrial dysfunction and deficient 
energy metabolism, oxidative stress and aberrant calcium signalling.
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Chapter 1. Introduction
1.1 Historical background of Huntington’s disease
A disease similar to Huntington’s disease has been clinically described for 
several centuries. George Huntington was, however, the first person to recognise 
and publicly record the salient features of the disease in 1872. George Huntington 
recognised the three foremost features of the disease: its hereditary nature, the 
late onset in life and the psychological consequences (Huntington 1872). The 
condition he described became known as Huntington’s disease (HD). The 
Mendelian dominant inheritance of HD was recognised by 1908, but it took 
another 85 years to identify the genetic cause for the disease (Harper 2002a).
1.2 Epidemiology of Huntington’s disease
The incidence of HD varies between countries and between ethnic groups. 
The overall prevalence in the Caucasian population worldwide is estimated at 
about 4-10 per 100,000. Prevalence in Japan, and probably in most of the Asian 
populations, is an order of magnitude lower that in the Caucasian population. The 
same trend is observed in sub-Saharan Africa. One of the reasons for this might 
be the higher frequency of alleles in the upper normal range (section 1.5.3), which 
could be subject to expansion between generations, in the Caucasian compared 
with the Asian and African populations (Harper 2002b). However, these estimates 
were made before HD genetic testing became available. More recent studies 
documented an increased prevalence over earlier estimates (Siesling et al. 2000;
13
Almqvist et al. 2001; Ramos-Arroyo et al. 2005). On the other hand, a study of the 
HD mortality rate in Austria failed to observe any difference after diagnostic 
testing became available, although this might have been on account of the low 
number of requests for predictive testing (Ekestem & Lebhart 2005).
1.3 Clinical features of Huntington’s disease
HD is characterised by a variety of features, not all of which are present in 
every patient and particularly not to the same degree. The motor symptoms are 
certainly the most distinctive feature of the disease. The majority of HD sufferers 
display chorea of the body and face, although the intensity of it can vary widely 
between patients. Chorea tends to feature mainly during the first phase of the 
illness, often replaced by a more disabling motor disorder later on. Bradykinesia, 
rigidity and dystonia gradually take over from the involuntary motor dysfunction, 
and often dominate the later stages of the disease. The majority of patients also 
suffer from a variety of other motor abnormalities, such as oculomotor 
disturbances, impairment of voluntary movements, hyperactive reflexes and gait 
disturbances. Most patients have a degree of speech abnormality as well (Kremer 
2002).
Although the motor abnormalities are the hallmark of the disorder, the 
cognitive and psychiatric symptoms are often far more intrusive in the daily lives 
of patients. Cognitive changes can frequently be detected before any of the motor 
symptoms become clear. The cognitive decline is progressive over the course of 
the disease, although the rate of decline varies widely between patients. The 
psychiatric aspects of HD include depression, anxiety, irritability, social
14
withdrawal, apathy and various sexual disorders. Again, the degree to which 
patients suffer from these is variable. In some cases, acute irritability can bring 
about severe aggression, and in others, depression and anxiety can become so 
severe that it leads to acts of suicide (Craufurd & Snowden 2002).
The age of onset of HD can vary widely. The youngest person described 
with HD was 2 years old, while some patients only develop the first symptoms in 
their eighties. However, the majority of HD patients are between 40 and 50 years 
old when the first signs are noticed. A number of patients develop the disease 
before the age of 20 and are classified as suffering from juvenile HD, as opposed 
to adult onset HD. Although the symptoms in juvenile HD are often more severe, 
disease progression and time from onset until death do not differ much. Death 
generally follows 15 to 20 years after onset and can be brought about by a wide 
range of associated causes, the principal one being pneumonia (Kremer 2002).
1.4 The neuropathology of Huntington’s disease
Final stage human HD brain shows a 10-20% weight loss compared with 
controls (Vonsattel et al. 1985). The most characteristic neuropathological 
element of HD is the gradual atrophy of the caudate nucleus and the putamen in 
the striatum. The striatum is part of the basal ganglia, a brain structure present in 
both hemispheres, that is associated with motor control, cognition, emotions, and 
learning. The two areas in the striatum are the dorsal striatum, comprising the 
caudate nucleus and the putamen, and the ventral striatum, which corresponds to 
the olfactory tubercle and the nucleus accumbens (Figure 1.1). The principal 
functions of the striatum involve planning and modulation of movement and a
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variety of cognitive processes. The striatal neuronal population consists primarily 
of medium spiny neurons (MSN) and a relatively small number of different aspiny 
neurons. The striatal atrophy in HD is for the greater part caused by the 
degeneration of the MSN, while the aspiny interneurons are largely unchanged.
Vonsattel et al. (1985) developed a classification system to assess 
pathological severity in the human brain, based on the pattern of striatal 
degeneration. The system consists of five grades, designated in ascending order 
of severity, ranging from no discernible neuropathological abnormalities in grade 0 
to very severe atrophy in grade 4. Further assessment of the severity of the 
disease in HD patients correlated the grades in Vonsattel’s classification closely 
with the degree of physical disability (Vonsattel et al. 1985; Myers et al. 1988). 
Structural imaging and functional studies established significant correlations 
between the changing striatal morphology described in this classification system 
and the development of cognitive deficits in HD (Montoya et al. 2006).
The cerebral atrophy in HD is not confined to the striatum, however. As the 
disease progresses, the pathological process involves other areas in the brain. In 
the basal ganglia other than the striatum, various degrees of neurodegeneration 
and neuronal loss have been reported in the globus pallidus, the ansae 
penducularis, the subthalamus and the substantia nigra (Gutekunst et al. 2002). 
Generalised atrophy was also described in the cerebral cortex in the end stages 
of the disease, with significant reductions seen in the prefrontal cortex (Sotrel et 
al. 1991), the angular gyrus (Macdonald et al. 1997; Ruocco et al. 2008), the post­
central gyrus (Jech et al. 2007) and the cingulate cortex (Ruocco et al. 2008). The 
hippocampus displayed a substantial amount of atrophy, although it was 
suggested that the changes might be region specific (Spargo et al. 1993; Jech et
16
al. 2007). The cerebellum is generally considered to be an area with minimal 
atrophy, and only a few studies reported some change (Jeste et al. 1984; Jech et 
al. 2007; Ruocco et al. 2008). Loss of neurones has also been described in the 
hypothalamus (Kremer et al. 1991; Kassubek et al. 2004a) and the thalamus 
(Heinsen et al. 1996; Heinsen et al. 1999). Little is known about the pathology of 
the brainstem, although some change has been noted in the posterior brainstem 
during MRI (Jech et al. 2007). For a long time, the research into HD 
neuropathology has for the greater part concentrated on the basal ganglia, and 
very few studies have looked at the rest of the brain. The majority of the brain 
regions mentioned in this section are indicated on Figure 1.1.
The number of CAG repeats has been positively correlated with the degree 
of selected but not global cerebral atrophy (Vonsattel & DiFiglia 1998; Kassubek 
et al. 2004b; Jech et al. 2007). A positive correlation was also found between the 
number of repeats and progressive atrophy over time as well as the rate of 
progression (Ruocco et al. 2008).
Neuronal atrophy occurs not only at the level of complete neuronal 
structures. Various morphological alterations have been seen in dendritic and 
axonal structures some time before the cell dies (Gutekunst et al. 2002).
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Figure 1.1 Schematic drawing of a coronal section and a parasagittal section of the 
complete human brain. Regions known to be affected by HD pathology are specified.
1.5 The genetics of Huntington’s disease
1.5.1 The HD gene
The genetic cause of HD has been known since 1993, when the HD gene 
was located in a region of 4p16.3 (Huntington’s Disease Collaborative Research 
Group 1993) to which it had been previously mapped by linkage analysis (Gusella 
et al. 1983). The gene was cloned and designated IT15 (Huntington’s Disease 
Collaborative Research Group 1993). It is translated into a large 348 kDa protein 
named huntingtin, the function of which is still unclear today. The HD mutation 
involves an unstable DNA segment with a polymorphic variation of a CAG 
trinucleotide repeat near the 5’ end of the gene. While the HD gene in the healthy 
population is polymorphic for the CAG repeat region too, the number of repeats is 
generally below 30, whereas an HD individual has 36 or more repeats. Initially the 
range between 30 and 40 repeats was considered the intermediate range with an 
uncertain outcome (Huntington’s Disease Collaborative Research Group 1993). 
Subsequent studies narrowed the intermediate range down to 36-41 repeats by
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ascertaining that there were no HD individuals with less than 36 CAG repeats 
(Rubinsztein etal. 1996; Brinkman et al. 1997).
The HD locus spans 180 kb of genomic DNA and consists of 67 exons, 
ranging in size from 48 bp to 341 bp. The gene is ubiquitously expressed, 
although not in equal abundance in different tissues (Strong et al. 1993; Ambrose 
et al. 1994). Differential polyadenylation results in a 13.7 kb transcript, 
predominantly expressed in adult and foetal brain, and a smaller 10.3 kb 
transcript, which is the predominant mRNA species in other tissues (Lin et al. 
1993). Huntingtin mRNA is ubiquitously expressed in all human tissues with 
highest levels found in the brain, where the expression dominates in neurons over 
glial cells (Li etal. 1993; Strong etal. 1993).
HD is a Mendelian autosomal dominant disorder (Harper & Jones 2002), 
which was thought to show true dominance (Durr et al. 1999). However, this idea 
has been questioned, supported by evidence from in vitro investigation (Narain et 
al. 1999) and genetic mouse models of HD (described later in this chapter).
1.5.2 CAG repeat size and age of onset
Being able to measure the CAG repeats in all individuals with HD, or at risk 
of it, made it possible for studies to define the relationship between CAG size and 
various disease characteristics. The most obvious aspect of this relationship was 
the inverse correlation between age of onset and CAG repeat size (Andrew et al. 
1993; Duyao et al. 1993). It was suggested that CAG size alone could account for 
up to 70% of the variance in age of onset. A study of large cohorts even allowed 
for the determination of a probability of onset at different ages for a given CAG 
size. It became clear that the difference of a single CAG repeat could have a
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significant effect on the expected age of onset for a carrier (Brandt et al. 1996; 
Brinkman et al. 1997; Rosenblatt et al. 2001). Although an association of CAG 
repeat length with clinical progression and age of death was first postulated, this 
correlation disappeared once age of onset had been controlled for (Andrew et al. 
1993; Brandt et al. 1996). A recent longitudinal MRI study of a cohort of patients 
over a period of one year indicated, however, that patients with higher numbers of 
repeats show faster developing and more widespread atrophy (Ruocco et al. 
2008).
1.5.3 Germline CAG instability
It was soon discovered that the HD repeat was unstable during meiosis, 
changing in length, with generally either small increases or small decreases in 
CAG number. Although CAG expansion is rare on normal chromosomes, it was 
discovered that approximately 70% of meiosis on HD chromosomes introduced a 
change in CAG number, 73% of these involving expansions. The largest 
increases appeared to occur in cases where the mutation was paternally 
transmitted (Duyao etal. 1993; Kremer etal. 1995), and occasionally large jumps 
in size occur. It was further noted that juvenile HD was inherited primarily from the 
father, and it was determined that the sex of the transmitting parent was the key 
factor in expansion of the CAG repeat (Telenius et al. 1993). Germline instability 
was also detected in knock-in HD mouse models, with a direct correlation 
between the number of repeats and the magnitude of the instability (Mangiarini et 
al. 1996; Shelboume etal. 1999).
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1.5.4 Somatic CAG instability
In conjunction with germline instability, several studies have also shown 
somatic instability of the CAG repeat, both in humans and in HD mouse models 
(Aronin et al. 1995, Manley et al. 1999; Kennedy & Shelbourne 2000; Kennedy et 
al. 2003; Gonitel et al. 2008). The somatic heterogeneity appeared to be more 
pronounced in patients with juvenile HD than in late onset cases, denoting a 
correlation between progenitor CAG size and level of instability. Furthermore, 
CAG instability was more evident in the cortex and striatum and least of all in the 
cerebellum (Aronin etal. 1995). Subsequent research confirmed these early 
findings, showing higher somatic instability in striatal tissue in HD mouse models. 
A hypothesis of CAG somatic expansion steered by the mismatch repair system 
has been put forward (Manley et al. 1999), particularly in the presence of the 
mismatch repair protein MSH3 (Gonitel et al. 2008). Increasing CAG expansion 
was also correlated with advancing age in HD mouse models (Kennedy & 
Shelbourne 2000; Kennedy et al. 2003).
1.5.5 Genetic modifiers
Although the variation in age of onset of HD is determined partly by the 
polymorphism in the CAG repeat of the HD gene (section 1.3.2), it cannot all be 
attributed to the HD locus. Studies in various HD populations suggested that the 
CAG repeat length determines up to 70% of the variance in age of onset (Ranen 
et al. 1995; Brinkman et al. 1997; Rosenblatt et al. 2001). Additional genetic and 
environmental factors which may modify the variance in onset have been 
suggested. The age of onset and the sex of the affected parent are thought to
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contribute significantly to the variance in age of onset of the offspring (Ranen et 
al. 1995; Rosenblatt et al. 2001). Other studies also suggested an effect of the 
normal HD allele on age of onset and disease progression (Snell et al. 1993; 
Kehoe et al. 1999; Leavitt et al. 2001).
Polymorphisms in various huntingtin interacting or associated genes have 
been found, and were put forward as modifiers of the course of the disease. The 
presence of the APOE e2s3 allele (Kehoe et al. 1999), a polymorphism in the 
ubiquitin carboxy-terminal hydrolase L1 gene (Naze et al. 2002; Metzger et al. 
2006), variations in the GluR6 kainate receptor gene (Rubinsztein et al. 1997; 
Chattopadhyay et al. 2003), a polymorphism in the transcriptional coactivator 
CA150 (TCERG1) (Holbert et al. 2001; Chattopadhyay et al. 2003), 
polymorphisms in the gene coding for the homocysteine metabolising enzyme 
methyltetrahydrofolate reductase (Brune et al. 2004), variations in GRIN2A and 
GRIN2B, the genes coding for the NR2A and NR2B glutamate receptor subunits 
(Aming et al. 2005) and the M441 polymorphism in the human huntingtin- 
associated protein-1 (HAP1) (Metzger et al. 2008), have all been linked to the 
variation in age of onset in HD. However, only the GRIN2A and the TCERG1 
results were replicated and may show true association with residual age of onset 
in HD (Andresen et al. 2007).
Recently, a high-throughput screen identified a large number of huntingtin 
interacting proteins, many of them not recognised before. A number of these were 
tested in a Drosophila model for HD and the larger proportion was found either to 
enhance or to suppress HD neurodegeneration in the Drosophila eye (Kaltenbach 
et al. 2007). This demonstrates again that the development of pathology in HD is
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a much more complex process than was first anticipated, and there is much that 
still needs to be learned.
1.6 Huntingtin
1.6.1 The structure of huntingtin
The HD gene encodes a 348 kDa protein called huntingtin. When the HD 
gene was cloned, there were no known protein homologues in the databases 
(Huntington’s Disease Collaborative Research Group 1993), and this remains 
largely true today.
Some sequence motifs have been identified in huntingtin, indicated on the 
schematic in Figure 1.2. The polyglutamine repeat starts at amino acid 18 
(Huntington’s Disease Collaborative Research Group 1993) and it has been 
suggested that this construct binds to other polyglutamine stretches to form a 
polar zipper structure, which might cause the protein to bind with other proteins 
(Perutz et al. 1994; Li & Li 2004), as well as accumulate into huntingtin 
aggregates (Wanker & Droge 2002). The polyglutamine region is followed by a 
polyproline stretch, which might be involved in the solubility of the protein (Steffan 
et al. 2004), and which is a common motif in transcription factors. Huntingtin also 
contains a considerable number of tandem arrays of HEAT repeats. Several other 
known proteins containing HEAT repeats appear to be regulatory proteins 
involved in cytoplasmic transport (Andrade & Bork 1995). A recent model even 
proposed that the entire huntingtin protein is made up of numerous HEAT repeats 
which interact to form an elongated superhelix (Li et al. 2006). A highly conserved 
nuclear export signal is located at the carboxy-terminal third of the huntingtin
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protein, suggesting a possible role for huntingtin in exporting proteins from the 
nucleus (Xia et al. 2003). A number of caspase (Goldberg et al. 1996; Wellington 
et al. 1998; Wellington et al. 2000) and calpain (Gafni & Ellerby 2002; Gafni et al. 
2004) cleavage sites, where cleavage generates huntingtin fragments, have been 
located. In addition, huntingtin is also subject to caspase-independent proteolytic 
cleavage (Ratovitski et al. 2007), and to post-translational modifications such as 
SUMOylation (Steffan et al. 2004), ubiquitination (Kalchman et al. 1996; Steffan et 
al. 2004) and phosphorylation (Humbert et al. 2002; Luo et al. 2005; Schilling et 
al. 2006).
region with caspase & calpain cleavage sites
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Figure 1.2 Schematic of the huntingtin amino acid sequence.
1.6.2 The localisation of huntingtin
In parallel with its mRNA, huntingtin is ubiquitously expressed, in both brain 
and peripheral tissue. Although higher levels of huntingtin are present in the brain 
compared with other tissues, the widespread expression of the protein throughout 
the body raises the question of why the disease results in selective neuronal loss. 
(Hoogeveen et al. 1993; Sharp et al. 1995; Wood et al. 1996).
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The first studies of the cellular localisation of huntingtin detected the protein 
only in the cytoplasm (DiFiglia etal. 1995; Gutekunst etal. 1995). Subsequent 
reports placed huntingtin in the nucleus, but suggested that the distribution of 
huntingtin between the cytoplasm and the nucleus was cell type specific. While 
huntingtin was contained within the cytoplasm in most somatic cells, it was 
detected in both the cytoplasm and the nucleus in neurons, spermatocytes and 
lymphoblastoid cells (Hoogeveen etal. 1993; De Rooij et al. 1996; Hilditch- 
Maguire et al. 2000). Further studies found only a low level of full-length huntingtin 
but a much higher level of huntingtin N-terminal and C-terminal fragments in the 
nucleus (Tao & Tartakoff 2001; Kegel et al. 2002; Cornett et al. 2005).
In the cytoplasm, huntingtin was found in close proximity to mitochondria, 
endoplasmic reticulum, Golgi and recycling endosomes (Hilditch-Maguire et al. 
2000; Tao & Tartakoff 2001). Within neurons, huntingtin was placed in neuronal 
cell bodies, dendrites, axons and pre- and post-synaptic regions, where it 
appeared to be highly expressed (DiFiglia et al. 1995; Gutekunst et al. 1995;
Sharp et al. 1995). Small N-terminal huntingtin fragments were found to interact 
with the nuclear pore protein translocated promoter region (Tpr), involved in 
nuclear export. Expansion of the polyglutamine region or increased length of the 
entire huntingtin protein reduced the level of binding to Tpr (Cornett et al. 2005).
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1.6.3 The proposed functions of huntingtin
Huntingtin during development
Knock-out mice, nullizygous for Hdh, died before gastrulation and the 
development of the nervous system, demonstrating that huntingtin is essential for 
embryonic and probably for neuronal development (Duyao et al. 1995; Nasir et al. 
1995; Zeitlin et al. 1995). However, these studies failed to provide any further 
insight into the function of the protein. Subsequent research in mice showed that 
decreased levels of huntingtin in the embryonic brain lead to reduced 
neurogenesis and profound cortical and striatal abnormalities, implying that 
huntingtin is involved in the development of the central nervous system (White et 
al. 1997). A similar outcome was obtained with embryonic HD stem cells, which 
showed that the expression of huntingtin follows the pattern of neurogenesis, 
although it did not seem to be required for neuronal differentiation (Metzler et al. 
1999; Metzler et al. 2000). In chimeric mice, many brain regions did not appear to 
require huntingtin for normal development, although it did seem to have a region- 
specific role in neuronal survival in the cortex and the basal ganglia (Reiner et al. 
2001; Reiner et al. 2003).
There is some indication that huntingtin might be essential in the postnatal 
brain too, as the site specific elimination of huntingtin in large proportions of the 
brain leads to neuronal degeneration and certain aspects of disease, while it 
affects spermatogenesis when being knocked out in the testis (Dragatsis et al. 
2000).
26
The neuroprotective role of huntingtin
A number of studies have indicated the neuroprotective effect of wild-type 
huntingtin in brain cells that are exposed to various apoptotic stimuli. Some 
attribute this to the anti-apoptotic property of huntingtin, which may be able to 
inhibit caspase-3 (Rigamonti et al. 2000) and caspase-9 (Rigamonti etal. 2001) 
activation. In the case of caspase-3, this may be achieved through the direct 
interaction with huntingtin (Zhang et al. 2006).
Huntingtin is also known to interact with numerous proteins, some of which 
are involved in pathways leading to neuroprotection or neuronal death. One of 
these is brain-derived neurotrophic factor (BDNF), a neurotrophin particularly 
important for the survival of striatal neurons. It was demonstrated that huntingtin 
facilitating BDNF transport, and in this way supports neuronal survival (Gauthier et 
al. 2004). It was also suggested that huntingtin regulates the BDNF promoter by 
inhibiting the neuron restrictive silencer element (NRSE), and in this way 
enhances transcription of BDNF (Zuccato et al. 2001; Zuccato et al. 2003).
Huntingtin also exerts its anti-apoptotic influence by binding huntingtin 
interacting protein (HIP1) (Wanker etal. 1997). HIP1 is thought to be involved in 
apoptosis through the caspase-1 and caspase-3 pathway, and high levels of the 
unbound form of this protein in the cell lead to increased neuronal death 
(Majumder et al. 2006). Huntingtin was also recognised as a substrate for Akt, a 
pro-survival serine-threonine kinase that exerts its protective function by 
phosphorylating several substrates (Colin et al. 2005).
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The role of huntingtin in intracellular transport
The association of huntingtin with BDNF, as discussed earlier, is one 
example of huntingtin as promoter of intracellular transport. Huntingtin acts as a 
processivity factor that facilitates the transport of BDNF-containing vesicles along 
the microtubules (Gauthier et al. 2004). Huntingtin-associated protein 1 (HAP1), 
the first huntingtin interacting protein identified, is associated with this transport 
enhancing capacity of huntingtin. HAP1 is enriched in neurons and is probably 
involved in axonal transport (McGuire et al. 2006). This putative role of huntingtin 
in mitochondrial trafficking has recently been demonstrated by showing that the 
absence of normal huntingtin in HD can impair this process (Trushina et al. 2004; 
Orr et al. 2008).
Huntingtin in synaptic signalling
Huntingtin is highly expressed in presynaptic nerve terminals (DiFiglia et al. 
1995) and is involved in synaptic transmission. Exactly how huntingtin contributes 
to this process is not yet clear, although various theories have been put forward, 
many of which probably hold a piece of the puzzle. First, direct interaction 
between huntingtin and proteins involved in vesicle transport, release or uptake 
could exert some level of control, and several of these proteins have been found 
to interact with huntingtin. It is also known that huntingtin can affect transcription 
(see below) and in this way it could impact on the level of proteins involved in 
synaptic transport and postsynaptic transduction present in the cell (Smith et al.
2005). One of the key proteins in synaptic transmission is postsynaptic density 
protein 95 (PSD-95). PSD-95 is located almost exclusively in the post synaptic 
density of neurons, and is involved in anchoring synaptic proteins. PSD-95
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binding partners include N-methyl-d-aspartate (NMDA) receptors and kainate 
receptors, and huntingtin is associated with these through binding with PSD-95 
(Sun et al. 2001).
Huntingtin as transcriptional regulator
There is increasing evidence that an important role of huntingtin is in 
mediating transcription. Recent studies confirmed this by identifying strong 
transcriptional dysregulation in HD (section 1.7.7). Huntingtin accomplishes this 
transcriptional regulation in various ways. Huntingtin can act as a direct 
transcriptional regulator by binding transcription factors. It has been suggested 
that the glutamine repeats present in huntingtin serve to interact with other 
polyglutamine containing proteins. Long glutamine repeats occur in many 
proteins, especially among transcription factors. For that reason it has been 
proposed that huntingtin might function as a transcriptional regulator (Perutz et al. 
1994). By now, a vast number of proteins involved in transcriptional regulation 
have been found to interact with huntingtin. Some of these are transcription 
factors, such as huntingtin yeast partner B (HYPB), specificity protein 1 (Sp1) and 
p53; others are transcriptional co-regulators, such as nuclear co-repressor 
(NCoR) and CREB-binding protein (CBP) (Luthi-Carter & Cha 2003).
The regulation of gene expression can also be accomplished through the 
interaction between huntingtin and histone modifying proteins. Histones are 
subjected to several types of post-translational modifications, including 
acetylation, methylation, phosphorylation, ubiquitination and SUMOylation, all of 
which can affect transcription. Many of the huntingtin interacting proteins display 
histone modifying activity (Luthi-Carter & Cha 2003). Although the role of
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huntingtin in histone modification is not at all clear, some research indicates that 
mutant huntingtin interferes with the activity of histone acetyltransferase (Sadri- 
Vakili & Cha 2006a; Anderson et al. 2008). It has also been suggested that 
huntingtin is involved in histone methylation by means of HYPB, which has been 
found to possess histone methyltransferase activity (Sun et al. 2005).
Huntingtin can also interact directly with RNA polymerases or with proteins 
acting on RNA polymerases. In this respect, huntingtin was found to interact with 
polyglutamine binding protein-1 (PQBP-1), which binds RNA pol II, and with TAFh 
130, which binds to the TATA-binding protein (Luthi-Carter & Cha 2003).
In conclusion, a picture has emerged of huntingtin as a participant in a wide 
range of molecular pathways through its interaction with a large number of 
proteins. Numerous studies have provided pieces in this puzzle (Jones 2002; Li & 
Li 2004; Li et al. 2007). However, the Kaltenback study (2007) showed that the 
manner in which these interactions have an impact on pathology in HD is still 
uncertain, and that many more direct and indirect interactions probably exist and 
have an impact on the pathophysiology of HD.
1.6.4 Aggregation of mutant huntingtin
A great deal of research has been carried out to determine the significance 
of aggregates of mutant huntingtin in HD. For a long time, the appearance of 
aggregates in HD brain was considered to be the signature of HD pathology, and 
aggregate formation was thought to set off the sequence of events culminating in 
cell death and generalised neurodegeneration. Mutant huntingtin undergoes
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cleavage and some of these N-terminal fragments form aggregates. Several 
models have been suggested to explain this aggregation event. One of these is 
the polar zipper model, according to which the expanded CAG repeat destabilises 
the tertiary structure of the protein, which leads to interactions by hydrogen 
bonding with other polyglutamine proteins, including other N-terminal huntingtin 
fragments. This can ultimately result in insoluble formations of B-pleated sheets 
(Perutz et al. 1994; Li & Li 2004). The transglutaminase model proposes that 
aggregates are formed by the increased transglutaminase activity caused by the 
expansion of the glutamine repeat. Transglutaminases catalyse the formation of 
covalent bonds between glutamine residues, and bonds formed in this fashion 
exhibit a high resistance to proteolytic degradation. It has been demonstrated that 
huntingtin is a substrate of transglutaminase and that the transglutaminase 
reaction increases in proportion to the length of the polyglutamine stretch (Kahlem 
etal. 1998).
Accumulation of mutant huntingtin aggregates has been seen in human 
brain (DiFiglia et al. 1997; Becher et al. 1998) and can be found in any part of the 
neuron, including the nucleus, perikaryon, dendrites and axons. Aggregates are 
found in most brain areas that show neurodegeneration, with largest numbers in 
areas of the cerebral cortex, but very few in the striatum. N-terminal fragments of 
nuclear huntingtin can enter the nucleus where they aggregate to form 
intranuclear inclusions. However the majority of aggregates are found in the 
neuropil, where they appear in different forms (Gutekunst et al. 1999).
The parallel between the distribution of aggregates and the pattern of 
neurodegeneration fuelled the notion that aggregation was the initial step in HD 
pathology. However, this theory has been fiercely debated. The presence of
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aggregates and nuclear inclusions could just be a secondary effect of the 
pathological process, or incidental to it. By and large it is agreed that soluble N- 
terminal fragments of huntingtin in the nucleus play a role in cellular toxicity. 
However, this is not so with regards to nuclear inclusions. The presence of 
nuclear inclusions did not correlate with neurodegeneration in cell models 
(Saudou et al. 1998; Arrasate et al. 2004). This outcome was also observed in the 
shortstop mouse model of HD, which displayed extensive nuclear inclusions but 
no neurodegeneration (Slow et al. 2005). Notably, exposing cells to conditions 
that suppressed the formation of inclusions accelerated cell death, suggesting a 
protective effect of aggregates during the early stages of the disease (Saudou et 
al. 1998; Arrasate et al. 2004), possibly through the sequestration of the toxic 
soluble fragments, which could be more harmful.
1.6.5 Gain of function or loss of function?
Despite concerted efforts to explain the method by which mutant huntingtin 
brings about HD, the answer is still unclear. Two theories exist and they are 
probably complementary. One is explained by the gain of function mechanism of 
mutant huntingtin mediated pathology, which is based on the acquisition of a toxic 
function, imparted to the huntingtin protein by the expansion of the polyglutamine 
stretch. It is generally recognised that a large number of consecutive glutamines 
convey some toxic property to the protein it is part of, born out by the numerous 
polyglutamine diseases, each characterised by a distinct pattern of 
neurodegeneration (Taylor et al. 2002). Some features of this common 
pathological pattern are protein misfolding, followed by proteolytic processing with 
the formation of soluble protein fragments, which might be toxic in their own right,
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and possibly subsequent aggregation of these fragments into insoluble constructs. 
In turn, these aggregates can sequester other proteins and as a result deplete the 
cell of vital components (Kazantsev et al. 1999).
On the other hand, the loss of function theory recognises the potential 
toxicity of the loss of wild-type huntingtin, given the many functions it most likely 
performs in the brain (section 1.6.3). Decreased activity of wild-type huntingtin 
could theoretically lead to impaired neural development, activation of proteases, 
disruption of intracellular transport, synaptic dysfunction and transcriptional 
dysregulation. On the other hand, it was demonstrated that mutant huntingtin can 
perform at least some of the functions of the normal protein (White et al. 1997).
Finally, the gain of function of mutant huntingtin could lead to the loss of 
wild-type huntingtin function by the sequestration of the normal protein into mutant 
huntingtin aggregates, and it is certainly possible that a combination of the two 
mechanisms is closer to the truth.
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1.7 Mechanisms of pathology in Huntington’s disease
The progression of HD pathology is complex. Various pathways leading to 
cell death are activated and a number of vital cellular support systems are 
impaired. All of these pathological mechanisms gradually develop during the 
course of the disease and may act synergistically. Some of these mechanisms are 
discussed below.
1.7.1 Excitotoxicitv
Excitotoxicity is the pathological process by which nerve cells are damaged 
and killed by excitatory neurotransmitters, such as glutamate. This occurs when 
receptors for these neurotransmitters, such as the NMDA receptor, are 
overactivated by pathologically high levels of neurotransmitters, allowing high 
levels of Ca2+ to enter the cell. In turn, this can activate phospholipases, 
endonucleases and proteases, as well as generate reactive oxygen species 
(ROS), all of which will damage and eventually destroy the cell.
The selective vulnerability of the MSN in the striatum has been intriguing, 
particularly considering the ubiquitous distribution of both wild-type and mutant 
huntingtin in the brain. Excitotoxicity is thought to be a substantial contributor to 
this discriminating susceptibility. Within the basal ganglia, MSN are part of several 
complex neuronal circuits. MSN are GABAergic neurons and hence have an 
inhibitory impact on the neurons they project to. In turn, MSN receive a vast 
amount of excitatory glutamatergic input from various brain regions, 
predominantly from the entire cerebral cortex. In addition, MSN express high 
levels of NMDA type glutamate receptors, particularly NR1 and NR2B subtypes,
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which contribute to excitatory synaptic transmission. This huge amount of 
glutamatergic input has been held responsible for the vulnerability of the MSN in 
HD, particularly as striatal interneurons, which are mostly spared in HD, have 
fewer excitatory inputs and express lower levels of NMDA receptors than the MSN 
projection neurons.
In vitro studies agree with this concept by showing that the co-expression 
of NMDA receptor subunits NR1 and NR2B with mutant huntingtin enhances 
excitotoxicity (Chen etal. 1999; Zeron etal. 2001). Transgenic YAC72 and 
CAG94 HD mice also exhibited hyperactive NMDA receptors in the brain, 
suggesting that mutant huntingtin can cause sensitisation and activation of NMDA 
receptors (Hodgson et al. 1999; Levine et al. 1999; Cepeda et al. 2001; Zeron et 
al. 2002; Tang et al. 2005). Similar results were obtained in transgenic R6/2 mice, 
where enhanced currents induced by selective activation of NMDA receptors and 
increased Ca2+ movement were recorded (Cepeda et al. 2001). In addition, while 
wild-type huntingtin inhibits NMDA receptor activity by the sequestration of PSD- 
95 in normal circumstances, it has been suggested that the polyglutamine 
expansion impedes mutant huntingtin binding to PSD-95. This would mark PSD- 
95 and mutant huntingtin as mediators in NMDA related neuronal toxicity (section 
1.6.3); (Sun etal. 2001).
There is also evidence to suggest that nigrostriatal dysfunction plays a part 
in excitotoxicity. The nigrostriatal neural pathway connects the substantia nigra 
with the striatum and is one of the major dopamine conduits in the brain. 
Nigrostriatal dysfunction has been implicated in HD, with a down regulation of the 
dopamine transporter and D1 and D2 dopamine receptors linked to motor and 
cognitive deficits in HD (Backman & Farde 2001). The dopaminergic input from
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the substantia nigra was shown to contribute to striatal excitotoxicity, and it was 
suggested that the dopamine signalling pathway acts synergistically with the 
glutamate pathway (Meldrum etal. 2001; Tang etal. 2007). Moreover, only low 
doses of dopamine were needed in the presence of mutant huntingtin to initiate 
apoptosis and the production of ROS (Charvin et al. 2005).
Numerous studies have indicated that the nuclear accumulation of mutant 
huntingtin interferes with transcriptional events (section 1.7.7). With regard to 
excitotoxicity, this effect on genes encoding neurotransmitter receptor proteins, 
especially those involved in glutamatergic neurotransmission, as well as on any 
proteins involved in the glutamate excitatory pathway, is of particular importance. 
Changes in these receptors may bring about a level of chronic excitotoxicity in the 
projection neurons of the striatum, which could ultimately lead to cell death 
(Sieradzan & Mann 2001). Examples of this are the significant decrease in the 
mRNA levels of the astroglial glutamate transporter GLT1 and the astroglial 
enzyme glutamine synthetase in the striatum and cerebral cortex of transgenic 
R6/2 mice. This would almost certainly result in a decrease in glutamate uptake 
from the synaptic cleft, which could contribute to a chronic excitotoxic insult on the 
MSN (Lievens et al. 2001).
Some corroboration of the glutamate-dopamine mediated excitotoxic 
mechanism in HD neurodegeneration was presented by Stack et al. (2007), when 
they demonstrated that lesions introduced in the corticostriatal and nigrostriatal 
pathways of transgenic R6/2 extended survival and ameliorated both the 
behavioural and neuropathological phenotype (Stack et al. 2007).
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1.7.2 Mitochondrial dysfunction
Mitochondrial dysfunction and a deficient energy metabolism have been 
recognised as early events in HD pathology. Significantly decreased activity of 
mitochondrial complexes was found in post-mortem brain tissue of HD patients 
(Brennan et al. 1985; Gu etal. 1996; Browne etal. 1997). Defects of energy 
metabolism have been demonstrated in vivo in skeletal muscle in both 
symptomatic and presymptomatic HD patients, suggesting mitochondrial 
dysfunction as an early component of HD pathophysiology (Tabrizi et al. 2000; 
Saft et al. 2005). Changes in the activity of complexes II and III in skeletal muscle 
of HD patients were subsequently correlated with disease duration (Turner et al.
2007). An inverse relationship was also identified between the length of the CAG 
repeat and the ATP/ADP ratio in human HD lymphoblasts, demonstrating a 
regulatory role for the polyglutamine tract in oxidative phosphorylation (Seong et 
al. 2005). Morphological changes and decreased membrane potential were also 
seen in human HD lymphoblasts, with an exacerbated condition in homozygote 
individuals (Squitieri et al. 2006).
In addition, it has been demonstrated that it is possible to curb metabolic 
energy insufficiency in HD by promoting the activity of complex III. The 
administration of coenzyme Q10 supplements enhanced mitochondrial activity in 
HD patients and as such reduced impaired energy metabolism (Koroshetz et al. 
1997; Andrich et al. 2004). A similar effect was found in rats treated with 3- 
nitropropionic acid (3-NP), where the energy deficit was reduced by increasing the 
concentration of coenzyme Q10 in the brain (Kasparova et al. 2006). In transgenic 
R6/2 mice, high doses of coenzyme Q10 significantly improved motor deficits, 
reduced brain atrophy and inclusion formation, and prolonged survival (Smith et
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al. 2006). The beneficial effect of coenzyme Q was enhanced when it was 
administered in combination with the tetracycline antibiotic drug minocycline 
(Stack et al. 2006) and the antioxidant vitamin E (Kasparova et al. 2006).
Consistent with this, biochemical analysis of R6/2 mouse brain 
demonstrated a significant reduction in mitochondrial complex IV activity in the 
striatum and some decrease in the cerebral cortex (Tabrizi et al. 2000). 
Mitochondrial dysfunction was also detected in muscle and muscle mitochondria 
of R6/2 mice, with a 15% reduction of complex IV in HD muscle (Gizatullina et al.
2006). A recent study identified a depletion of mitochondrial DNA in leucocytes of 
HD patients and the degree of the reduction was negatively correlated with the 
number of CAG repeats (Liu et al. 2008).
The dysfunction of the oxidative phosphorylation (OXPHOS) pathway may 
be the result of OXPHOS inhibitors, of mutations in genes encoding OXPHOS 
subunits (Leonard & Schapira 2000a; Leonard & Schapira 2000b), or of 
transcriptional dysregulation through the interference of mutant huntingtin with 
transcription factors involved with mitochondrial biogenesis and function. Mutant 
huntingtin was shown to interfere with the transcriptional coactivator PGC-1a in 
the nucleus. PGC-1a regulates several metabolic processes, including 
mitochondrial biogenesis and oxidative phosphorylation, and repression of PGC- 
1a and its targets may contribute to mitochondrial dysfunction and striatal 
degeneration in HD (Cui et al. 2006; Weydt et al. 2006).
Another mechanism by which mutant huntingtin could bring about 
mitochondrial dysfunction is through direct interaction with mitochondria. Mutant 
huntingtin was found to associate with neuronal mitochondrial membranes in 
YAC72 mice (Panov et al. 2002), Hdh0111 mice (Choo et al. 2004) and Hdh0150
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mice (Orr et al. 2008). In Hdh0111 mice, a truncated mutant huntingtin fragment 
could directly induce the opening of the mitochondrial permeability pore, 
accompanied by the release of a considerable amount of cytochrome c (cyt c) 
(Choo et al. 2004). In turn, cyt c can lead to caspase activation, which can cleave 
mutant huntingtin and thus promote its entry into the nucleus, where it can 
interfere with transcription. One of these transcription factors is p53, a tumour 
suppressor known to regulate genes involved in mitochondrial function and 
oxidative stress. Mutant huntingtin was shown to bind p53 and increase p53 levels 
and transcriptional activity in neuronal cultures, in HD transgenic mice and in HD 
patients, leading to mitochondrial membrane depolarisation (Bae et al. 2005) and 
further mitochondrial abnormalities.
Cyt c as caspase activator can also promote cell death (section 1.7.4); 
(Green & Reed 1998). A significant release of cyt c was observed in mitochondria 
isolated from Hdh0150 mouse liver cells after a calcium-induced increase of 
mitochondrial permeability (Choo et al. 2004) and upon glutamate-induced 
apoptosis in YAC128 mice (Tang et al. 2005).
1.7.3 Oxidative stress
While mitochondria are a major source of ROS production, they also 
contain various antioxidants, such as coenzyme Q10 and superoxide dismutase 
(SOD), to protect the cell against oxidative damage. ROS levels can accumulate 
in the cell, particularly in case of respiratory chain dysfunction or when SOD 
function is altered (Raha & Robinson 2000). For that reason, mitochondrial 
dysfunction in HD may lead to accumulation of ROS, which can reach toxic levels 
in conjunction with ROS generated during glutamate-dopamine mediated
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excitotoxicity, and result in significant damage to the cell. This condition is known 
as oxidative stress and it may play a significant part in HD neurodegeneration. 
Supporting this, reduced expression of nitric oxide synthase was found in 
transgenic R6/2 (Deckel et al. 2001; Deckel et al. 2002) and decreased SOD was 
observed in transgenic R6/1, in a 3-NP acid rat model of HD (Santamaria et al. 
2001), and in peripheral blood of HD patients (Chen et al. 2007). In cells 
expressing mutant huntingtin, oxidative stimuli enhanced the aggregation of 
truncated N-terminal mutant huntingtin, proteasomal malfunction and cell death, 
while overexpression of SOD reversed these detrimental processes (Goswami et 
al. 2006).
Interestingly, analysis of the localisation of the cytosolic SOD1 and the 
mitochondrial SOD2 in different types of striatal neurons in normal rhesus monkey 
indicated that the striatal projection neurons express only low levels of both SOD1 
and SOD2, which might explain to some extent why projection neurons are 
particularly vulnerable to neurodegenerative processes, and confirm the notion 
that superoxide free radicals are at least partly involved in the differential neuronal 
loss observed in the striatum in HD (Medina et al. 1996).
1.7.4 Pathways to cell death
In recent years a number of findings suggested a role for apoptosis in HD 
(Friedlander 2003). Apoptosis is a form of programmed cell death which involves 
characteristic cell morphology, including blebbing, nuclear condensation, cell 
shrinkage and DNA fragmentation. Many chemical signals may lead to apoptosis, 
after which a cell will undergo organised degradation of cellular organelles by 
activated proteolytic caspases. Numerous studies have recognised huntingtin as a
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substrate for caspase activity, and a number of caspase binding sites have been 
identified on the protein (section 1.6.1). This has led to the suggestion that 
caspase-mediated cleavage of huntingtin generated the toxic mutant huntingtin 
fragments crucial to the development of neurodegeneration in HD.
Throughout HD disease progression, caspase 1 and caspase 3 were 
found to be increasingly upregulated, coinciding with the release of excessive cyt 
c and eventually leading to neuronal dysfunction and cell death (Friedlander 
2003). Increased levels of cyt c and caspases, associated with cell death and 
disease progression, have also been observed in cell cultures of HD patients, 
including unaffected mutation carriers, as well as in genetic mouse models (Li et 
al. 2000; Kiechle et al. 2002; Wang et al. 2003; Ciammola et al. 2006). In addition, 
research in transgenic YAC72 mice demonstrated that caspase cleavage of 
mutant huntingtin precedes the onset of neurodegeneration in HD (Wellington et 
al. 2002). Recent work has suggested, however, that it might not be caspase 3 
but caspase 6 which is the key player in the damaging proteolytic process (Warby 
et al. 2008). This clearly shows that the mechanism underlying these cleavage 
events is still not well understood. Then again, further evidence for the role of the 
caspase signalling pathway in HD neurodegeneration comes from the application 
of a caspase inhibitor in R6/2 mice (Chen et al. 2000) and from the use of 
caspase inhibitors as therapeutic treatment in HD patients, which delay 
degeneration and ameliorate symptoms in the patient (Bonelli et al. 2004).
Some evidence has also suggested a role for autophagy in the HD disease 
process. Autophagy involves sequestration of cellular components within 
autophagosomes, which fuse with lysosomes where their content is degraded 
(Mizushima et al. 2002). Pronounced autophagic vacuoles have been observed in
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HD lymphoblasts, and a positive correlation was found between the number of 
vacuoles and the length of the polyglutamine expansion (Nagata et al. 2004). It 
has also been suggested that the expression of mutant huntingtin induces 
lysosomal activity (Kegel et al. 2000). Furthermore, it was hypothesised that 
aggregated proteins may not be able to access the proteasome (section 1.7.6), 
and therefore rely on autophagy for degradation. This would imply that impaired 
autophagy can contribute to HD pathology. In this context it was shown that 
autophagosome-lysosome fusion can be impaired by a decreased function of 
dynein, a molecular motor which transports cellular components along the 
microtubules to the perinucleus. In this way dynein mutations may be linked to 
impaired clearance of aggregates, which could be toxic to neurons (Ravikumar et 
al. 2005).
1.7.5 Loss of trophic support
A deficiency in neurotrophic support for the degenerating cells of the 
striatum has also been singled out as a mechanism perhaps reinforcing HD 
pathology. The main mediator under investigation in this is brain-derived 
neurotrophic factor (BDNF), the transport and transcription of which is partly 
regulated by wild-type huntingtin (section 1.6.3). The loss of BDNF upregulation 
by wild-type huntingtin in HD, and the reduction in cortical BDNF messenger as a 
result (Zuccato etal. 2001), correlated with the progression of the disease in 
transgenic R6/2 mice (Zucker et al. 2005) and points towards the involvement of 
trophic factors in HD pathology (Zuccato & Cattaneo 2007). Expression profiling 
based on striatal gene expression data supported the hypothesis that reduced 
trophic support is a major pathway contributing to striatal degeneration in HD. As
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striatal BDNF is synthesised mainly in the cortex, the data also imply that cortical 
dysfunction contributes to striatal pathology in HD (Strand et al. 2007).
1.7.6 Impaired ubiauitin-proteasome system
It has been proposed that the ubiquitin proteasome system (UPS) is 
impaired in HD and that this contributes to HD pathology. The UPS is a major 
protein degradation pathway in cells, degrading short-lived and damaged proteins. 
Through this, the proteasome impacts on many cellular pathways, and impairment 
of the UPS might have considerable consequences on normal cellular functions.
It has been suggested that the UPS is impaired in HD through the 
sequestration of ubiquitin and proteasome subunits in polyglutamine aggregates 
(Bence et al. 2001; Bennett et al. 2005). Another hypothesis proposes that 
expanded polyglutamine containing proteins are not easily degraded by the 
proteasome. As a result, they block the proteasome and prevent proteasomal 
degradation of other substrates (Holmberg et al. 2004).
In HD, however, the impairment of the UPS is controversial. Some studies 
report decreased proteasome activity (Bence et al. 2001; Seo et al. 2004; Bennett 
et al. 2005), some see no change (Ding et al. 2002), and others even show 
increases in proteasome subunits and proteasome activity (Diaz-Hemandez et al. 
2003; Bett et al. 2006). It is clear that further study is required to resolve the 
conflict involving UPS participation in HD pathogenesis.
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1.7.7 Transcriptional dvsreaulation
The detection of accumulated cleaved mutant huntingtin fragments in the 
nucleus (section 1.6.4) fuelled the idea that mutant huntingtin might interfere with 
transcription. Moreover, the presence of a polyglutamine stretch in wild-type 
huntingtin had already suggested a possible role in transcription (Perutz et al. 
1994), and the way in which wild-type huntingtin could perform this transcriptional 
regulatory function has been described in section 1.6.3.
Recent gene expression studies have confirmed the association of strong 
transcriptional dysregulation and the presence of mutated huntingtin in HD (Luthi- 
Carter et al. 2000; Chan et al. 2002; Fossale et al. 2002; Kita et al. 2002; Luthi- 
Carter et al. 2002a; Luthi-Carter et al. 2002b; Zucker et al. 2005; Desplats et al. 
2006; Hodges et al. 2006; Kuhn et al. 2007; Woodman et al. 2007; Hodges et al.
2008). Various hypotheses to explain the way in which the mutation in huntingtin 
could have this dysregulatory effect have been put forward. One model suggests 
that the intranuclear aggregates of mutant huntingtin fragments sequester soluble 
proteins essential for transcription (Luthi-Carter & Cha 2003). Another theory, 
discussed in section 1.6.3, involves the interference of mutant huntingtin with 
histone modification, possibly through its interaction with histone acetyltransferase 
(Sadri-Vakili & Cha 2006a; Sadri-Vakili & Cha 2006b; Anderson et al. 2008). 
Mutant huntingtin can also interfere with transcription and affect changes by 
interacting directly with soluble transcriptional regulators, perhaps through an 
altered affinity for certain proteins (Dunah et al. 2002). One example of this is the 
repression of the transcriptional coactivator PGC-1a by mutant huntingtin (section 
1.7.2), which may be through direct binding of mutant huntingtin to PGC-1a 
(Weydt et al. 2006), or by the down regulation of PGC-1a transcription through
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association of mutant huntingtin with the CREB/TAF4 complex on the PGC-1a 
promoter (Cui et al. 2006), or a combination of the two. The ineffective binding of 
mutant huntingtin with the transcriptional repressor REST/NRSF is another 
illustration of the direct interference of mutant huntingtin with transcriptional 
regulators. Normal huntingtin binds REST/NRSF and allows transcription of 
proteins regulated by this repressor, one of which is BDNF. The polyglutamine 
expansion in mutant huntingtin is thought to reduce this affinity and allow 
repression of these proteins (Zuccato et al. 2003).
Aside from the mechanisms of transcriptional dysregulation in HD, it is also 
not at all certain what functional effect a change in mRNA level would have. Some 
of these effects have been discussed earlier. Altered levels of neurotransmitters 
can bring about excitotoxicity, changes in OXPHOS subunits can result in 
mitochondrial dysfunction, impaired energy metabolism and oxidative stress, and 
a reduction in BDNF might cause a deficiency in neurotrophic support. However, 
the assumed impact of transcriptional dysregulation in the cell, and on the 
organism as a whole, is based on the assumption that a change in mRNA is 
translated to a change at the protein level, which is not at all certain.
Furthermore, it is likely that some of the changes in mRNA levels are not a 
direct consequence of mutant huntingtin interactions with transcription, but may 
correspond to secondary effects of disease progression, almost certainly involving 
a large number of compensatory responses.
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1.8 Animal models of Huntington’s disease
Animal models of human diseases are important in order to study all stages 
of disease development, and to investigate possible therapies before they are 
translated into human clinical trials. Chemical models of HD, that mimicked some 
of the known phenotypes in HD brain, were originally used, but the identification 
of the HD gene (Huntington's Disease Collaborative Research Group 1993) 
allowed the development of genetically accurate HD models in which the 
pathophysiology and aetiology of the disease caused by the expanded CAG 
repeat could be examined. The development of animal models recapitulating 
aspects of the human HD phenotype opened new lines of investigation, 
particularly in the study of the presymptomatic and early stages of the disorder, 
and offered the possibility of testing therapeutic interventions.
The disease has been modelled in mouse and rat (Yamamoto et al. 2000; 
Regulier et al. 2003; von Horsten et al. 2003), in fish (Lumsden et al. 2007), in 
invertebrates such as the fruitfly Drosophila melanogaster (Jackson et al. 1998; 
Steffan et al. 2001; Lee et al. 2004) and the nematode Caenorhabditis elegans 
(Faber et al. 1999; Parker et al. 2001; Brignull et al. 2006), and in yeast (Krobitsch 
& Lindquist 2000). The development of a non-human primate HD model is still in 
progress (Yang et al. 2008).
Animal models of HD have been generated by the administration of toxins 
and by genetic means. Until the identification of the genetic mutation responsible 
for HD in 1993 (Huntington's Disease Collaborative Research Group 1993), only 
toxin induced models were available. These models are typically generated either 
by the administration of an excitotoxic agent, which induces excitotoxic cell death,
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or by the disruption of the mitochondrial machinery by a mitochondrial toxin. The 
main excitotoxic agents used in rodent models are kainic acid (KA) (Coyle & 
Schwarcz 1976), ibotenicacid (IA) (Isacson etal. 1985), quinolinic acid (QA) 
(Schwarcz et al. 1983) and homocysteic acid (L-HCA) (Beal et al. 1990). The 
main mitochondrial toxin is 3-nitropropionic acid (3-NP), which brings about cell 
death in striatal neurons through the irreversible inhibition of succinate 
dehydrogenase (complex II) of the electron transport chain, and as such mimics 
mitochondrial impairment seen in human HD brain (Beal etal. 1993). Although 
toxin induced animal models have certainly been of great help in HD research, 
they have limitations. The principal problem lies in the way they are generated, 
and they are therefore a representation of only a particular stage in the disease 
process, dissociated from the genetic cause of HD. While the pathology in HD 
develops gradually, toxin induced models present only the stage after which cell 
death has already occurred. Therefore, they cannot provide any information on 
the mechanism and importance of mutant huntingtin misfolding, the development 
of aggregates and inclusions, or the progressive nature of the disease to the point 
of severe pathology. They are also inefficient for studying the development of 
cognitive, motor and behavioural disturbances and their relationship to neuronal 
pathology.
Sequencing Hdh, the murine homologue of the HD gene, revealed a high 
degree of conservation between the mouse and the human HD gene, with 86% 
nucleotide sequence identity and 90% amino acid sequence identity. However, 
the CAG repeat length differed, with only 7 repeats in mice (Lin et al. 1994). This 
homology presented the opportunity to create genetic mouse models 
recapitulating aspects of human HD. The first genetic technique used, knocking
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out the Hdh locus, did not create a model of the disease, although it did explain 
some aspects of normal huntingtin (Duyao et al. 1995; Nasir et al. 1995; Zeitlin et 
al. 1995). The majority of HD genetic mouse models have been developed by 
either the transgenic or the knock-in genetic method. The transgenic approach 
involves the random insertion of genomic or cDNA transgenes, expressing 
truncated or full-length human huntingtin, into the mouse genome. The knock-in 
technique involves the insertion of the mutation into the mouse HD gene. Some 
conditional models were also developed using the tetracycline-regulatable 
system. A summary of the HD genetic mouse models can be found in Table 1.1.
1.8.1 Knock-out mouse models of HD
Knock-out mice were generated by three groups (Duyao et al. 1995; Nasir 
et al. 1995; Zeitlin et al. 1995) and all nullizygous embryos showed abnormal 
development during gastrulation and died around day 8 of gestation. This 
demonstrated that huntingtin is vital during embryonic development, but it did not 
contribute further to the understanding of the normal function of the protein or of 
its role in HD pathology.
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Table 1.1 Mouse models of Huntington’s disease.
Mouse model 
line Promoter Construct Models + number CAG repeats Reference
Transgenic 
R6 lines
Human HD Human exon 1 R6/1 (116 CAG), R6/0 (142 CAG), R6/2 
(144 CAGL R6/5 (128-156 CAG)
Mangiarini et al., 1996
Transgenic 
N171 lines Mouse prion Human HD first 171 aas N171-18Q, N171-44Q, N171-82Q Shilling etal., 1999
Transgenic 
HD lines
Rat neuron 
specific enolase
Human HD ± first 1000 aas CT18, HD46, HD100 Laforet et al., 2001
Transgenic 
cDNA lines CMV Human full-length cDNA HD16, HD48, HD89 Reddy etal., 1998
T ransgenic 
YAC lines Human HD Human full-length genomic
YAC18, YAC46, YAC72 Hodgson etal., 1999
YAC128 Slowet al., 2003
Transgenic 
BAC line Human HD Human full-length genomic BACHD (97 CAG) Gray et al., 2008
Knock-in Mouse HD
Mouse full length genomic 
exon 1 replaced with human 
exon 1 + expanded repeat
Hdh092, Hdh 0111
Wheeler etal., 1999 and 
2000
Knock-in Mouse HD Mouse full length genomic + 
expanded repeat
H d h (CAG)80. H d h (CAG)150 Lin et al., 2001
Knock-in Mouse HD Human full-length genomic
Hdh4/Q80, Hdh6/Q72 Shelbourne etal., 1999
CAG71, CAG94 Levine et al., 1999
CAG 140 Menalled et al., 2003
Mouse models used in this project are in red. CMV = cytomegalovirus.
1.8.2 Transgenic mouse models with a truncated human HD gene
The R6 transgenic mouse models
The R6 lines were the first transgenic models generated by the 
microinjection of a 1.9 kb genomic fragment containing the human promoter 
sequences and exon 1 of the human HD gene with approximately 130 CAGs. One 
male founder (R6) was obtained and backcrossed to CBAxC57BL/6 females. 
Integration of the fragment into five different regions of the founder’s genome 
gave rise to five mouse lines. R6/T had a single highly truncated copy with no 
CAG repeats. R6/0 had a single copy with 142 repeats, integrated adjacent to a 
repetitive genomic structure which probably caused the suppression of the 
transgene expression. These two lines were rejected for obvious reasons. Lines 
R6/1 with 116 repeats, R6/2 with 144 repeats and R6/5 with 5 copies integrated 
ranging from 128 to 156 repeats, were established. All three lines showed a 
phenotype similar to the human one, with components of the motor disorder, 
weight loss and characteristic vocalisations. Although brains of transgenic animals 
were smaller than those of controls, there was no apparent neurodegeneration 
and it was suggested that localised atrophy might not be the prime cause of the 
clinical symptoms in HD. R6/1 mice developed disease symptoms between 15-21 
weeks and died at 32-40 weeks. In R6/2 mice, age of onset was observed as 
early as 4 weeks and death followed at about 10-13 weeks. For reasons that are 
unclear, the phenotype in the R6/5 homozygotes was a great deal milder than in 
the R6/1 and R6/2 lines and did not develop before 9 months of age. R6/5 
heterozygotes showed no phenotype (Mangiarini et al. 1996).
Subsequent neurological profiling of the R6 lines identified nuclear 
localisation of the transgene protein. While normal huntingtin was detected only in
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the neuronal cytoplasm, dendrites and axons in control animals, the transgene 
protein was also identified within the neuronal nucleus. These neuronal 
intranuclear inclusions (Nils) were present in all the R6 lines exhibiting a disease 
phenotype, but absent in the ones that were not symptomatic. The largest 
inclusions were found in the cerebral cortex, striatum and cerebellum. In striatal 
neurons, the appearance of inclusions was followed by increased nuclear 
abnormalities and it was suggested that this may be the result of a neuronal 
response of the striatum to axonal injury (Davies et al. 1997). Further to the 
original study by Mangiarini (1996), comprehensive characterisation of the R6/1 
and R6/2 lines was carried out to evaluate them as a model for HD.
In the R6/1 line, although overt behavioural changes were not apparent 
before 4 months of age (Mangiarini et al. 1996; Hansson et al. 1999; Clifford et al. 
2002; Naver et al. 2003; Hodges et al. 2008), sensitive tests recorded the 
development of motor deficits in R6/1 transgenic mice from 7 weeks (van Dellen 
et al. 2000; Hansson et al. 2001b; van Dellen et al. 2008), and differences in 
exploratory behaviour were observed as early as 4 weeks (Bolivar et al. 2004). On 
the other hand, gait abnormalities were not registered before 38 weeks (Clifford et 
al. 2002). Immunocytochemical analysis identified Nils of the transgene and 
associated nuclear changes, including invaginations of the nuclear membrane and 
increased nuclear pore density, in symptomatic R6/1 mice (Davies et al. 1997; 
lannicola et al. 2000; Turmaine et al. 2000). These neuronal inclusions were 
subsequently detected in a small percentage of brain cells from as early as 8 
weeks and were widespread in the brain by the 16th week (Hansson et al. 2001b; 
Naver et al. 2003). Nils were also found in skeletal muscle in conjunction with 
ultrastructural changes in muscle in 15 month old R6/1 (Sathasivam etal. 1999).
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Abnormal nuclear morphology (Davies et al. 1997; Turmaine et al. 2000) and 
neurodegeneration, including neuronal condensation and shrinkage, in transgenic 
R6/1 striatum, hippocampus, cortex and cerebellum (lannicola et al. 2000; 
Turmaine et al. 2000; Spires et al. 2004a; Lazic et al. 2007) were observed in 
animals at 5 months. It was also noted that the survival of neural precursor cells in 
the dentate gyrus, the part of the hippocampus which undergoes a relatively high 
rate of neurogenesis under normal circumstances, was compromised in 
transgenic R6/1 animals (Lazic et al. 2006). On the other hand, changes in the 
physiology of transgenic R6/1 striatal neurons offered some measure of 
resistance to striatal cell death induced by either quinolinic acid or malonate at 18 
weeks of age. This was not observed in 6 week old animals, implying it could be 
an age dependent protective mechanism (Hansson et al. 1999; Hansson et al. 
2001a). Histological examination demonstrated weight reduction of the whole 
brain as well as reduced striatal volume in 15 week old transgenic R6/1 (Hansson 
etal. 1999; Lazic etal. 2007).
Altered brain gene expression was detected in 18 and 22 week transgenic 
R6/1 (lannicola et al. 2000; Kuhn et al. 2007; Hodges et al. 2008) and one study 
showed that 81% of a set of genes, selected for predominant expression in the 
striatum, were downregulated by the time the animals were 6 months old 
(Desplats et al. 2006). Several proteins were also found to be differentially 
expressed, some from as early as 8 weeks. R6/1 animals also showed a loss in 
dopamine receptors in the striatum at 43 weeks (Clifford et al. 2002) and a 
reduction of BDNF protein in the striatum and the hippocampus as well as a 
downregulation of the dopamine regulator DARPP-32 in the striatum at 5 months 
(Spires et al. 2004b). Alterations in the release of striatal neurotransmitters
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(Nicniocaill et al. 2001; Smith et al. 2006) and the reduction of the synaptic vesicle 
protein rabphilin 3A in the cerebral cortex and the striatum were detected by 16 
weeks (Smith et al. 2006). The earliest protein change observed was the 
down regulation of the cannabinoid receptor 1 at 8 weeks (Naver et al. 2003). A 
summary of the disease characteristics of transgenic R6/1 mice, with the earliest 
timepoints at which these present, is shown in Figure 1.3 and Table 1.2.
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Figure 1.3 Timeline of disease development in the R6/1 HD mouse model. The diagram 
shows the earliest timepoints at which different aspects of the behavioural, molecular and 
neuropathological phenotypes have been detected.
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Table 1.2 Summary of disease development in the R6/1 HD mouse model.
BEHAVIOURAL PHENOTYPE Earliest
timepoint
References
differences in exploratory behaviour 4 weeks Bolivar et a l., 2004
motor deficits 7 weeks Van Dellen et a l., 2000 and 2008; Hansson et al., 2001 b; Hodges et a l., 2008
loss of body weight 12 weeks Van Dellen et a l., 2000; Clifford et al., 2002; Naver et a l., 2003
behavioural changes 4 months
Mangiarini et a l., 1996; Hansson et a l., 1999; 
Clifford et a l., 2002; Naver et a l., 2003; 
Hodges et a l., 2008
gait abnormalities 38 weeks Clifford et al. ,2002
MOLECULAR PHENOTYPE
protein changes (striatal 
neurotransmitters) 8 weeks
NicNiocaill et a l., 2001; Clifford et al., 2002; 
Naver et a l., 2003; Spires et a l., 2004b; 
Smith et a l., 2006
Nils 8 weeks
Davies et a l., 1997; lannicola et a l., 2000; 
Turmaine et a l., 2000; Hansson et al., 2001b; 
Naver et al., 2003
changes in physiology of striatal 
neurons 18 weeks Hansson et al., 1999 and 2001a
differences in gene expression 18 weeks lannicola et a l., 2000; Hodges et at., 2008
nuclear abnormalities 4.5 months Davies et a l., 1997; Turmaine et a l., 2000
Nils in skeletal muscle + 
ultrastructural changes in muscle
12-15
months Sathasivam e ta l., 1999
NEUROPATHOLOGY
compromised survival neural 
precursor cells 10 weeks Lazic et a l., 2006
reduced striatal volume 15 weeks Hansson et al., 1999; Lazic et al., 2007
reduced brain weight 15 weeks Lazic et a l., 2007
neurodegeneration 5 months lannicola et a l., 2000; Turmaine et a l., 2000; Spires et a l., 2004a; Lazic et al., 2007
The table lists the earliest timepoints at which different aspects of the behavioural, 
molecular and neuropathological phenotypes have been detected.
Other transgenic mouse models with a truncated HD gene 
The N171 lines express a cDNA encoding an N-terminal fragment of 171 
amino acids of the human HD gene with 18, 44 or 82 CAG repeats. Only the 
transgenic N171-82Q presented behavioural and neuropathological abnormalities, 
with Nils and neuritic aggregates (Schilling etal. 1999).
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The HD lines express the first 3 kb of the human HD gene with 18, 46 and 
100 CAG repeats. The HD48 and HD100 lines showed neuropathological 
changes, such as cortical and striatal Nils, nuclear localisation of huntingtin and 
dysmorphic cortical dendrites. Striatal electrophysiological abnormalities were 
marked in HD100 mice, even preceding the onset of a phenotype (Laforet et al. 
2001).
1.8.3 Transgenic mouse models with a full length human HD gene
cDNA of the human HD gene was used to create transgenic mouse model 
with 16, 48 or 89 CAG repeats. HD48 and HD89 showed behavioural and motor 
dysfunction and a neuropathology similar to that in human HD patients, but only a 
relatively small number of Nils. This model also displayed a marked difference 
between heterozygote and homozygote transgenic mice (Reddy et al. 1998).
The first animal model expressing the full length human HD gene under the 
control of its own promoter was generated by means of yeast artificial 
chromosomes (YACs) with 18, 46 and 72 CAG repeats. YAC72 mice exhibited a 
progressive behavioural and neuropathological phenotype, with translocation of 
N-terminal fragments of huntingtin into the nucleus and significant striatal atrophy 
by 12 months (Hodgson et al. 1999). Although a YAC model with 128 CAG 
repeats developed early cognitive and motor deficits, striatal atrophy was evident 
only much later, reflecting the condition in human patients, where cognitive and 
motor deficits precede the onset of neurodegeneration (Slow et al. 2003; Van 
Raamsdonk et al. 2005).
A new model with human full length genomic huntingtin with 97 mixed 
CAA- CAG repeats has recently been generated using the bacterial artificial
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chromosome (BAC) transgenic approach. The BACHD model was designed with 
two LoxP sites to allow for Cre-mediated excision of exon 1 of mutant huntingtin, 
and as such it can be used as a conditional inactivation model. The BACHD mice 
exhibit progressive motor deficits and selective late-onset neuropathology. There 
is no somatic polyglutamine repeat instability in these mice due to the 
interruptions of the CAG repeat (Gray et al. 2008).
1.8.4 Knock-in mouse models of HD
Knock-in mouse models are considered a better genetic representation of 
the human disease than the transgenic models because the mutation is framed in 
a homologous genomic context to that in humans. On the other hand, the 
presence of a mild, or the total absence of an overt phenotype has initially 
severely reduced their value in research, but closer examination and the 
development of more sensitive tests have revealed an early though subtle 
phenotype.
The introduction of 72 and 80 CAG repeats into the murine Hdh gene 
generated two HD mouse models which, apart from increased male aggression, 
developed no overt phenotype during their lifetime. However, analysis of the 
mutation showed significant germline instability (Shelbourne etal. 1999).
The Hdh092 knock-in mouse model
To investigate this length-dependent inter-generational instability of the HD 
gene, single CAG tracts of 18, 48, 90 and 111 repeats were inserted in exon 1 of 
the Hdh gene, creating four new mouse lines. The increasing number of repeats 
correlated with an increase in repeat instability. Although none of these animals
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displayed a clear behavioural phenotype (Wheeler et al. 1999), the Hdh092 and 
Hdh0111 mice presented with progressive nuclear relocation of the expanded 
huntingtin protein in MSN in the striatum, starting at 1.5 months in HdhQU1 and at
2.5 months in HdhQ92 transgenic mice. Subsequent aggregation of mutant 
huntingtin took place around 10 months in HdhQU1 and around 12 months in 
Hdh092 mice (Wheeler et al. 2000). Further study, however, detected inclusions as 
early as 5 months in Hdhw 1 mice (Wheeler et al. 2002). A similar course of 
events was observed in the Hdh092 colony used in the present study (Bayram- 
Weston, unpublished results).
Further to the original studies by Wheeler et al. (1999, 2000, 2002), 
additional characterisation of these mouse models was carried out to assess their 
value as a model for HD. In the light of this study, only the emerging picture of the 
Hdh092 will be detailed. Tests with increased sensitivity revealed a mild 
behavioural phenotype without the conventional motor deficit, but with an implicit 
learning deficit at 4 months and an impairment in response selection from 5 
months of age (Trueman et al. 2007; Trueman et al. 2008). Molecular and 
neuropathological changes were detected from as early as 5 months. Hdh0921092 
demonstrated a time-specific change in striatal physiology, in the form of a 
supersensitivity to Ca2+, at the age of 5 months, but this had disappeared by the 
time the animals were a year old (Brustovetsky et al. 2005). Long-term 
potentiation was impaired in the hippocampus at 6 months (Lynch et al. 2007). 
Gene expression studies revealed an increase in Rrs1 mRNA, encoding a 
ribosomal protein, in 8.5 month Hdh092 (Fossale et al. 2002) and significant gene 
expression changes in the striatum at 18 months, but not at 3 months (Kuhn et al.
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2007). A summary of the disease characteristics of transgenic HdhQ92, with the 
earliest timepoints at which these present, is shown in Figure 1.4 and Table 1.3.
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Figure 1.4 Timeline of disease development in the HdhQ92 mouse model. The diagram 
shows the earliest timepoints at which different aspects of the behavioural, molecular and 
neuropathological phenotypes have been detected.
Table 1.3 Summary of disease development in the Hdh092 mouse model.
BEHAVIOURAL PHENOTYPE Earliesttimepoint
References
no behavioural phenotype Wheeler et al. , 1999 and 2000
sensitive tests show implicit learning 
deficit
4 months Trueman et al. , 2007
impairment in response selection 5 months Trueman et al. , 2008
MOLECULAR PHENOTYPE
gametic instability jWheeler et al. , 1999
nuclear localisation of mutant 
huntingtin in medium spiny neurons 
in striatum
5 months Wheeler et al. , 2000
Nils, initially in dorsal caudate and 
olfactory tubercle
5 months Wheeler et al. , 2000; Trueman et al. , 2008; 
Bay ram-Weston, unpublished
long-term potentiation impaired in 
hippocampus
6 months Lynch et al. , 2007
increased Rrs1 mRNA 8.5 months Fossale et al. , 2002
significant gene expression changes 
in striatum
18 months Kuhn et al. , 2007
NEUROPATHOLOGY
striatal supersensitivity to calcium 5 months Brustovetsky et al. , 2005
The table lists the earliest timepoints at which different aspects of the behavioural, 
molecular and neuropathological phenotypes have been detected.
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The Hdh0150 knock-in mouse model
In order to create a mouse model that displayed a disease phenotype 
without overexpressing the mutant HD gene, the short murine CAG repeat was 
replaced by 80 and 150 CAG repeats. HdhQm,+ mice showed no behavioural 
phenotype. HdhQ150/+ developed the symptoms of late-onset HD, such as motor 
deficits, gait abnormalities and decreased activity by 40 weeks of age, while 
^^oism iso  S played this phenotype as early as 15 weeks. HdhQ150/+ were 
susceptible to seizures and suffered weight loss from 25 weeks. No major cell 
death was observed, but 40 week old HdhQ150/+ presented with reactive gliosis in 
the striatum and Nils in some brain regions (Lin et al. 2001).
The behavioural phenotype described in knock-in Hdh0150 by Lin et al. 
(2001) proved difficult to substantiate in subsequent studies. Except for a 
decreased grip strength at 10 months, no phenotype could be detected before 12 
months of age, only some behavioural changes by 15 months, and motor deficit 
no earlier than 18 months (Woodman et al. 2007). Another study confirmed the 
difference between HdhQ150/'* and Hdh0150/0150. While HdhQ150/Q15°  showed 
reduced activity, hindleg clasping and weight loss at 16 months and resting 
tremor, unsteady movements, gait abnormalities and motor impairment by 23 
months, HdhQ150/+ displayed very little phenotype (Heng et al. 2007). Hdh0150/0150 
even displayed cognitive and memory deficits as early as six months (Brooks et 
al. 2006). The relatively early presentation of aggregates was confirmed in 
subsequent studies, with nuclear localisation of mutant huntingtin and aggregates 
as early as 6 months in the striatum and later in other brain regions (Tallaksen- 
Greene et al. 2005; Woodman et al. 2007).
59
Gene expression changes were detected in the striatum and cerebellum 
from the age of 22 months, but not at 15 months, and in the cortex by 22 months 
(Kuhn etal. 2007; Woodman et al. 2007). In skeletal muscle ot Hdh0150/0150, gene 
expression was already dysregulated by 6 months (Strand et al. 2005). The 
distinction between Hdh0150/0150 and Hdh0150/+ was again demonstrated when 
alterations in Di and D2 receptor binding was found in Hdh0150/0150 at 16 months, 
but not before 23 months in Hdh0150/+ (Heng et al. 2007).
A neuropathological phenotype with reactive gliosis and degenerating 
neurons was observed from 14 months of age and a substantial reduction in the 
number of striatal neurons and in striatal volume by 23 months (Yu et al. 2003; 
Heng et al. 2007). Impaired mitochondrial trafficking through association with N- 
terminal mutant huntingtin was first observed at three months (Orr et al. 2008). A 
summary of the disease characteristics of knock-in Hdh0150 mice, with the earliest 
timepoints at which these present, is shown in Figure 1.5 and Table 1.4.
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Figure 1.5 Timeline of disease development in the HdhQ150 mouse model. The diagram 
shows the earliest timepoints at which different aspects of the behavioural, molecular and 
neuropathological phenotypes have been detected.
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Table 1.4 Summary of disease development in the Hdh0150 mouse model.
BEHAVIOURAL PHENOTYPE Earliesttimepoint References
diabetes in homozygotes 3 months Strand et a l., 2005
motor deficits in homozygotes 15 weeks Lin et a l., 2001; Woodman etal., 2007; Heng etal., 2007
gait abnormalities in homozygotes 15 weeks Lin et al., 2001; Heng etal., 2007
seizure susceptibility 25 weeks Lin etal., 2001
weight loss 25 weeks Lin et al., 2001; Woodman et al, 2007; Heng etal., 2007
cognitive deficit 6 months Brooks et a l., 2006
memory deficit 6 months Brooks et a l., 2006
behavioural changes 15 months Woodman et a l., 2007; Heng etal., 2007
MOLECULAR PHENOTYPE
N-terminal mutant huntingtin 
associates with mitochondria, 
impairing mitochondrial trafficking
3 months Orretal., 2008
gene expression changes in skeletal 
muscle in homozygotes 6 months Strand et a l., 2005
aggregates in striatum and 
hippocampus 6 months Woodman et al., 2007
aggregates in most brain regions 10 months Woodman et al., 2007
Nils striatum, earlier in homozygotes 40 weeks Lin et al., 2001; Yu et a l., 2003; Tallaksen- Greene et al., 2005
Nils in some layers of the cortex 75 weeks Tallaksen-Greene et al., 2005
gene expression changes in striatum 
and cerebellum 18 months Woodman etal., 2007; Kuhn e ta l., 2007
widespread Nils 100 weeks Tallaksen-Greene e ta l., 2005
chaperones decreased in cortex 22 months Woodman et a l., 2007
NEUROPATHOLOGY
reactive gliosis 14 months Lin et al., 2001; Yu et a l., 2003
neuronal degeneration 14 months Yu et a l., 2003; Heng et a l., 2007
reduced striatal neuron numbers 100 weeks Heng et a l., 2007
reduced striatal volume 100 weeks Heng et a l., 2007
The table lists the earliest timepoints at which different aspects of the behavioural, 
molecular and neuropathological phenotypes have been detected.
Other knock-in mouse models
Two knock-in mouse models have been established by exchanging the 
mouse HD exon 1 by a mouse/human chimeric exon 1 with an expanded repeat. 
The first contained 94 CAG repeats (Levine et al. 1999) and developed a biphasic 
behavioural phenotype some time before aggregates and Nils were detected 
(Menalled et al. 2002). The second model with 140 CAG repeats displayed a
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similar biphasic behavioural phenotype as the Hdh094, but with an earlier onset. 
Again, neuropathological features followed behavioural symptoms by several 
months (Menalled et al. 2003).
1.8.5 A conditional mouse model of HD
A conditional mouse model was developed using the tetracycline- 
regulatable system, with the bidirectional tetracycline responsive promoter flanked 
by a chimeric mouse/human exon 1 with 94 CAG repeats in one direction, and the 
P-galactosidase reporter in the other. Continuous expression of mutant huntingtin 
showed an early behavioural phenotype, followed by neuropathological changes. 
Shutting off expression of the transgene halted and even reversed the pathology 
(Yamamoto et al. 2000).
1.8.6 Advantages and disadvantages of genetic HD mouse models
The development of an animal model is not straightforward. The ultimate 
HD model should recapitulate the symptoms and the neuropathology of the 
human disease, as well as the genetic and molecular mechanisms that underlie 
the degenerative processes involved. For practical reasons, onset of the 
phenotype in this model should be early, with a measurable disease progression 
in a reasonable time frame. None of the mouse models available today fulfils all 
these requirements.
In transgenic mouse models (section 5.5.2 -  5.5.3), the full-length or 
truncated human mutant huntingtin gene is inserted randomly into the mouse 
genome, so three copies of the huntingtin gene, two mouse endogenous and one
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human mutant copy, are expressed. Because of this, transgenic mice are not 
considered an accurate representation of human HD in genetic terms. In addition, 
the expression of the mutant huntingtin gene in these animals is driven by various 
exogenous promoters, so expression may be significantly different from what it 
would be under the control of the endogenous mouse promoter, or of the human 
promoter in a human background. Moreover, it is uncertain what the consequence 
is of the integration of the mutant gene sequence in an indiscriminate part of the 
mouse genome, or whether this brings about a degree of pathology unrelated to 
HD. An additional issue with transgenic mouse models generated with truncated 
mutant huntingtin is that these fragments are synthetic and therefore may have 
different properties from the full length endogenous gene (Hersch & Ferrante 
2004). All transgenic mice develop some phenotypes relevant to the human 
disease, but none is a perfect match with the human pathology.
In knock-in mouse models (section 1.8.4), part of the mouse huntingtin 
gene is replaced by the mutant human copy with an expanded CAG region or an 
expanded CAG has been inserted into the mouse HD gene. This approach 
eliminates some of the concerns raised about the transgenic models, as the 
knock-in mice have only two copies of the huntingtin gene, the expression of 
which is driven by the endogenous mouse huntingtin promoter. For that reason, 
knock-in mouse models are considered the more accurate genetic model for HD. 
On the other hand, the lack of a strong phenotype, and the time the disease takes 
to develop in these animals, make these models less practical to use in research 
and in therapy driven studies.
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1.9 Aims of this study
While widespread changes in brain gene expression in both human HD 
brain and mouse models of HD have been described, there have been fewer 
studies of the equivalent changes in the brain proteome. The proteome in the 
brains of mouse models of HD was examined to complement ongoing studies of 
gene expression changes.
The specific aims were:-
1. To determine whether the patterns of protein expression in the brains of HD 
mice were altered in a concerted and specific fashion in comparison with their 
wild-type littermates, by means of two complementary proteomic techniques:
>  Surface-Enhanced Laser Desorption Ionization - Time Of Flight (SELDI- 
TOF);
> 2-D fluorescence Difference Gel Electrophoresis (DIGE).
2. To identify the changes observed with SELDI-TOF and DIGE by MALDI 
TOF/TOF ananlysis.
3. To confirm the changes observed with SELDI-TOF and DIGE, for some of the 
proteins identified by MALDI TOF/TOF, by western blot analysis.
4. To compare the changes in protein levels observed with changes in gene 
expression known to occur in human HD and genetic mouse models of HD.
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Chapter 2. Materials and methods
2.1 Materials
2.1.1 Chemicals
CHAPS, HCI and KCI were supplied by BDH Biochemical Laboratories, 
Poole, UK. Glycerol, Glycine, Acetic acid, Ethanol, Methanol, Tris base, Na2HP04 , 
NaCI and Trifluoroacetic acid were supplied by Fisher Scientific UK Ltd., 
Loughborough, UK. Tween 20, Antifoam A, Ammonium acetate, CAPS, Lysine 
and DTT were supplied by Sigma-Aldrich, Gillingham, UK. Triton-x-100, 
Bromophenol blue, SDS, Tris-HCI, Agarose, lodoacetamide, Acrylamide, 
Bisacrylamide, Temed and APS were supplied by GE Healthcare, Giles, UK. 
Chemicals not listed will be specified elsewhere.
Sinapinic acid
Sinapinic acid (SPA) (Ciphergen Biosystems, Guildford, UK) was made up 
to a total volume of 400 pi of 50% acetonitrile (Acros Organics through Fisher,
UK) and 0.5% trifluoroacetic acid (TFA), vortexed for 5 min and left to settle for 5 
min.
2.1.2 Buffers
PBS and PBS-T
Phosphate Buffered Saline (PBS) was made up with 8.18 g/l NaCI, 0.2 g/l 
KCI, 1.43 g/l Na2HP04 and 0.24 g/l KH2PC>4 (Fisons Scientific Equipment,
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Loughborough, UK). Phosphate Buffered Saline -  Tween (PBS-T) was PBS with 
0.1% Tween 20.
Urea-thiourea lysis buffer
Urea-thiourea lysis buffer was made up with 7M Urea-Ultra Pure (MP 
Biomedicals, Cambridge, UK), 2M Thiourea-AnalaR (VWR International Lie., 
Lutterworth, UK), 2% w/v CHAPS and 4% v/v complete EDTA-free protease 
inhibitor cocktail (Roche Diagnostics Ltd., Burgess Hill, UK).
2.1.3 Gels for DIGE
Six 10% polyacrylamide gels of 1 mm were prepared simultaneously in the 
Ettan DALT six Gel Caster (GE Healthcare) between low fluorescing LF glass sets 
(GE Healthcare), with 150 ml 30% Acrylamide/0.8% Bisacrylamide, 113 ml 1.5 M 
Tris pH 8.8, 4.5 ml 10% SDS, 4.5 ml 10% APS and 77 pi TEMED in a total volume 
of 450 ml. They were covered with 0.1 % SDS solution and left to set for 5 h.
2.1.4 Animals
All the animals used in this study were bred in-house. The R6/1 colony is 
routinely maintained by outbreeding male R6/1 from the colony with B6CBA F1 
(isolator breed: offspring of a cross between C57BL/6JOIaHsd inbred female and 
the CBA/CaOlaHsd inbred male) from Harlan, Bicester, UK. In the experiments,
18 week old littermates, all male, were used. The Hdh092 colony was derived from 
HdhQ92/Q92 mice on a mixed 129SvEv/CD1 background strain (founders from JAX, 
Maine, USA), crossed in-house onto C57BL/6J for four generations. From these,
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HdhQ92/+ were mated and the HdhQ92/Q92 and their Hdh+/+ littermates used in the 
experiments. The 12 and 10 month old animals used in the experiments were all 
females. The 18 month old animals used in the experiments were a combination 
of five female and one male wild types against three female and three male 
homozygotes. The Hdh0150 mice were bred in-house on the original C57BL/6J x 
129 background (Lin et al. 2001), and again HdhQ150/+ were mated and the 
Hdh0150/0150 and their Hdh+/+ littermates used in the experiments. The 15 and 10 
month old animals used in the experiments were all female, the 3 and 4 month old 
animals were all male and the 18 month old animals used in the experiments were 
a combination of three female and six male wild types against five female and four 
male homozygotes in the SELDI experiment and two female and four male wild 
types against three female and three male homozygotes in the DIGE experiment.
All animals were housed with three or four per cage, on sawdust flooring 
and enriched with a cardboard tube. Animals had access to food and water ad 
libitum.
At the chosen timepoints, animals were killed by cervical dislocation. 
Subsequent procedures were different between cohorts. For some, the brain was 
snap frozen in liquid nitrogen and stored at -80 °C before being defrosted for 
either micro-dissection or protein extraction. For others, micro-dissection was 
performed immediately, followed by protein extraction, or brain regions were snap 
frozen in liquid nitrogen and stored at -80 °C before being defrosted for protein 
extraction. The exact course of action for the different cohorts is listed in table 2.1. 
Micro-dissection was carried out by Dr. S. Brooks, School of Biological Sciences, 
Cardiff University. All procedures were carried out in accordance with the 
requirements of the United Kingdom Animals Scientific Procedures Act 1986.
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Table 2.1 Successive steps from brain to protein sample.
Mouse model Timepoint
successive steps from brain to protein sample
snap
frozen
micro­
dissection
snap
frozen
protein
extraction
frozen
-80°C
R6/1 18 weeks
HdhQ92
18 months
12 months
10 months
Hdh0150
18 months
15 months
10 months
3+4 months
Snap freezing whole and microdissected brain tissue was done in liquid nitrogen. Gray fill 
indicates that a particular step was performed.
2.1.5 Antibodies
Primary antibody Mouse monoclonal anti-COX (cytochrome c oxidase) Vlb 
(A21366) and Rabbit anti-Calmodulin (61-8500) were purchased from Invitrogen, 
Paisley, UK. Primary antibody Rabbit polyclonal anti-Myelin Basic Protein (MBP) 
(AB980) was purchased from Chemicon-Millipore, Watford, UK. All other 
commercial primary antibodies were purchased from Abeam, Cambridge, UK: 
Rabbit polyclonal to Cnp 10 (ab53106), Rabbit polyclonal to Calcineurin A 
(ab3673), Rabbit polyclonal to Creatine Kinase BB (ab38211), Rabbit polyclonal 
to Glutamine Synthetase (ab49873), Mouse monoclonal [2A1] to Superoxide 
Dismutase 2 (ab16956), Rabbit monoclonal [EP1374Y] to Apolipoprotein E 
(ab52607) and Rabbit polyclonal to Hsp60 (ab46798). Primary antibody against a- 
tubulin was produced in-house from the I2G10 hybridoma (Iowa Hybridoma Cell 
Bank, Iowa, USA) following standard procedures. Secondary antibody raised 
against mouse IR Dye 800 anti-mouse was purchased from Lome Laboratories, 
Reading, UK. Secondary antibody raised against rabbit Alexa Fluora 680 goat 
anti-rabbit IgG was purchased from Invitrogen.
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2.2 Methods
2.2.1 Sample homogenisation and quantitation 
Homogenate of half cerebra
Cerebral halves were divided into three parts, weighing 60-100 mg each. 
Each part was homogenised in 1 ml of ice cold Urea-Thiourea Lysis Buffer with 1 
pi of Antifoam-A in a pre-chilled Lysing Matrix D tube (Q-BIOgene, Cambridge, 
UK). The tubes were shaken in a Thermo Savant FastPrep (Thermo Scientific, 
Basingstoke, UK) for 15 sec at speed-setting 4.0 and then centrifuged in a Fresco 
Biofuge (Kendro Laboratories Products Pic., Bishops Stortford, UK) at 2,000 rpm 
for 1 min at 4 °C. The homogenate of all tubes was combined and split in 1.5 ml 
Eppendorf tubes (» 750 pl/tube).These were centrifuged in the Fresco Biofuge at 
13,000 rpm for 1 h at 4 °C. Homogenate was frozen in 50 pi aliquots at -80 °C.
Homogenate of microdissected brain regions 
The complete microdissected brain tissue was put in 300 pi of ice cold 
Urea-Thiourea Lysis Buffer and 1 pi of Antifoam-A in a pre-chilled 0.5 ml 
microtube (Bioquote Ltd., York, UK) filled with 0.5 g of Lysing Matrix D (Q- 
BlOgene). The tube was shaken in the FastPrep machine for 15 sec at speed- 
setting 4.0 and centrifuged in the Fresco Biofuge at 2,000 rpm for 1 min at 4 °C. 
The homogenate was transferred to a clean 1.5 ml Eppendorf tube and 
centrifuged in the Fresco Biofuge at 13,000 rpm for 1 h at 4 °C. The homogenate 
was frozen in 50 pi aliquots at -80 °C.
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Quantitation of protein homogenate
Protein concentration was assayed with the Bradford assay (Bradford
1976).
2.2.2 All-in-1 Protein Standard II Calibration Chip
2 pi of reconstituted All-in-1 Protein Standard II (Ciphergen Biosystems) 
was mixed with 8 pi of sinapinic acid (SPA) (Ciphergen Biosystems). Each spot of 
an NP20 protein chip (Ciphergen Biosystems) was washed with 3 pi of dH20  and 
blotted dry without touching the spots. 1 pi of the SPA/AII-in-1 mix was placed on 
each spot and air dried.
2.2.3 2-D Clean-up
The 2-D Clean-Up Kit from GE Healthcare was used following the 
manufacturer’s instructions. The protocol has Enhanced Procedure A for sample 
volumes of 1-100 pi containing 1-100 pg of protein, and Enhanced Procedure B 
for larger samples with more than 100 pg of protein. Both procedures were used.
2.2.4 Protein fractionation
Protein samples were fractionated in SC1000 SigmaPrep spin columns 
(Sigma) with polymeric reversed phase media PLRP-S (Polymer Laboratories 
Ltd., Church Stretton, UK). 50 pi of sample (250-500 pg protein) was made up to 
200 pi of 10% ACN and 0.5% TFA. The initial volume could vary when starting 
with a pellet from 2-D clean-up, but was always made up to a final volume of 200
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jliI. 100 pi of polymeric reversed phase beads were suspended in 300 pi of 50% 
ACN. The spin column was washed with 300 pi of 50% ACN and spun at 2,000 
rpm for 15 sec to remove the wash. The suspended beads were added to the spin 
column, mixed on the rotator for 1 min, and spun at 2,000 rpm for 15 sec. The 
flow-through was discarded. The spin column containing the beads was washed a 
number of times for 1 min on the rotator, followed by a 15 sec spin at 2,000 rpm: 
two washes with 300 pi of 50% ACN, four washes with 300 pi of 10% ACN and 
two washes with 300 pi of 10% ACN+0.1% TFA. Finally 100 pi of 10% ACN+0.1% 
TFA was added and the column vortexed at setting 1000 for 1 min. The 200 pi of 
prepared sample was now added to the spin column containing the beads, mixed 
on the rotator for 30 min and centrifuged at 2,000 rpm for 15 sec. The fractions 
obtained were the flow-through, followed by fractions obtained by increasing 
concentrations of ACN in 300 pi (10%, 20%, 30%, 40%, 50%, 60% and 80%), 
each mixed on the rotator for 10 min and centrifuged at 2,000 rpm for 15 sec. The 
fractions were kept at -20 °C for short-term storage and at -80 °C for long-term 
storage.
2.2.5 Isoelectric focusing of proteins
Isoelectric focusing of proteins for 2-DE using NuPage mini-gels
A 7 cm 3-10NL IPG strip (GE Healthcare) was rehydrated overnight in 125 
pi rehydration buffer (7 M Urea, 2 M Thiourea, 2% w/v CHAPS, 0.008% w/v 
Bromophenol blue, 1.6% strip specific IPG buffer (GE Healthcare) and 50 mM 
DTT), covered with 0.5 ml of DryStrip Cover Fluid (GE Healthcare). Isoelectric 
focusing (IEF) was performed on the Ettan IPGPhor3 platform (GE Healthcare). 
Samples were loaded on the rehydrated focusing strips by means of loading cups
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and focused overnight at 20 °C under the conditions listed in table 2.2. The 
following morning the IEF strips were equilibrated, first with 5 ml of reducing 
solution (10% of 10X NuPAGE Sample Reducing agent and 90% of 1X NuPAGE 
LDS Sample Buffer, both from Invitrogen) and next with 5ml of alkylating solution 
(2.32% w/v iodoacetamide in 1X NuPAGE LDS Sample Buffer). Both equilibration 
steps were performed for 15 min whilst gently rocking.
Table 2.2 Isoelectric focusing conditions.
50 pA per strip
Voltage (V) Time (h)
1. Step and hold 500 1
2. Gradient 1,000 2
4. Step and hold 1,000 1
5. Gradient 8,000 2
6. Step and hold 8,000 8
Samples were focused overnight on 7 cm 3-1ONL IPG strips on the IPGphor platform.
Isoelectric focusing of proteins for 2-DE using large gels 
A 24 cm 3-1 ONL IPG strip (GE Healthcare) was rehydrated overnight in 
450 jliI rehydration buffer (7 M Urea, 2 M Thiourea, 4% w/v CHAPS, 0.005% w/v 
Bromophenol blue, 0.5% strip specific IPG buffer and 20 mM DTT), covered with 
4 ml of DryStrip Cover Fluid. Isoelectric focusing (IEF) was performed on the 
Ettan IPGPhor3 platform. Samples were loaded on the rehydrated focusing strips 
by means of loading cups and focused overnight under the conditions listed in 
table 2.3. The next morning, the IEF trips were equilibrated, first with 15 ml of DTT 
equilibration buffer (50 mM Tris-HCI pH 8.8, 6 M Urea, 2% w/v SDS, 30% v/v 
Glycerol, 0.002% w/v Bromophenol blue and 1% w/v DTT) and next with 15 ml of 
IAA equilibration buffer (50 mM Tris-HCI pH 8.8, 6 M Urea, 2% w/v SDS, 30% v/v
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Glycerol, 0.002% w/v Bromophenol blue and 2.5% w/v IAA). Both equilibration 
steps were performed for 15 min whilst gently rocking. Focusing of protein 
samples for DIGE analysis was performed in the dark.
Table 2.3 Isoelectric focusing conditions.
Voltage (V) Time (h) kVh
1. Step and hold 500 1 0.5
2. Gradient 1,000 7 5.2
3. Gradient 10,000 3 16.5
4. Step and hold 10,000 4 40
5. Gradient 500 1 5.2
6. Step and hold 500 6 30
Samples were focused overnight on 24 cm 3-1 ONL IPG strips on the IPGphor platform.
2.2.6 SDS-PAGE
SDS-PAGE of protein fractions on NuPage mini-gels
Protein fractions were dried in the Speedvac, on manual setting at 43 °C 
for 40 min initially. Then they were checked every 10 min and the Eppendorf tube 
closed when a fraction was dry. The fractions were separated on polyacrylamide 
mini-gels with the XCell SureLock Mini-Cell system (Invitrogen). The pellets were 
resuspended in 20 pi 2xLDS sample buffer, provided with Invitrogen’s gel system, 
and heated on the Thermomixer Comfort (Eppendorf UK, Cambridge, UK) at 80 
°C for 10 min. The fractions were loaded onto a 12% Bis-Tris NuPage gel with 10 
pi of Seeblue Plus-2 Pre-Stained Standard (Invitrogen) in the outer lane. SDS- 
PAGE was carried out in MES running buffer (Invitrogen) under non-reducing 
conditions at 200 V until the 4 kDa marker reached a point %  down the gel.
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SDS-PAGE of proteins on NuPage mini-gels for western blotting 
SDS-PAGE was performed with the XCell SureLock Mini-Cell system. 
Unless otherwise specified, all pre-cast gels, buffers and chemicals were provided 
by Invitrogen. Depending on the size of the protein, samples were run on 10% or 
12% Bis-Tris NuPage gels. Samples were prepared with 20-50 pg of protein to a 
total concentration of 25% LDS Sample Buffer (x4) and 10% Sample Reducing 
Agent (x10). Samples were vortexed and heated to 70 °C for 10 min. SDS-PAGE 
on 10% gels was carried out in MES running buffer and in MOPS running buffer 
for 12% gels, with 500 pi of anti-oxidant, at 150V until the dye front reached the 
bottom of the gel.
SDS-PAGE of proteins in the second dimension of 2DE on mini-gels 
SDS-PAGE was carried out with the XCell SureLock Mini-Cell system. All 
gels and buffers were provided by Invitrogen. The focused IEF strip (section 2.2.5) 
was applied to a 1 mm NuPAGE 4-12% Bis-Tris Zoom Gel and SDS-PAGE was 
carried out in 1X MOPS running buffer at 200V for approximately 50 min, until the 
dye front reached the bottom of the gel.
SDS-PAGE of proteins in the second dimension of 2DE on large gels 
The focused IEF strip (section 2.2.5) was applied to the gel (section 2.1.3) 
and sealed with 200 pi agarose sealing solution (250 mM Tris, 1.92 M Glycine,
1% w/v SDS and 0.5% Agarose). SDS-PAGE was carried out with up to six gels 
simultaneously in the Ettan DALT six electrophoresis unit (GE Healthcare), in 
chilled anodic 1 x SDS electrophoresis buffer (250 mM Tris, 1.92 M Glycine and 
1% w/v SDS) in the lower chamber and cathodic 2 x SDS electrophoresis buffer in
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the upper chamber. The run was carried out overnight at 12 °C, 10 mA/gel and 80 
V for 1 h, followed by 14-16 h at 12 mA/gel and 150 V until the dye front reached 
the bottom of the gel. SDS-PAGE of DIGE gels was carried out in the dark.
2.2.7 Staining gels
Staining NuPage mini-gels with Colloidal Blue 
NuPage gels were stained in a glass dish which had been cleaned with 
detergent, ethanol and methanol, and air dried. The Colloidal Blue Staining Kit 
from Invitrogen was used, following the manufacturer’s instructions.
Silver staining of proteins on NuPage mini-gels 
NuPage mini-gels were stained in a glass dish which had been cleaned 
with detergent, ethanol and methanol, and air dried. The SilverQuest Silver 
Staining Kit from Invitrogen was used, as this is compatible with mass 
spectrometry, following the manufacturer’s instructions.
Silver staining of proteins on large 2DE gels 
Silver staining of proteins on large 2DE gels was automated in the 
Processor Plus with the PlusOne Protein Staining Kit, both from GE Healthcare. 
The gel was placed in 250 ml of fixative (10% v/v acetic acid and 40% v/v ethanol) 
for 30 min, then in 250 ml of sensitizer (30% v/v ethanol, 4% v/v Na-thiosulphate 
5% w/v stock and 6.8% w/v Na-acetate) for 30 min, followed by three washes in 
250 ml dH20  for 5 min each. The gel was stained in 250 ml silver stain (10% v/v 
silver nitrate 2.5% w/v stock) for 20 min, followed by two washes in 250 ml dH20  
for 1 min each. The gel was then placed in 250 ml developer (2.5% w/v Na-
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carbonate and 0.4% v/v formaldehyde 37% w/v stock) for up to 10 min. When the 
gel was sufficiently stained, the staining process was stopped with 250 ml of stop 
solution (1.46% w/v EDTA) for 10 min, followed by three washes in 250 ml dH20  
for 5 min each. The gel was preserved in 1% acetic acid.
2.2.8 Collecting gel plugs from gels
Gel plugs were collected from NuPage mini-gels and DIGE gels using a 
spot picker 1.5 mm diameter One Touch Plus, with spot picker tips One Touch 
Plus 1.5 mm, both from Web Scientific Ltd., Crewe, UK. To avoid contamination, a 
glass screen was placed between the gel and the operator.
2.2.9 Western blotting
Blotting paper (Schleicher and Schuell, London, UK) and sponge pads 
(Invitrogen) were soaked in transfer buffer (Invitrogen), made up to a final 
concentration of 10% methanol. The PVDF Immobilon-P membrane (Millipore, 
Watford, UK) was first soaked in methanol for 15 sec, washed in dH20  for 2 min 
and left in transfer buffer until used. Protein transfer was achieved by applying 30 
V for 1 h.
Blots were dismantled and membranes blocked with 200 ml of 5% milk 
(Marvel) in PBS-T for 1 h. Next, membranes were incubated in primary antibody in 
10 ml PBS-T + 5% milk in 50 ml Falcon tubes (Greiner Bio-One, Stonehouse, UK) 
on the spiramix (Thermo Electron Corporation, Rugby, UK) for 1 h. Primary 
antibody raised against a-tubulin was added to each incubation at a 1/50,000 
dilution, as previously optimised in the lab. Membranes were rinsed twice in the
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Falcon tubes with PBS-T, followed by one 15 min and two 5 min washes in 200 ml 
PBS-T. Membranes were then incubated in a 1/5,000 dilution of IR Dye 800 anti­
mouse secondary antibody (Lome Laboratories) for primary antibodies raised in 
mouse, and in a 1/5,000 dilution of Alexa Fluora 680 goat anti-rabbit IgG 
secondary antibody (Invitrogen) for primary antibodies raised in rabbit. This 
incubation was performed in 10 ml PBS-T + 5% milk in 50 ml Falcon tubes on the 
spiramix for 30 min in the dark. Membranes were rinsed twice in the Falcon tubes 
with PBS-T, followed by a 15 min and a 5 min wash in 200 ml PBS-T and a final 5 
min wash in 200 ml PBS in the dark.
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Chapter 3. Comparison of the proteome in brain tissue of HD mouse 
models using surface-enhanced laser desorption ionisation -  time of 
flight (SELDI-TOF) mass spectrometry
3.1 Introduction to SELDI-TOF
Surface-Enhanced Laser Desorption Ionisation -  Time Of Flight (SELDI- 
TOF) mass spectrometry, the Ciphergen ProteinChip system, was first described 
15 years ago (Hutchens & Yip 1993), and has since been used successfully in a 
variety of research projects: for protein expression profiling in schizophrenia (Mei 
et al. 2006), in the search for biomarkers in Alzheimer’s disease (Carrette et al. 
2003; Davidsson & Sjogren 2006), and in a large number of cancer research 
projects (Petricoin et al. 2002; Engwegen et al. 2006; Lee et al. 2006).
SELDI-TOF simplifies protein mixtures by separating them according to 
their chemical properties, before analysing them quantitatively using mass 
spectrometry. While the technique is able to detect proteins that are hard to 
visualise by other proteomic methods, such as 2D-gel electrophoresis, the 
detection limits of the system restrict the analysis to proteins of a molecular weight 
between 5-20 kDa, as it cannot detect the bulk of higher molecular weight cellular 
proteins. The SELDI system produces a linear chromatogram that is used to 
measure and compare the relative quantities of proteins over multiple samples.
In the present study, SELDI-TOF analysis was used to determine whether 
the patterns of protein expression in the brains of transgenic mice were altered in 
a concerted and specific fashion in comparison with their wild-type littermates.
The brain proteomes of three genetic mouse models of HD were analysed: the
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R6/1 line, (Mangiarini et al. 1996 and section 1.8.2), the Hdh092 line, (Wheeler et 
al. 1999 and section 1.8.4) and the Hdh0150 line (Lin etal., 2001 and section
1.8.4). This comparison therefore included one line with a human exon 1 
transgene (R6/1), one with a human exon 1 knocked into the mouse Hdh locus 
replacing mouse exon 1 (Hdh092), and one line with the full mouse Hdh gene with 
150 CAG repeats (Hdh0150) replacing the normal mouse seven CAG repeats at 
this locus. The pathology in the R6/1 mouse is widespread throughout the brain 
(section 1.8.2), and in this line half cerebra were used to generate samples for 
experimentation. The effect of the more specific pathology in the two knock-in 
lines was examined by using microdissected brain areas for analysis: caudate- 
putamen was used in both lines as this is known to be affected early and 
specifically in both these mouse lines (section 1.8.4) and in human brain (section
1.4). In addition, a comparison was made with other brain areas in the Hdh092 
model to see if the more restricted pathology in these regions was reflected in a 
more restricted pattern of proteome changes.
Protein peaks found to be differentially expressed by SELDI-TOF analysis 
were identified using Matrix Assisted Laser Desorption Ionisation Time-Of-Flight 
tandem (MALDI TOF/TOF) mass spectrometry.
3.2 Identification of differentially expressed proteins in HD mouse brain 
using SELDI-TOF
3.2.1 The SELDI-TOF procedure
An overview of the workflow for identifying differentially expressed proteins 
by SELDI-TOF is shown in Figure 3.1. SELDI-TOF works by simplifying protein
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mixtures using the intrinsic properties of the proteins, such as charge, size, 
hydrophobicity, metal affinity or specific biological affinities. Mixed protein samples 
are applied to spots on a ProteinChip array with a specific chromatographic 
surface, to selectively bind proteins in a protein mixture, based on the properties 
of the proteins. The coupling surface chemistry can be chemical (anionic, cationic, 
immobilized metal affinity, hydrophobic, normal phase) or biological (pre­
activated, antibody-antigen, receptor-ligand, DNA-protein). Energy Absorbing 
Molecules (EAM) are applied to each spot as well. EAM have a high molar 
absorptivity at laser wavelength and are responsible for converting laser energy to 
thermal energy, which facilitates desorption and ionisation of proteins in the 
sample. Commonly used EAM are CHCA (a-cyano-4-hydroxycinnamic acid), SPA 
(sinapinic acid) and EAM-1 (Ciphergen’s in house EAM). The EAM used in this 
study were SPA, as advised by Ciphergen, as it is suitable for matrix ions with a 
mass both higher and lower than 15 kDa. The EAM solubilise a large proportion of 
the proteins on the chip surface, which then co-crystallise with the EAM as the 
solution dries.
The ProteinChip arrays are read in the ProteinChip SELDI reader, which 
consists of a vacuum chamber in which the samples on the ProteinChip are eluted 
by laser desorption and ionisation. The EAM-protein crystals absorb the laser 
energy and instigate desorption and ionisation. A short electrical pulse sends the 
ions down the TOF-MS tube towards the detector. Protein measurement is based 
on the mass-to-charge ratio (m/z). The signal is processed by a converter and 
translated into a spectrum. The peak intensity on the y-axis indicates the relative 
abundance of the detected protein, while the m/z ratio, calculated by the time 
taken for the ions to reach the detector, is read on the x-axis.
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Figure 3.1 Workflow of the SELDI-TOF ProteinChip system.
A. Whole or microdissected mouse brain lysate was prepared in urea-thiourea lysis 
buffer.
B. Samples were applied to spots on a ProteinChip array, each with a specific 
chromatographic surface to bind selected proteins from the mixture, based on the intrinsic 
properties of the proteins. Up to 12 chips could be processed simultaneously in a 
bioprocessor.
C. Energy Absorbing Molecules (EAM) were applied to each spot. EAM convert laser 
energy to thermal energy, thus facilitating the desorption and ionisation of the proteins.
D. The ProteinChip is fed into the SELDI-TOF mass spectrometer, which consists of a 
vacuum chamber in which the samples are hit with a laser, causing desorption and 
ionisation of the proteins. The ions are projected down the TOF MS tube towards the 
detector. Protein mass is determined based on their mass-to-charge ratio (m/z). 
Reproduced from General Ciphergen seminar Microsoft PowerPoint presentation.
See next page
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E. a. The signal received from the detector is translated into a spectrum, 
showing relative abundance against m/z of the detected proteins, b. Individual 
peaks are identified and their relative abundance compared with that of the 
corresponding peaks on the other spectra, c. Statistical analysis by Student’s 
t-test gives a list of proteins which show a significant difference between the 
sample groups, d. Part of a spectrum zoomed in on masses 8100-8700. The 
stars indicate the peaks with p < 0.01. WT = wild type; T = transgenic.
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3.2.2 Mouse brain samples
Each experiment used the maximum number of biological replicates 
available and two technical replicates of each sample. All the samples were 
randomly distributed over the ProteinChip arrays, based on a randomised set-up 
generated by Microsoft Excel, as demonstrated in Tables 3.1 A and B.
The samples were homogenates from either half cerebra or micro­
dissected brain regions of HD mice and their wild type littermates. The mouse 
models studied were R6/1 (Mangiarini et al. 1996), Hdh092 (Wheeler et al. 1999) 
and Hdh0150 (Lin et al. 2001). For the Hdh092 and Hdh0150, only homozygous 
animals were used to compare with their wild type littermates. An overview of the 
experimental design can be found in Table 3.2.
Table 3.1 Random distribution of samples in an experiment.
Sample Model Genotype Age
CA-CP Hdh™2 WT 18 months
CB-CP Hdh™2 WT 18 months
CC-CP Hdh™2 HOM 18 months
CD-CP Hdh™2 HOM 18 months
CE-CP Hdh™2 HOM 18 months
CF-CP Hdh™2 HOM 18 months
CG-CP Hdh™2 HOM 18 months
CH-CP Hdh™2 HOM 18 months
CI-CP Hdh™2 WT 18 months
CJ-CP Hdh™2 WT 18 months
CK-CP Hdh™2 WT 18 months
CL-CP Hdh™2 WT 18 months
spot Chip 1 Chip 2 Chip 3
A CD-CP(2) CC-CP(2) CI-CP(2)
B CH-CP(1) CI-CP(1) CA-CP(2)
C CB-CP(2) CA-CP(1) CK-CP(1)
D CJ-CP(2) CK-CP(2) CJ-CP(1)
E CL-CP(2) CF-CP(1) CF-CP(2)
F CD-CP(1) CH-CP(2) CE-CP(2)
G CB-CP(1) CG-CP(2) CL-CP(1)
H CG-CP(1) CE-CP(1) CC-CP(1)
Table B
Table A
Table A lists the samples (CA-L refers to the individual; CP=caudate-putamen), the 
mouse model, genotype and age. Table B shows the random distribution of the samples 
in duplicate over three chips.
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Table 3.2 Experimental design of the ProteinChip experiments.
mouse model age brain tissue number samples gender samples ProteinChip type
R6/1 18 weeks whole brain 3 WT x3 T M CM10; Q10; IMAC-Cu
HdhQ92
18 months
caudate-putamen 6 WT x 6 HOM WT: 5 F + 1 M HOM:3 F + 3 M CM10; Q10
hippocampus 6 WT x 6 HOM WT: 5 F + 1 M HOM:3 F + 3 M CM10
cerebellum 6 WT x 5 HOM WT: 5 F + 1 M HOM:3 F + 2 M CM10
motor + prefrontal 
cortex 6 WT x 6 HOM
WT: 5 F + 1 M 
HOM:3 F + 3 M CM10
12 months caudate-putamen 5 WT x 5 HOM F CM10
10 months caudate-putamen 3 WT x 6 HOM F CM10
Hdh0150 18 months caudate-putamen 9 WT x 9 HOM
WT: 3 F + 6 M 
HOM:5 F + 4 M CM10
15 months caudate-putamen 3 WT x 5 HOM F CM10
The different mouse models are listed with the ages and brain tissues used, the number 
of transgenic (T) / homozygous (HOM) samples that were compared with their wild type 
(WT) littermates, indicating the gender of the samples (F=female; M=male), on the 
different ProteinChip arrays.
3.2.3 ProteinChip arrays
Table 3.2 gives an overview of the ProteinChip arrays used in the different 
experiments. The ProteinChip CM10 array incorporates a negatively charged 
carboxylate chemistry and acts as a weak cation exchanger. The surface of the 
ProteinChip binds proteins through positively charged residues, such as lysine, 
arginine and histidine, under low pH and low salt conditions.
The ProteinChip Q10 array incorporates a positively charged quaternary 
amine chemistry and acts as a strong anion exchanger. The surface of the 
ProteinChip binds proteins through negatively charged residues, such as aspartic 
acid and glutamic acid residues, under high pH and low salt conditions.
The ProteinChip IMAC-Cu array incorporates a nitrilotriacetic acid surface 
which chelates metal ions, in this case copper sulphate. The charged ProteinChip 
surface binds phosphorylated proteins and proteins with histidine, tryptophan and 
cysteine residues under high salt conditions and a pH 6.0-8.0.
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The ProteinChip NP20 array incorporates a silicon dioxide surface that 
binds proteins by hydrogen bonds through hydrophilic and charged residues on 
the protein surface. The binding conditions are determined by the buffer.
3.2.4 Preparation of ProteinChip arrays and samples for SELDI-TOF
All the ProteinChips used in one experiment were prepared in a 
bioprocessor, which can hold up to 12 ProteinChips in a 96-well format, as shown 
in Figure 3.2. The bioprocessor was washed in 1% Triton-x100 in PBS for 1-24 h. 
Protein samples were diluted to 2 mg/ml by adding appropriate volumes of urea- 
thiourea lysis buffer. The required number of CM10, Q10 or IMAC-Cu 
ProteinChips were placed in the bioprocessor.
Prior to equilibration, IMAC-Cu ProteinChip arrays were charged with 50 pi 
of 100 mM copper sulphate and incubated on the Micromix (Euro/DPC Ltd, 
Caernarfon, UK) (form 20; amplitude 5) for 5 min. Each well was rinsed with 150 
pi dhbO and incubated with 50 pi of 50 mM sodium acetate (pH 4.0) on the 
Micromix for 5 min to remove unbound copper. Each well was rinsed with 150 pi 
dH20  before the equilibration step with the binding buffer was performed.
The spots were equilibrated with 150 pi each of the appropriate binding 
buffer, an overview of which can be found in Table 3.3. The ProteinChips were 
incubated on the Micromix for 5 min. The buffer was removed and the 
equilibration step repeated. The samples were diluted 1/5.5 in the appropriate 
binding buffer to a total volume of 55 pi and applied to the spot. The wells were 
sealed with tape and incubated on the Micromix for 40 min at room temperature. 
To eliminate sample noise, non-specific binding proteins and buffer contaminants 
were washed away during three wash steps with 150 pi of appropriate wash buffer
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for 5 min each on the Micromix. A final wash was performed with 150 j jI  of 1 mM 
HEPES (pH 7.0), for 1 min on the Micromix. The bioprocessor was dismantled 
and the ProteinChips air dried. 1 pi of SPA solution was applied to the spots twice, 
each with an air dry time of 20 min.
Figure 3.2 Bioprocessor with up to 12 ProteinChip arrays in a 96-well format.
Table 3.3 ProteinChip arrays used in the present study.
Protein
Chip
Chromatographic
Surface
Protein
Selection
Binding
Conditions
Binding & 
Wash Buffer
Buffer
PH.
CM10 anionic surface cationic
exchanger
-low pH 
(pH<pl-1) 
-low salt
50mM
ammonium
acetate
pH 4.0
Q10 cationic surface anionic
exchanger
-high pH 
(pH>pl+1) 
-low salt
50mM CAPS pH 10.0
IMAC-
Cu
nitrilotriacetic acid 
+ 100mM copper 
sulphate
immobilized 
metal affinity 
capture
-pH 6-8 
-high salt
PBS pH 7.2
NP20 Si02 surface normal phase 
chip
buffer
conditions
dH20
8 6
3.2.5 Reading ProteinChip arrays
The ProteinChip data are time-of-flight measurements converted to mass 
measurements by the calibration equation. Before each experiment, the machine 
was re-calibrated with the All-in-1 Protein Standard II calibration ProteinChip 
(section 2 .2 .2).
Every new experiment needs an updated spot and chip protocol. Spot 
protocols hold the instructions for automatic data collection from a single spot, as 
shown in Figure 3.3. Most parameters, such as the optimised mass range, the 
acquisition settings and the detector sensitivity, were held constant for all the 
experiments. The laser intensity and warming positions varied between 
experiments, and were determined before data collection by manually reading 
chosen points on each spot of the ProteinChip. The laser intensity that generated 
the clearest spectra, with the highest peak no higher than 100 and the majority of 
the peaks ideally between 50-75, was chosen for automatic data collection. The 
warming position was always set at laser intensity +5, as advised by the supplier. 
Figure 3.4 shows an example of a ProteinChip protocol, which contains the 
instructions for automatic data collection from a series of spots on an array.
LOW MW SPOT PROTOCOL
1: Set high mass to 50000 Daltons, optimised from 3000 Daltons to 50000 Daltons.
2: Set starting laser intensity to 230.
3: Set starting detector sensitivity to 10.
4. Focus mass at 15000 Daltons.
5: Set data acquisition method to Seldi Quantitation
6: Set Seldi acquisition parameters 20. delta to 4. transients per to 10 ending position to 82.
7: Set warming positions with 2 shots at intensity 235 and Don't include warming shots.
8: Process sample.___________________________________________________________________
Figure 3.3 Spot protocol for automatic data collection from a single spot. Instructions 
indicated in red were held constant for all experiments. Laser intensity (2) varied and was 
determined by manually reading chosen points on each spot of a new ProteinChip before 
automatic data collection. Warming positions (7) were always set at laser intensity +5. 
The data from the warming shots were not included in the resulting spectra.
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Spot Spectrum Tag Spot Protocol
A Q150-EA-CP-unb Low MW
B Q150-EA-CP-10% Low MW
C Q150-EA-CP-20% Low MW
D Q150-EA-CP-30% Low MW
E Q150-EA-CP-40% Low MW
F Q150-EA-CP-50% Low MW
G Q150-EA-CP-60% Low MW
H Q150-EA-CP-80% Low MW
Figure 3.4 Chip protocol for automatic data collection from all spots on a ProteinChip. For 
each spot (A-H), the sample and the spot protocol are listed.
3.2.6 Analysis bv ProteinChip software: detecting peaks
The data collected by the ProteinChip reader for each spot is translated 
into a spectrum. An eight-spot ProteinChip gives eight spectra, one spectrum for 
each spot. To compensate for variations in sample loading, the spectra are 
normalised using the Total Ion Current method. This method calculates the 
average intensity for each spectrum by dividing the total ion current by the number 
of data points on that spectrum. The mean of all average intensities of all spectra 
gives the normalisation coefficient. For each spectrum, the normalisation 
coefficient is divided by the average intensity for that spectrum, which gives the 
normalisation factor. Finally, the intensity of each data point in a given spectrum is 
multiplied by the normalisation factor for that spectrum.
The m/z range used for normalisation in these experiments was 3,000- 
50,000 Da, which means that average intensities were calculated only within this 
range. The normalisation range of 3,000-50,000 Da was chosen because the 
initial goal was to screen for proteins within this band. However, the results of the 
early experiments demonstrated that only peaks under 20,000 Da were 
sufficiently consistent for comparison over multiple samples. Determining the size
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of peaks over 20,000 Da became increasingly inaccurate, so that it was often not 
feasible to identify the same peak in different spectra with sufficient certainty. In 
addition, the shapes of the peaks in this higher molecular weight range became 
somewhat amorphous and they eventually disappeared into the background 
noise. However, to standardise all the SELDI experiments, the original 
normalisation range of 3,000-50,000 Da was used throughout, although only 
peaks with a molecular weight less than 20,000 Da were taken into account.
ProteinChip Software 3.1, from Ciphergen Biosystems Inc., was used to 
detect the individual peaks, with the default settings. All the detected peaks were 
manually checked for accuracy and presence in all the spectra. When a peak was 
not present in some of the spectra, it was manually selected. However, when a 
peak appeared in less than 30% of the spectra, it was rejected for further analysis 
and manually de-selected.
3.2.7 Statistical analysis of detected peaks
The details of the aligned peaks of a selected spectrum can be found in the 
‘List substances’ window in the ProteinChip Software, shown in Figure 3.5. The 
mass and intensity data for all the peaks in each spectrum were used for 
statistical analysis in Microsoft Excel. The mass refers to the predicted masses of 
the proteins corresponding to the peaks and the intensity relates to the amount of 
that protein present in the sample.
The mass of each peak was averaged over all the spectra in an 
experiment. The intensities of the two technical replicates of each sample were 
also averaged. For each peak, a two-tailed student’s t-test with unequal variance 
was performed on the intensities of the biological replicates, testing the null
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hypothesis that there was no difference between HD and WT animals. As it was 
planned to confirm results by western blot analysis, the threshold chosen for 
exploratory significance was p < 0.1. For each peak with p < 0.1, the log2 fold 
change was calculated on the averaged intensities of HD and WT samples.
High: — -j Da Optimize: |~ ^ 3  *° F 3  Da Deflector: f~"
A
MZ M a8S=T TOP j Intensity MZ Area | TOP Area | SiH
--- 1 1037.98 1036.98 14.19 8.0774 52.47 0.3539 3.25
B 2 1052.75 1051.75 14.291 12.0298 108.38 0.7258 4.84
3 1066.96 1065.95 14.39' 11.6111 110.00 0.7319 | 4.661
4 1081.58 1080.57 14.48: 12.6644 113.19 0.7477 5.08
— 5 1097.93 1096.92 14.591 15.2163 149.59 0.9812 6.09
E 6 1115.71 1114.70 14.71; 10.4696 101.33 0.6585 4.19
- T 4-1 "iO H t 4  1 ftfti 4 4  4 A 4 C T 7 A  IO O Q A A*1
Figure 3.5 ‘List substances’ window in the ProteinChip Software. Details are given on all 
peaks of a selected spectrum. The red boxes indicate the data (Mass and Intensity) that 
was used for statistical analysis in Microsoft Excel.
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3.3 Optimisation of SELDI-TOF for mouse brain samples
3.3.1 Protein concentration
To determine the optimal protein concentration of mouse brain 
homogenate to use in experiments, a concentration range of an HdhQ92/+ half 
cerebra homogenate was run on a Q10 ProteinChip array. Figure 3.6 shows that, 
while a concentration of 2 mg/ml presented more peaks than the lower 
concentrations of 1 or 0.5 mg/ml, using the higher concentration of 4 mg/ml 
produced no more peaks and they were less well defined. It was concluded that 2 
mg/ml was the optimal protein concentration.
20
40
30
20
1 mg/ml
10
30
10.5 mg/ml
5 0 0 0 1 0 0 0 0 15 00 0 2 0 0 0 0
Figure 3.6 Spectra of four spots on a Q10 ProteinChip array in a protein concentration 
optimisation experiment. HdhQ92/+ half cerebra homogenate was used, at four different 
protein concentrations (4 mg/ml, 2 mg/ml, 1 mg/ml and 0.5 mg/ml).
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3.3.2 Homogenate volume
To determine the effect of different volumes of homogenate applied to the 
spots, three optimisation experiments were carried out. The first two used All-in-1 
Protein Standard II, provided by Ciphergen. All-in-1 Protein Standard II is a 
mixture of 7 proteins, used to calibrate the ProteinChip reader. The mixture 
consists of hirudin BHVK (6,964 Da), bovine cytochrome C (12,230 Da), equine 
myoglobin (16,951 Da), bovine carbonic anhydrase (29,023 Da), yeast enolase 
(46,671 Da), bovine albumin (66,433 Da) and bovine IgG (147,300 Da). Figure 3.7 
shows a representative spectrum of this standard.
Figure 3.8 shows the spectra of three spots on the first ProteinChip, with a 
1/50 and a 1/200 dilution of All-in-1 Protein Standard II in 50 pi of 50 mM CAPS 
buffer. EAM/AII-in-1 Protein Standard II mixture was used as a control. The 
spectra showed that a dilution factor of 1/50 or more was too high.
Figure 3.9 shows the spectra of five spots on the second ProteinChip, with 
a selection of different concentrations of All-in-1 Protein Standard II in different 
volumes of 50 mM CAPS buffer: 1/2.5 in 5 pi, 1/5 in 10 pi, 1/10 in 20 pi and 1/15 
in 30 pi. EAM/AII-in-1 Protein Standard II mixture was used as a control. The 
spectra showed that the sample dilution and the total volume have an effect on 
the reading and that a 1/5 dilution produced the highest and best defined peaks.
Figure 3.10 shows the spectra of three spots on the third ProteinChip, with 
a 1/10 dilution of Chicken Lysozyme in 50 pi, 100 pi and 200 pi of 50 mM CAPS 
buffer. The spectrum clearly showed that the total volume had an impact on the 
size and the shape of the peaks. Although increasing the volume gave stronger 
peaks, the shapes of the peaks became less defined. In combination with the
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previous experiments, it was decided that a total volume of 50 pi with a lower 
dilution factor of 1/5 would present the best defined spectra.
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Figure 3.7 Representative spectra for ProteinChip All-in-1 Protein Standard II.
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Figure 3.8 Spectra of three spots on a Q10 ProteinChip array in a sample volume 
optimisation experiment using different dilutions.
1. the spectrum of 1 pi of EAM/AII-in-1 Protein Standard II mix, used as control, 
shows the expected peaks;
2. the spectrum of 50 pi of 1/50 All-in-1 Protein Standard II in 50 mM CAPS buffer 
shows no peaks over the noise level.
3. the spectrum of 50 pi of 1/200 All-in-1 Protein Standard II in 50 mM CAPS buffer 
shows no peaks over the noise level.
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Figure 3.9 Spectra of five spots on a Q10 ProteinChip array in a sample volume 
optimisation experiment using different dilutions in different total volumes. On each spot, 
a different dilution of All-in-1 Protein Standard II in a different volume of 50 mM CAPS 
buffer was applied:
1. the spectrum of 1 pi of EAM/AII-in-1 Protein Standard II mix, used as control, 
shows the expected peaks;
2. spectrum of 5 pi of 1/2.5 All-in-1 Protein Standard II;
3. spectrum of 10 pi of 1/5 All-in-1 Protein Standard II;
4. spectrum of 20 pi of 1/10 All-in-1 Protein Standard II;
5. spectrum of 30 pi of 1/15 All-in-1 Protein Standard II.
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Figure 3.10 Spectra of three spots on a Q10 ProteinChip array in a sample volume 
optimisation experiment using the same dilution in different total volumes. A 1/10 dilution 
of Chicken Lysozyme in different volumes of 50 mM CAPS buffer was applied:
1. spectrum of 50 pi of 1/10 Chicken Lysozyme;
2. spectrum of 100 pi of 1/10 Chicken Lysozyme;
3. spectrum of 200 pi of 1/10 Chicken Lysozyme.
3.3.3 Binding and washing pH
To investigate the effect of pH on Q10 and CM 10 ProteinChip arrays, 
HdhQ92/+ half cerebra homogenate was applied to both ProteinChips, each spot 
pre-treated with a different buffer with different pH: 50 mM Ammonium Acetate 
(pH 4.0), 50 mM Tris/HCI (pH 6.0), 50 mM Tris (pH 8.0) and 50 mM CAPS (pH 
10.0). The spectra in Figure 3.11 show the importance of the pH for optimal 
protein binding on the different ProteinChips arrays. Protein binding was 
significantly increased on the anionic exchange Q10 ProteinChip under alkaline 
conditions (pH 10.0) (Figure 3.11 A), while the cationic exchange CM 10 
ProteinChip needed acidic conditions (pH 4.0) for optimal protein binding (Figure 
3.11B). Both sets of spectra put together illustrate the divergence between the 
two, demonstrating the different subset of proteins they select for. The strongest
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signal is generated under alkaline conditions on the Q10 ProteinChip and under 
acidic conditions on the CM 10 ProteinChip, as expected.
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Figure 3.11 Spectra of four spots on a Q10 (A) and CM 10 ProteinChip (B), each spot 
pre-treated with a different buffer.
1. 50 mM Ammonium Acetate (pH 4.0);
2. 50 mM Tris/HCI (pH 6.0);
3. 50 mM Tris (pH 8.0);
4. and 50 mM CAPS (pH 10.0).
3.3.4 Technical and biological replicates
The number of biological replicates was determined by the number of 
animals available. To assess the need for multiple technical replicates, eight 
technical replicates of an R6/1 half cerebra homogenate were assayed on a 
CM 10 ProteinChip array. From the spectra, 25 consecutive peaks with masses 
within the range of interest for this project were analysed for lot to lot 
reproducibility of peak intensity. The chart in Figure 3.12 shows the peak masses
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and the means of peak intensities, with the coefficient of variance ranging 
between 9-27%. As the aim of the project was to compare biological replicates, 
two technical replicates of each were considered adequate. This would allow 
samples with technical artifacts to be removed from the analysis, while limiting the 
cost and saving sample, which was already in short supply.
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Figure 3.12 The reproducibility of peak intensity on a CM10 ProteinChip array.
For 25 consecutive peak, the mean of peak intensity of eight technical replicates of an 
R6/1 half cerebra homogenate on a CM 10 ProteinChip was calculated. Blue error bars 
indicate the coefficient of variance for each of the means, ranging between 9-27%.
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3.4 Comparison of R6/1 and wild type mouse brain proteome
Homogenates of half cerebra of 18 week old R6/1 were examined using 
CM 10, Q10 and IMAC-Cu ProteinChip arrays. Table 3.4 lists the peaks which 
were significantly different between transgenic and WT animals (p <0.1).
The CM10 ProteinChips identified five peaks which were significantly 
different, corresponding to 11 % of the total number of peaks detected. Three of 
these were increased and two decreased in transgenic R6/1 brain compared with 
wild type. The magnitude of the changes ranged between 19-81%.
The Q10 ProteinChips showed fewer differences, with three of 46 (=7%) 
peaks significantly different, all of which were decreased in transgenic animals 
compared with wild type. The magnitude of the changes ranged between 27-64%, 
similar to the ones on the CM10 ProteinChips. Two of the three peaks were also 
detected and significant on the CM 10 ProteinChips.
The IMAC-Cu ProteinChips showed only one peak out of 20 with a 
significant difference. However, the total number of peaks detected on these chips 
was very low and less than half of the number on the CM 10 and Q10 
ProteinChips. It was also clear that the total number of peaks detected on any of 
the ProteinChips was well below that expected, based on previous experiments 
with similar samples (B. Hoogendoorn; personal communication).
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Table 3.4 Protein peaks shown to be changed in intensity in 18 month R6/1 mouse brain 
compared with controls.
mouse model R6/1
age 18 weeks
brain tissue half cerebra half cerebra half cerebra
ProteinChip CM10 Q10 IMAC-CU
total nr peaks 46 46 20
Av. Mass p-value log2 FC Av. Mass p-value log2 FC Av. Mass p-value log2 FC
6781 0.0159 -0.35 6919 0.0291 -0.53 5465 0.0362 -0.30
8567 0.0355 0.20 6717 0.0921 -0.64
6720 0.0375 -0.81 7648 0.0987 -0.27
6926 0.0756 -0.55
9079 0.0846 0.19
Protein peaks with a significant (p < 0.1) difference, detected by SELDI-TOF on CM10, 
Q10 and IMAC-Cu ProteinChip arrays. The lists show the average mass of the peaks with 
corresponding p-value, the log2 fold change (negative=decrease; positive=increase) and 
the total number of peaks detected. The red entries are the peaks found to be significant 
on more than one ProteinChip array.
3.5 Comparison of HdhQ92/Q92 and Hdh+/+ brain proteome
The HdhQ92/Q92 and Hdh+/+ animals compared were 18, 12 and 10 months 
old. The microdissected brain regions used were caudate-putamen (CP), 
hippocampus (HC), cerebellum (CB) and a combination of motor and prefrontal 
cortex (MC+PFC). The motor and prefrontal cortex were jointly homogenised 
because the prefrontal cortex alone gave a homogenate with a protein 
concentration below 2 mg/ml, the minimum needed to load the ProteinChips.
Initially, 18 month HdhQ92/Q92 and Hdh+/+were analysed on both CM10 and 
Q10 ProteinChip arrays. However, the results (Table 3.5) showed the same trend 
as in the R6/1 experiment, with more peaks detected and more significant results 
with CM10 than with Q10 arrays. Because of the cost of the ProteinChips, it was 
decided to use only CM10 chips in future, and screen more brain regions as well 
as a different mouse model (HdhQ15°). On the CM10 ProteinChips, a substantial
99
proportion of the protein peaks showed a significant difference in the caudate- 
putamen of the 18 month animals: 17 of 94 peaks (=18%), eight increased and 
nine decreased. The magnitude of the changes ranged between 21-114%, with 
some slightly larger changes than in the R6/1 experiments.
Caudate-putamen of 18, 12 and 10 month HdhQ92/Q92 and Hdh+/+ was 
compared on CM 10 ProteinChips. A substantial proportion of the peaks were 
significantly different at all ages, this only being marginally lower in the younger 
animals: 18% of peaks differed at 18 months, 14% at 12 months and 13% at 10 
months (Table 3.6). At 10 months, half of these peaks were increased and half 
decreased. At 12 months, all peaks apart from one were decreased. The 
magnitude of the changes was larger in the older animals, with a maximum 
change of 114% at 18 months, 77% at 12 months and 60% at 10 months.
Peaks in different spectra are considered to correspond when their m/z 
ratios lie close together and when, upon comparison of the spectra, the shapes of 
the peaks and of the areas around the peaks are similar. Of the 17 significant 
peaks at 18 months, seven were likely to be the same as those significant at one 
of the previous timepoints, all but one showing the same directional change. The 
trace view of this seemingly ambiguous peak indicated however that this was 
indeed likely to be the same peak at both timepoints. None of the peaks appeared 
to be significant at all three timepoints.
Table 3.7 shows the results of a comparison between different brain 
regions in 18 month HdhQ92/Q92 and Hdh+/+ on CM 10 ProteinChip arrays. The high 
level of differences in the caudate-putamen (18%) was not observed in the other 
regions. The hippocampus and cortex showed a few differences, respectively four 
(5%) and three (4%), while there was only one change in the cerebellum. The
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magnitude of the changes in these regions was considerably smaller than in the 
caudate-putamen, with a maximum change of 38% in the cortex, 26% in the 
hippocampus and 23% in the cerebellum against 114 % in the caudate-putamen. 
Only one peak appeared to be different in more than one region, showing a 
change in the same direction but larger in the caudate-putamen (57%) than in the 
cortex (38%).
Table 3.5 Evaluation of the CM10 and Q10 ProteinChip arrays for comparing the 
caudate-putamen proteome of 18 month Hdh092™2 and Hdh+/+.
mouse model Hdh092
age 18 months
brain tissue caudate-putamen caudate-putamen
ProteinChip CM10 Q10
total nr peaks 94 71
Av. Mass p-value log2 FC Av. Mass p-value log2 FC
10604 0.0020 0.52 3215 0.0044 0.39
5372 0.0076 0.65 8446 0.0186 -0.32
6066 o.oioi -0.34 4961 0.0365 0.25
7662 0.0266 0.57 5397 0.0366 0.80
7490 0.0316 -0.73 7647 0.0719 -0.18
5103 0.0407 0.21 13773 0.0871 0.24
13991 0.0450 0.33 15442 0.0966 -0.28
3555 0.0465 0.50
10872 0.0656 -0.23
7366 0.0689 0.45
7805 0.0740 -1.14
15835 0.0775 -0.29
5490 0.0787 0.35
15180 0.0831 -0.37
15274 0.0886 -0.28
14971 0.0950 -0.50
15608 0.0978 -0.86
Protein peaks with a significant (p < 0.1) difference, showing average mass with 
corresponding p-value, log2 fold change (negative=decrease; posrtive=increase) and total 
number of peaks.
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Table 3.6 Comparison of changes in the caudate-putamen of HdhQ92/Q92 at 18,12 and 10 
months.
mouse model Hdh 092
age 18 months 12 months 10 months
brain tissue caudate-putamen caudate-putamen caudate-putamen
ProteinChip CM10 CM10 CM10
total nr peaks 94 91 82
Av. Mass p-value log2 FC Av. Mass p-value log2 FC Av. Mass p-value log2 FC
10604 0.0020 0.52 4899 0.0016 -0.77 8770 0.0019 0.30
5372 0.0076 0.65 11351 0.0022 0.49 14987 0.0102 -0.48
6066 0.0104 -0 .34 13478 0.0088 -0.42 8563 0.0149 0.20
7662 0.0266 0.57 6784 0.0139 -0.34 11083 0.0172 0.22
7490 0.0316 -0 .73 5103 0.0160 -0.37 15716 0.0341 -0.60
5103 0.0407 0.21 15624 0.0185 -0.64 15198 0.0431 -0.38
13991 0.0450 0.33 9624 0.0236 -0.46 5196 0.0479 0.52
3555 0.0465 0.50 6828 0.0367 -0.47 4271 0.0589 0.30
10872 0.0656 -0 .23 10719 0.0642 -0.54 8026 0.0775 0.21
7366 0.0689 0.45 9331 0.0727 -0.30 14126 0.0838 -0.33
7805 0.0740 -1 .14 7812 0.0764 -0.46 7489 0.0851 -0.33
15835 0.0775 -0 .29 15854 0.0958 -0.32
5490 0.0787 0.35 11797 0.0981 -0.72
15180 0.0831 -0 .37
15274 0.0886 -0 .28
14971 0.0950 -0 .50
15608 0.0978 -0 .86
Protein peaks with a significant (p < 0.1) difference between HdhQ92/Q92 and Hdh+/+ 
caudate-putamen at 18, 12 and 10 months on CM 10 ProteinChip arrays are listed with 
their average mass, p-value, log2 fold change (negative=decrease; positive=increase) 
and total number of peaks. The red entries are the peaks found to be significant on more 
than one ProteinChip array.
Table 3.7 Comparison of changes in different brain regions of 18 month HdhQ92/Q92.
mouse model H d h 092
age 18 months 18 months 18 months 18 months
brain tissue hippocampus cerebellum motor+prefrontal cortex caudate-putamen
ProteinChip CM10 CM10 CM10 CM10
total nr peaks 76 74 84 94
Av. Mass p-value log2 FC Av. Mass p-value log2 FC Av. Mass p-value log2FC Av. Mass p-value log2 FC
10209 0.0070 0.16 8391 0.0821 0.23 18454 0.0289 -0.25 10604 0.0020 0.52
7005 0.0091 -0.13 7663 0.0453 0.38 5372 0.0076 0.65
10127 0.0128 0.26 7066 0.0994 -0.30 6066 0.0104 -0.34
9919 0.0297 0.20 7662 0.0266 0.57
7490 0.0316 -0.73
5103 0.0407 0.21
13991 0.0450 0.33
3555 0.0465 0.50
10872 0.0656 -0.23
7366 0.0689 0.45
7805 0.0740 -1.14
15835 0.0775 -0.29
5490 0.0787 0.35
15180 0.0831 -0.37
15274 0.0886 -0.28
14971 0.0950 -0.50
15608 0.0978 -0.86
Protein peaks with a significant (p < 0.1) difference in the hippocampus, cerebellum, 
motor+prefrontal cortex and caudate-putamen of 18 month Hdh092/092 compared to Hdh+/+ 
on CM10 ProteinChip arrays are listed with their average mass, p-value, log2 fold change 
(negative=decrease; positive=increase) and total number of peaks detected. The red 
entry is the only peak found to be significant in more than one brain region.
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3.6 Comparison of HdhQ1S0/Q1S0 and Hdh+/+ caudate-putamen proteome
A comparison was carried out between Hdh0150/0150 ancj Hdh+/+ caudate- 
putamen of 18 and 15 month animals on CM10 ProteinChip arrays. There were 
also animals of 10 months of age and a combination of 3 and 4 months old, but 
these samples became available after the ProteinChip analysis was finished and 
were used only in western blot analysis. A substantial proportion of the protein 
peaks in the 18 month samples were significantly different: 31 out of 97 peaks 
(=32%), nearly all of which were increased in Hdh0150/0150 (Table 3.8). The 
magnitude of the changes ranged between 12-92%, similar to the changes seen 
in the R6/1. There were considerably fewer differences in the 15 month 
HdhQ150/Q15°; seven out of 85 peaks (=8%), half increased and half decreased. 
The magnitude of the changes was noticeably smaller in the younger animals: a 
maximum change of 43% at 15 months compared with 92% at 18 months. Only 
two of the significant peaks at 18 months appeared to be significant at 15 months.
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Table 3.8 Comparison of Hdh0150/0150 and Hdh+/+ caudate-putamen proteome.
mouse model H dh
age 18 months 15 months
brain tissue caudate-putamen caudate-putamen
ProteinChip CM10 CM10
total nr peaks 97 85
Av. Mass p-value log2 FC Av. Mass p-value log2 FC
6219 0.0031 0.37 6775 0.0052 -0.19
15196 0.0088 0.37 8025 0.0102 0.22
15626 0.0090 0.68 8979 0.0181 0.43
12441 0.0104 0.37 7931 0.0229 0.42
14988 0.0109 0.55 6568 0.0281 -0.26
15858 0.0119 0.30 9325 0.0722 -0.23
6541 0.0133 0.46 8788 0.0763 0.20
8383 0.0142 0.47
13477 0.0165 0.34
10501 0.0168 0.26
8985 0.0269 0.23
7810 0.0280 0.67
10719 0.0343 0.30
4094 0.0344 0.92
10261 0.0345 0.25
8107 0.0367 0.23
4050 0.0488 0.27
8660 0.0554 0.27
15926 0.0567 0.27
9330 0.0620 0.32
3356 0.0657 -0 .65
10375 0.0661 0.20
7494 0.0705 0.47
6927 0.0719 -0 .58
9623 0.0757 0.21
6825 0.0842 0.26
5651 0.0854 0.26
15292 0.0864 0.25
4897 0.0949 0.23
5443 0.0952 0.12
7569 0.0961 -0 .43
Protein peaks with a significant (p < 0.1) difference at 18 and 15 months on CM 10 
ProteinChip arrays with their average mass, p-value, log2 fold change (negative= 
decrease; positive=increase) and total number of peaks detected. Red entries are peaks 
significant at both timepoints.
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3.7 Similarities and differences in the brain proteome of the HD genetic 
mouse models
The total number of peaks with a significant difference in all experiments 
with the three HD mouse models was 103. More than half were significant in more 
than one experiment. These peaks are listed in Table 3.9. Out of these, 83% were 
significant not only in multiple experiments, but also in different mouse models.
Figure 3.13 shows the total number of peaks detected in all experiments, 
the number of peaks that was found in multiple experiments, and the number that 
was unique to one experiment. Figures 3.13 A-B illustrate the expected overlap 
between CM10 and Q10 ProteinChip arrays. Figures 3.13 C-D demonstrate that 
the majority of the peaks detected at different ages in the same mouse model are 
the same. Figure 3.13 E shows that about half of the proteins detected are 
present in all brain regions examined and that the caudate-putamen and the 
cerebellum have the highest number of proteins detected only in these regions.
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Table 3.9 Peaks with p < 0.1 in more than one experiment.
av. mass p-value log2 FC model age ProteinChip brain tissue
4897 0.0949 0.23 Q150 18 months CM10 caudate-putamen
4899 0.0016 -0.77 Q92 12 months CM10 caudate-putamen
5103 0.0407 0.21 Q92 18 months CM10 caudate-putamen
5103 0.0160 -0.37 Q92 12 months CM10 caudate-putamen
6717 0.0921 -0.64 R6/1 18 weeks Q10 half cerebra
6720 0.0375 -0.81 R6/1 18 weeks CM10 half cerebra
6775 0.0052 -0.19 Q150 15 months CM10 caudate-putamen
6781 0.0159 -0.35 R6/1 18 weeks CM10 half cerebra
6784 0.0139 -0.34 Q92 12 months CM10 caudate-putamen
6825 0.0842 0.26 Q150 18 months CM10 caudate-putamen
6828 0.0367 -0.47 Q92 12 months CM10 caudate-putamen
6919 0.0291 -0.53 R6/1 18 weeks Q10 half cerebra
6926 0.0756 -0.55 R6/1 18 weeks CM10 half cerebra
6927 0.0719 -0.58 Q150 18 months CM10 caudate-putamen
7489 0.0851 -0.33 Q92 10 months CM10 caudate-putamen
7490 0.0316 -0.73 Q92 18 months CM10 caudate-putamen
7494 0.0705 0.47 Q150 18 months CM10 caudate-putamen
7647 0.0719 -0.18 Q92 18 months Q10 caudate-putamen
7648 0.0987 -0.27 R6/1 18 weeks Q10 half cerebra
7662 0.0266 0.57 Q92 18 months CM10 caudate-putamen
7663 0.0453 0.38 Q92 18 months CM10 motor+prefrontal cortex
7805 0.0740 -1.14 Q92 18 months CM10 caudate-putamen
7810 0.0280 0.67 Q150 18 months CM10 caudate-putamen
7812 0.0764 -0.46 Q92 12 months CM10 caudate-putamen
8025 0.0102 0.22 Q150 15 months CM10 caudate-putamen
8026 0.0775 0.21 Q92 10 months CM10 caudate-putamen
8383 0.0142 0.47 Q150 18 months CM10 caudate-putamen
8391 0.0821 0.23 Q92 18 months CM10 cerebellum
8563 0.0149 0.20 Q92 10 months CM10 caudate-putamen
8567 0.0355 0.20 R6/1 18 weeks CM10 half cerebra
8770 0.0019 0.30 Q92 10 months CM10 caudate-putamen
8788 0.0763 0.20 Q150 15 months CM10 caudate-putamen
8979 0.0181 0.43 Q150 15 months CM10 caudate-putamen
8985 0.0269 0.23 Q150 18 months CM10 caudate-putamen
9325 0.0722 -0.23 Q150 15 months CM10 caudate-putamen
9330 0.0620 0.32 Q150 18 months CM10 caudate-putamen
9331 0.0727 -0.30 Q92 12 months CM10 caudate-putamen
9623 0.0757 0.21 Q150 18 months CM10 caudate-putamen
9624 0.0236 -0.46 Q92 12 months CM10 caudate-putamen
10719 0.0343 0.30 Q150 18 months CM10 caudate-putamen
10719 0.0642 -0.54 Q92 12 months CM10 caudate-putamen
13477 0.0165 0.34 Q150 18 months CM10 caudate-putamen
13478 0.0088 -0.42 Q92 12 months CM10 caudate-putamen
14971 0.0950 -0.50 Q92 18 months CM10 caudate-putamen
14987 0.0102 -0.48 Q92 10 months CM10 caudate-putamen
14988 0.0109 0.55 Q150 18 months CM10 caudate-putamen
15180 0.0831 -0.37 Q92 18 months CM10 caudate-putamen
15196 0.0088 0.37 Q150 18 months CM10 caudate-putamen
15198 0.0431 -0.38 Q92 10 months CM10 caudate-putamen
15274 0.0886 -0.28 Q92 18 months CM10 caudate-putamen
15292 0.0864 0.25 Q150 18 months CM10 caudate-putamen
15624 0.0185 -0.64 Q92 12 months CM10 caudate-putamen
15626 0.0090 0.68 Q150 18 months CM10 caudate-putamen
15835 0.0775 -0.29 Q92 18 months CM10 caudate-putamen
15854 0.0958 -0.32 Q92 12 months CM10 caudate-putamen
15858 0.0119 0.30 Q150 18 months CM10 caudate-putamen
Each block contains the peaks which, in all probability, represent the same protein. Q92 
refers to Hdh092 and Q150 refers to Hdh0150.
107
A. B.
H d h 092
(18 m onths-CP)
29 Q10CM10
Total = 123
D
R6/1
(18 months) CM10
22
24
IMAC-Cu Q10
Total = 87
c
H d h 092
(C M 1 0-C P ) 18 months
9 \
V / h x y  \
1 \ 2 j  10 )
10 months 12 months
Total = 107
H d h 0150 
(C M 1 0 -C P )
15 months18 months
Total = 100
E.
brain
regions CP HC MC+PFC
CB MC+PFCCB
HC
CB
HC
MC+PFC
HC
MC+PFC
CB
CP 13 0 7 2 3 1 15 53
HC 0 2 1 0 4
MC+PFC 7 1 0 1 4
CB 2 0 1 10 4
Total = 112
Figure 3.13 Total number of peaks detected in all experiments and overlap between 
experiments.
A. R6/1: 18 month samples on CM10, Q10 and IMAC-Cu ProteinChip arrays.
B. Hdh092: 18 month caudate-putamen (CP) samples on CM 10 and Q10 ProteinChip 
arrays.
C. Hdh092: 18,12 and 10 month CP samples on CM 10 ProteinChip arrays.
D. Hdh0150: 18 and 15 month CP samples on CM 10 ProteinChip arrays.
E. Hdh092-. 18 month CP, cerebellum (CB), motor cortex (MC) + prefrontal cortex 
(PFC) and hippocampus (HC) samples on CM10 ProteinChip arrays.
The Venn diagrams in A-D and the Table in E show the number of peaks detected in 
multiple experiments and the number unique to one experiment. The light grey fills in E 
denote combinations that have already been entered and the dark grey fills are non­
existent combinations.
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3.8 Identification of proteins from SELDI-TOF analysis
3.8.1 Method of protein identification
Figure 3.14 gives an overview of the identification of proteins found to be 
significantly different in HD mouse brain by SELDI-TOF analysis. To identify the 
protein represented by a peak in SELDI, it was isolated on a 1D-gel, extracted, 
trypsin digested and analysed with the MALDI TOF/TOF analyzer.
To single out and extract a specific protein from a complex protein sample 
on a 1D-polyacrylamide mini gel, it was necessary to simplify the sample. This 
was achieved through protein fractionation, using hydrophobic interaction 
chromatography on a polymeric reversed phase media. The proteins in the 
sample were separated as a result of their differences in surface hydrophobicity. 
The fractions were analysed on a ProteinChip and a polyacrylamide mini gel and 
the resulting images compared. The significant peaks detected by SELDI-TOF 
were first identified on the ProteinChip spectrum. To assist in relating the 
ProteinChip reading with the image obtained by running the same fractions on a 
gel, the ProteinChip software offers the facility to view the spectrum as a gel 
image. When the relevant bands on the gel were identified, a single gel plug was 
removed, trypsin digested, analysed in the MALDI TOF/TOF analyzer and the 
ensuing data compared with online protein databases SWISS-PROT and NCBI for 
protein identification.
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Figure 3.14 Work flow for isolating, analysing and identifying proteins found to be 
differentially expressed by SELDI-TOF analysis.
A. Protein samples are fractionated by hydrophobic character in spin columns with 
reversed phase beads. The fractions are run on a polyacrylamide gel, which is stained 
with colloidal coomassie to visualise the protein bands. The same fractions are analysed 
on normal phase ProteinChip arrays in the SELDI-TOF mass spectrometer. The gel view 
of the spectra is compared with the stained polyacrylamide gel to identify the appropriate 
bands.
B. Gel plugs are collected from the bands identified on the gel and trypsin digested.
C. The digests are analysed in the ABI 4800 MALDI TOF/TOF analyzer. The sample is 
spotted onto a metal plate and excited with laser light. The ionised peptides are sparated 
on the basis of their molecular weight. During the second TOF analysis, individual 
peptides are selected and fragmented in a collision chamber, generating the ions which 
produce the fragmentation spectra.
D. The SWISS-PROT and NCBI online databases are searched to identify the proteins.
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3.8.2 Optimisation of fractionation
Protein samples were fractionated (section 2.2.4) and fractions analysed 
on normal phase (NP20) ProteinChip arrays. As some of the protein is already 
lost during fractionation, NP20 arrays were chosen to avoid further reduction in 
protein of the sample. The spots were prepared with 3 pi of dH20  and air dried, 
after which 3 pi of the fractions were applied and air dried, followed by 1 pi of SPA 
solution twice, each with an air dry time of 20 min. The ProteinChips were read 
and analysed as in section 3.2.1.
Some optimisation experiments were performed to determine the optimal 
number of fractions, method and materials. A repetitive signal was seen on these 
spectra and attempts were made to identify its source and eliminate the signal.
Number of fractions
A homogenate of half cerebra of an 18 week WT R6/1 was fractionated into 
flow-through and fractions eluted with 10%, 15%, 20%, 23%, 26%, 29%, 32%, 
35%, 38%, 41%, 44%, 47%, 50%, 53%, 56% and 80% acetonitrile (ACN). The 
spectra in Figure 3.15 show there was no need for fractions between 20-29%, as 
very little sample was eluted. The same was the case for fractions > 47% ACN. 
Although there were more peaks in the 32-47% fractions, many of these were 
present in more than one fraction. The low intensity of the peaks indicated that the 
protein concentration in these fractions was low, which suggested that too many 
fractions between 30-50% diluted the proteins, making it difficult to visualise them 
on a gel. It was decided that a 10%, 20%, 30%, 40%, 50%, 60% and 80% ACN 
fraction would be adequate. The additional benefit of this was that all eight 
fractions could be analysed on one ProteinChip.
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Figure 3.15 Spectra of 16 spots on two NP20 ProteinChips with fractions of 18 week old 
WT R6/1 half cerebra. From top to bottom are the flow-through and 10%, 15%, 20%, 
23%, 26%, 29%, 32%, 35%, 38%, 41%, 44%, 47%, 50%, 53%, 56% and 80% ACN 
fractions. The red box indicates the 32-47% fractions, in which most of the protein was 
eluted. The green boxes show a few examples of peaks that were present in more than 
one fraction. The red arrow points out the low intensity of the peaks.
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Method of fractionation
To determine the best method and materials for fractionation, four reversed 
phase chromatography approaches were compared:
• method 1: use of Sigma spin columns with PLRP-S beads (section 2.2.4);
each fraction eluted in one step with 300 jul of the appropriate concentration 
of ACN.
• method 2: use of Sigma spin columns with PLRP-S beads; each fraction
eluted in three steps with three times 100 pi of the appropriate 
concentration, combining the flow-through.
• method 3: use of 1.5 ml Eppendorf tubes with PLRP-S beads; each fraction
eluted in one step with 300 pi of the appropriate concentration of ACN.
• method 4: use of Methyl Ceramic HyperD F Spin Columns (reversed phase
column from Ciphergen Biosystems), following the company’s instructions; 
fractions obtained by a decreasing concentration of ammonium sulphate.
For the first three methods, a homogenate of half cerebra of 10 week 
transgenic R6/1 was fractionated in flow-through and 10%, 20%, 30%, 40%, 50%, 
60% and 80% fractions. For method four, the same homogenate was fractionated 
in flow-through and 2M, 1.6M, 1.2M, 0.8M, 0.4M and 0M fractions. All fractions 
were analysed on NP20 ProteinChip arrays. The four ProteinChips were 
processed and read in one batch. The spectra in Figure 3.16 show that method 1, 
fractionation in Sigma spin columns in one step by adding 300 pi of the 
appropriate concentration of ACN, produced an adequate separation as well as 
more and better defined peaks. This protocol was used for further fractionation.
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Figure 3.16 Spectra of eight spots comparing four method of reversed phase 
chromatography fractionation. The spectra were selected from a 31 spot experiment on 
NP20 ProteinChip arrays. Homogenate of half cerebra of 10 week transgenic R6/1 was 
fractionated in eight fractions by the first three methods (spectra 1-6) and in seven 
fractions by the fourth method (spectra 7-8). The spectra chosen correspond to two 
fractions from each method:
1. fraction eluted with 300 pi of 30% ACN in Sigma spin column;
2. fraction eluted with 300 pi of 40% ACN in Sigma spin column;
3. fraction eluted in three steps with 3 x 100 pi of 30% ACN in Sigma spin column;
4. fraction eluted in three steps with 3 x 100 pi of 40% ACN in Sigma spin column;
5. fraction eluted with 300 pi of 30% ACN in Eppendorf tube;
6. fraction eluted with 300 pi of 40% ACN in Eppendorf tube;
7. 0.8M ammonium sulphate fraction in Methyl Ceramic HyperD F spin column;
8. 0.4M ammonium sulphate fraction in Methyl Ceramic HyperD F spin column.
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Troubleshooting a repetitive signal
The spectra of the fractionation optimisation experiments showed a 
repetitive signal below 6,000 Da that could not be explained. This was likely to 
interfere with the signal from proteins being fractionated, so attempts were made 
to remove it.
Figure 3.17 shows the signal, made up of two distinct peaks of different 
intensities and repeated roughly every 600 Da. The intensity of the repeats 
dropped with increasing mass. The repetitive nature of the signal and its even 
spacing suggested it was, in all probability, generated by a chemical breakdown 
product of one of the reagents, formed during fractionation. Tests were run to 
determine the cause of the signal and to find a way of removing it.
(a) 2-D C le a n -U p
2-D clean-up was performed on homogenate of half cerebra of 10 week 
transgenic R6/1 with 98 jug of protein (procedure A, section 2.2.3). The pellet was 
resuspended in 10 pi of urea-thiourea lysis buffer and fractionated (section 2.2.4). 
The fractions were analysed on an NP20 ProteinChip. The spectra in Figure 3.18 
show that, although the intensity of the repeat was lower, the 30% fraction still 
showed as many repeats as it did without the 2D-clean up. In the other fractions, 
the repeat had nearly disappeared. However, as the 30% fraction contained most 
of the proteins, further investigation was needed.
(b) U r ea -T h io u r e a  Ly s is  B u f f e r
To test whether the urea-thiourea lysis buffer was causing the signal 
repeat, three different fractionations were compared: (1) 50 pi homogenate of half 
cerebra of 10 week transgenic R6/1 in HEPES lysis buffer in a total volume of 200
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pi of 10% ACN and 0.5% TFA; (2) 200 pi of 10% ACN and 0.5% TFA without 
sample; (3) 50 jliI of urea-thiourea lysis buffer without protein in a total volume of 
200 pi of 10% ACN and 0.5% TFA. Figure 3.19 shows the spectra of the fractions 
analysed on an NP20 ProteinChip. The spectra generated by fractions from 
methods (1) and (2) showed no repeat signal, while those from method (3) 
showed the repeat signal. These results suggested that the signal repeat was 
produced by the breakdown product of one of the constituents of the urea- 
thiourea lysis buffer.
(c) T h io u re a
To test if the thiourea was causing the signal repeat, fractions of a 
homogenate of half cerebra of 10 week transgenic R6/1 were analysed on an 
NP20 ProteinChip without thiourea present. Because all samples were 
homogenated in urea-thiourea lysis buffer, a 2D-clean-up with 50 pg of protein 
was performed (procedure A, section 2.2.3) to remove the thiourea. The pellet 
was resuspended in 50 pi of 9 M urea + 2% CHAPS and fractionated. Figure 3.20 
shows that the signal repeat was present in all fractions, indicating it was not the 
thiourea causing the problem. The spectra also showed very few protein peaks, 
suggesting that the clean-up procedure removes some of the protein and that 50 
pg of protein is insufficient to withstand the protein loss caused by 2D-clean-up.
(D) CHAPS
To test whether the CHAPS was causing the signal repeat, fractions of a 
homogenate of half cerebra of 10 week transgenic R6/1 with only 10% of the 
CHAPS were analysed on an NP20 ProteinChip. To remove the CHAPS from the
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homogenate, a 2D-clean-up with 98 jug of protein was performed (procedure A, 
section 2.2.3). The pellet was resuspended in 20 pi of 9 M urea + 0.5% CHAPS 
and fractionated. Figure 3.21 shows that the repeat was still there, but its intensity 
was considerably reduced.
Next, the CHAPS concentration was reduced to 5%. 2D-clean-up was 
performed on a homogenate of half cerebra of 10 week transgenic R6/1 with 130 
pg of protein (procedure B, section 2.2.3). The pellet was resuspended in 20 pi of 
9 M urea + 0.25% CHAPS and fractionated in Methyl Ceramic HyperD F Spin 
Columns (Ciphergen) to find out whether this new combination would eliminate 
the signal repeat. The fractions were analysed on an NP20 ProteinChip. Figure 
3.22 shows that the intensity of the repeat was again greatly reduced. However, 
there was very little protein in the fractions, although more protein had been used 
to start with. Part of the problem may be that the CHAPS was used at a 
concentration too low to resuspend the pellet adequately from the 2D-clean-up. In 
fact, it was no longer possible to resuspend the pellet when the concentration of 
CHAPS was lowered any further.
The CHAPS was subsequently replaced with ASB-C80 (Calbiochem- 
Merck Chemicals, Beeston, UK), an alternative zwitterionic detergent. 20-clean- 
up was carried out on a homogenate half cerebra of 10 week old transgenic 
R6/1with 96 pg of protein (procedure A, section 2.2.3). The pellet was 
resuspended in 50 pi of 7 M urea + 2 M thiourea + 2% ASB-C80 and fractionated. 
The fractions were analysed on an NP20 ProteinChip. Figure 3.23 shows a very 
clear and intense repeat in most fractions. However, the pattern of the repeat is 
different from that in the spectra with CHAPS. The repeat generated by ASB-C80 
had two distinctive peaks, changing to one peak over 5,000 Da. There were more
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repeats, closer together and they continued further down the spectrum to about
10.000 Da. These differences suggest that the detergent is broken down during 
fractionation, with different detergents generating different breakdown products.
The CHAPS experiments also showed there was a trade-off between the 
amount of detergent used and the number and concentration of proteins obtained: 
reducing the level of detergent gave a weaker signal with fewer peaks. In addition, 
the 2D-clean-up removed a substantial amount of protein. Taking into 
consideration that this procedure did not eliminate the signal repeat, it was 
decided not to use 2D-clean-up. As the signal repeat was present only below
6.000 Da, any peaks lower than this would be disregarded.
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Figure 3.17 Spectra of three spots showing a repetitive signal. The spots were selected 
from the experiment described in Figure 3.16. The spectra correspond to three fractions 
obtained in Sigma spin columns with 300 jil of 20%, 30% and 40% ACN. The three 
spectra are shown twice, with a different zoom range. The window in (A) is zoomed in on 
the masses between 2,000-20,000 Da. The red box indicates the area with the repetitive 
signal. The window in (B) is zoomed in on the masses between 2,000-6,000 Da. The red 
box indicates the same area as in (A). The green boxes show the individual copies of the 
repeat, illustrating its repetitive nature. It is also clear that the intensity of the peaks falls 
with an increase in mass. The mass of the main peak of each of the repeats is indicated 
in red next to it. The repeats are evenly spaced, with an interval of roughly 600 Da.
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Figure 3.18 Spectra of three spots after 2-D clean-up. The spectra correspond to the 
20%, 30% and 40% fractions of a homogenate of half cerebra of 10 week transgenic 
R6/1, on which 2-D clean-up was performed on an NP20 ProteinChip. The repeat signal 
is still present, but at a considerably lower intensity in the 20% and 40% fractions and 
even somewhat lower in the 30% fraction.
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Figure 3.19 Spectra of six spots testing if the urea-thiourea lysis buffer was causing the 
signal repeat. The spectra correspond to three fractionations on an NP20 ProteinChip: 
1-2 20% and 30% fraction of 50 pi homogenate of half cerebra of 10 week old
transgenic R6/1 in HEPES lysis buffer in a total volume of 200 pi of 10% ACN and 
0.5% TFA;
3-4 20% and 30% fraction of 200 pi of 10% ACN and 0.5% TFA without sample;
5-6 20% and 30% fraction of 50 pi urea-thiourea lysis buffer without protein in a total 
volume of 200 pi of 10% ACN and 0.5% TFA.
Only spectra 5 and 6 show the signal repeat.
121
2000 30 00 4 0 0 0  50 00 6000
75
50
25
0
75
50
25
0 _  
2000 3000 4000 5000 0000
Figure 3.20 Spectra of two spots testing if the thiourea in the lysis buffer was causing the 
signal repeat. The spectra correspond to the 20% and 30% fractions of homogenate of 
half cerebra of 10 week transgenic R6/1 without thiourea on an NP20 ProteinChip. 2-D 
clean-up removed the thiourea from the sample. The pellet was resuspended in 50 pi of 9 
M urea + 2% CHAPS and fractionated. The signal repeat is present in all fractions.
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Figure 3.21 Spectra of two spots testing if the CHAPS in the lysis buffer was causing the 
signal repeat. The spectra correspond to the 20% and 30% fractions of homogenate of 
half cerebra of 10 week transgenic R6/1 with only 10% of the original amount of CHAPS 
on an NP20 ProteinChip. 2-D clean-up removed the CHAPS from the sample. The pellet 
was resuspended in 20 pi of 9 M urea + 0.5% CHAPS and fractionated. The signal repeat 
is present in all the spectra, but at a much lower intensity.
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Figure 3.22 Spectra of two spots with further reduction of CHAPS. The spectra 
correspond to fractions eluted with 1.4M and 1.1M ammonium sulphate in Methyl 
Ceramic HyperD F spin columns on an NP20 ProteinChip. Homogenate of half cerebra of 
10 week transgenic R6/1 was fractionated with only 5% of the original amount of CHAPS 
present. Prior to fractionation, 2-D clean-up removed the CHAPS from the sample. The 
pellet was resuspended in 20 pi of 9 M urea + 0.25% CHAPS. The signal repeat is 
strongly reduced in all the spectra.
5 0 0 0
50
30df l -
75
Figure 3.23 (1) Spectra of three spots with CHAPS replaced by ASB-C80. The spectra 
correspond to the 30%, 40% and 50% fractions of homogenate of half cerebra of 10 week 
transgenic R6/1 after replacing CHAPS with ASB-C80 on an NP20 ProteinChip. 2-D 
clean-up removed the CHAPS from the sample. The pellet was resuspended in 50 pi of 7 
M urea + 2 M thiourea + 2% ASB-C80 and fractionated. The spectra show a strong 
repetitive signal, indicated by the green boxes. The pattern of this repeat is different from 
that in the spectra with CHAPS (2): the ASB-C80 spectra show more repeats that are 
closer together. The repeats have two distinct peaks, with one of the peaks disappearing 
over 5,000 Da.
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3.8.3 Isolation of protein bands using 1 D-ael electrophoresis
After 3 pi of each fraction of a sample was analysed on an NP20 
ProteinChip, the remainder of the fractions were separated on a 12% Bis-Tris 
NuPage gel (section 2.2.6). The gel was stained with colloidal blue (section 2.2.7). 
Figure 3.24 shows how the gel was compared with the spectra and how peaks 
from the spectra were identified as bands on the gel. Both the trace view and the 
gel view of the spectra were used. First, bands between 5,000-20,000 Da were 
identified on both gel and spectra for landmarking. Then, bands in that area on the 
gel were matched to peaks on the spectra. A single gel plug of each band 
identified as a protein of interest was removed for trypsin digestion and MALDI 
TOF/TOF analysis. Table 3.10 lists the bands that were isolated.
Fractions of four Hdh092 samples were analysed. The first were 18 month 
Hdh+/+ caudate-putamen fractions. Five bands were isolated. The second were 12 
month Hdh+/+ caudate-putamen fractions. Two more bands were found. The last 
two were 10 month HdhQ92/Q92 caudate-putamen fractions and 18 month Hdh+/+ 
hippocampus fractions. No bands were isolated on either. Fractions of two 
Hdh0150 samples were analysed. The first were 18 month Hdh+/+ caudate-putamen 
fractions. Five bands were isolated. The second were 15 month HdhQ150/Q15° 
caudate-putamen fractions. Two more bands were found. For the R6/1, several 
fractionated samples were separated on gels, but no relevant peaks could be 
isolated.
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Figure 3.24 Identifying peaks from SELDI-TOF spectra on a 1D-gel.
(A) Image of a fractionated caudate-putamen homogenate of an 18 month Hdh* . 
separated on a 12% Bis-Tris NuPage gel, stained with colloidal blue.
(B) Gel view of the SELDI-TOF spectra of the same fractions analysed on an NP20 
ProteinChip. The window is zoomed in between 5,000-17,000 Da. The green arrows 
illustrate two of the bands that were identified on the spectra for landmarking. The red 
arrows indicate the five bands that were identified as some of the significant peaks for the 
Hdh092 model.
(C) The same gel view as in (B), but with the relevant bands identified.
(D) Trace view of the 30%, 40% and 50% fractions of the spectra in (B) and (C). The 
same peaks have been identified.
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Table 3.10 SELDI-TOF peaks identified as bands on a gel with fractionated samples.
Fractionated sample
Fraction Mass
SELDI-TOF results
Model Age Genotype Tissue Age Tissue Chip p-value Log2FC
HdhQ92 18 months WT CP 30% 9333 12 months CP CM10 0.0727 -0.30
HdhQ92 18 months WT CP 40% 10883 18 months CP CM10 0.0656 -0.23
HdhQ92 18 months WT CP 40% 14107 10 months CP CM10 0.0838 -0.33
HdhQ92 18 months WT CP 40% 15021 18 months CP CM10 0.0950 -0.50
10 months CP CM10 0.0102 -0.48
HdhQ92 18 months WT CP 50% 9627 12 months CP CM10 0.0236 -0.46
HdhQ92 12 months WT CP 60% 11340 12 months CP CM10 0.0022 0.49
HdhQ92 12 months WT CP 60% 13806 18 months CP Q10 0.0871 0.24
HdhQ150 18 months WT CP 40% 8955 15 months CP CM10 0.0181 0.43
18 months CP CM10 0.0269 0.23
HdhQ150 18 months WT CP 40% 9630 18 months CP CM10 0.0757 0.21
HdhQ150 18 months WT CP 40% 12449 18 months CP CM10 0.0104 0.37
HdhQ150 18 months WT CP 40% 15025 18 months CP CM10 0.0109 0.55
HdhQ150 18 months WT CP 40% 6579 15 months CP CM10 0.0281 -0.26
HdhQ150 15 months HOM CP 30% 9338 18 months CP CM10
0.0620 0.32
15 months CP CM10 0.0722 -0.23
HdhQ150 15 months HOM CP 30% 15644 18 months CP CM10 0.0090 0.68
The first four columns give details on the fractionated samples separated on a 12% Bis- 
Tris NuPage gel. The next two columns record the masses of the bands isolated and the 
fraction they were found in. The last five columns give the SELDI-TOF results on the 
equivalent peaks. A total of 14 bands were found, seven each for Hdh092 and Hdh0150.
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3.8.4 MALDI TOFATOF analysis and results
Trypsin digestion was carried out by Mrs S.H.V. Nixon and MALDI 
TOF/TOF analysis by Dr. I. Brewis at the Proteomics Unit of the Central 
Biotechnology Services at Cardiff University. All 14 gel plugs provided protein 
identification, detailed in Table 3.11. The criteria for identification take into account 
the expectation (E) value, both for the final identification and for the peptide 
matches. The expectation value is the probability that the match is a chance 
event. There are four MALDI TOF/TOF identification categories:
• Category 1: Conclusive identification with excellent tandem MS data for two
or more peptides, each peptide with E < 0.05.
• Category 2: Conclusive identification with good tandem MS data for one
peptide with E < 0.0001.
• Category 3: Probable/possible identification with tandem MS data for one or
more peptides with overall 0.05 < E < 0.0001.
• Category 4: Probable/possible identification with MS (not tandem MS) with E
< 0 .01.
However, category 1 and 2 identifications are a great deal more significant than 
category 3 identifications and a category 4 identification would generally only be 
accepted if there are additional factors supporting the identification.
Seven identifications were category 1. Two proteins were identified in both 
the Hdh092 and the Hdh0150 model: Cytochrome c oxidase subunit Vlb and 
Calmodulin.
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Table 3.11 MALDI TOF/TOF identifications of proteins found to be changed in the Hdh092
and Hdh0150 mouse models by SELDI-TOF analysis.
The left section of the table gives the SELDI-TOF results for the relevant peaks, the right 
section shows the MALDI TOF/TOF identifications, with the protein match and name, the 
gene name and the amino add code for each peptide match. The identification criteria 
uses the expectation value (E.), both for the overall identification and for the peptide 
matches. The four MALDI TOF/TOF identification categories are: (Cat.1) Condusive 
identification with excellent tandem MS data for two or more peptides, each peptide with 
E < 0.05; (Cat.2) Condusive identification with good tandem MS data for one peptide with 
E < 0.0001; (Cat.3) Probable/possible identification with tandem MS data for one or more 
peptides with overall 0.05 < E < 0.0001; (Cat.4) Probable/possible identification with MS 
(not tandem MS) with E < 0.01.
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Model SELDI-TOF results MALDI TOF/TOF identification
Age p-value Lofl2FC Match Protein Gene name Cat. E. overall Peptide match E. peptide
HdhQ92
12 months 0.0727 -0.30 CX6B1J/IOUSE Cytochrome c oxidase subunit Vlb isoform 1 Cox6b1 1 7.60E-11
TAPFDSRFPNQNQTK 1.20E-04
FPNQNQTK 1.10E-02
18 months 0.0656 -0.23 QCR7_MOUSE Cytochrome b-c1 complex subunit 7 Uqcrb 3 1.40E-03 RLPEDLYNDR 2.20E-02
10 months 0.0838 -0.33 HBA_MOUSE Hemoglobin subunit alpha Hba 2 6.00E-08 IGGHGAEYGAEALER 1.00E-09
18 months 0.0950 -0.50
CALMJ/IOUSE Calmodulin Cafml, Calm2 and Calm3 1 1.90E-21
DTDSEEEIREAFR 1.90E-07
10 months 0.0102 -0.48 VFDKDGNGYISAAELR 1.30E-11
12 months 0.0236 -0.46 FKB1AJ/IOUSE FK506-binding protein 1A Fkbpla 3 1.20E-06
GVQVETISPGDGR 6.40E-04
GWEEGVAQMSVGQR 1.90E-01
12 months 0.0022 0.49 MBP_MOUSE Myelin basic protein, 14 kDa Mbp 2 3.80E-12
TQDENPWHFFK 1.50E-05
FFSGDRGAPK 1.50E-01
18 months 0.0871 0.24 HBA_MOUSE Hemoglobin subunit alpha Hba 1 9.60E-31
IGGHGAEYGAEALER 7.00E-15
TYFPHFDVSHGSAQVK 1.00E-12
HdhQ150
15 months 0.0181 0.43
CH10_MOUSE 10kDa heat shock protein, mitochondrial Hspel 1 1.10E-21
WLDDKDYFLFR 1.20E-09
18 months 0.0269 0.23 KFLPLFDR 5.20E-04
FLPLFDR 3.50E-03
18 months 0.0757 0.21 CX6B1_MOUSE Cytochrome c oxidase subunit Vlb isoform 1 Cox6b1 1 3.80E-08
TAPFDSRFPNQNQTK 1.30E-03
FPNQNQTK 2.80E-03
18 months 0.0104 0.37 CYC.BOVIN Cytochrome c Cycs 3 1.20E-02 TGPNLHGLFGR 1.90E-04
18 months 0.0109 0.55 CALMJ/IOUSE Calmodulin Calml, Calm2 and Calm3 2 4.80E-12 VFDKDGNGYISAAELR
2.90E-13
15 months 0.0281 -0.26 UBIQJ/IOUSE Ubiquitin
Rps27a, 
Uba52, Ubb 
and Ubc
1 6.00E-26
TITLEVEPSDTIENVK 1.70E-08
IQDKEGIPPDQQR 8.90E-10
EGIPPDQQR 4.00E-02
18 months 0.0620 0.32
CX6B1J/IOUSE Cytochrome c oxidase subunit Vlb isoform 1 Cox6b1 1 1.20E-24
GGDVSVCEWYR 1.50E-07
FPNQNQTK 2.20E-04
15 months 0.0722 -0.23
TAPFDSRFPNQNQTK 5.60E-04
IAEGTFPGKI 2.20E-03
18 months 0.0090 0.68 STMN1J/IOUSE Stathmin Stmnl 2 3.70E-05 ASGQAFELILSPR 3.40E-07
3.9 Discussion
The work reported in this chapter was carried out using a relatively new 
proteomics technique, SELDI-TOF, to investigate the brain proteomes of three 
genetic mouse models of Huntington’s Disease. SELDI-TOF has been 
successfully used in biological and medical research (section 3.1), particularly to 
screen for serum-based biomarkers and for the development of diagnostic tests 
for a variety of cancers (section 3.1). Although the majority of these projects used 
serum samples, most of the issues identified in these studies apply to the 
experiments with brain samples in the present study. One of the advantages of 
SELDI-TOF is that the technique is particularly well suited for investigating low 
molecular weight proteins, which are a subset of the proteome that is difficult to 
access with other methods, such as 2D-electrophoresis.
One of the main problems in proteomic research is the vast number of 
proteins involved. Proteomic techniques, even powerful ones such as protein 
arrays which can select thousands of proteins simultaneously, can identify only 
the most abundant proteins in a sample. This presents a challenge particularly in 
neuroscientific research, as a wide variety of proteins are expressed in the brain 
and many proteins of interest are expressed at relatively low levels (Freeman & 
Hemby 2004). By focusing on the fraction of the proteome below 20 kDa, SELDI- 
TOF probes a much reduced number of proteins and can detect proteins that 
might not be found by techniques such as 2-DE and DIGE. The use of different 
ProteinChip coupling surfaces simplifies the protein sample, again making lower 
abundance proteins more accessible. In spite of this, even when the full battery of
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available ProteinChip arrays is used, an experiment can detect only a few 
hundred proteins, a fraction of the proteome.
To maximise the number of proteins captured in this project, samples were 
analysed on three different ProteinChip arrays: the weak ionic exchange CM10 
ProteinChip array, the strong anionic exchange Q10 ProteinChip array and the 
immobilized metal affinity capture IMAC-Cu ProteinChip array. However, the initial 
experiments indicated that the CM 10 ProteinChip array detected more proteins 
and presented more significant results than the Q10 and IMAC-Cu ProteinChip 
arrays. The additional findings obtained by running the samples on Q10 and 
IMAC-Cu ProteinChips after processing them on CM10 ProteinChips did not 
weigh up against the substantial additional cost in both money and time. It was 
therefore decided to analyse further samples on CM10 ProteinChip arrays only.
Many studies, particularly in the field of cancer research, have used SELDI- 
TOF to identify protein fingerprints that are indicative of pathology, without trying 
to identify the proteins involved (Veenstra et at. 2004). These projects have 
sidestepped what is probably SELDI’s main drawback, which lies in the 
considerable difficulty in identifying the proteins represented by peaks in the 
spectra. The need to identify protein peaks as protein bands on a 1 D-gel proved 
to be a major bottleneck. One complication is the variation introduced by the 
differences in methodology for analysing the samples on ProteinChips and on 
gels. In addition, lining up gel images with spectra is not at all straightforward. 
Although the ProteinChip software provides the option to show the spectra in gel 
view, the SELDI image still deviates a great deal from the 1 D-gel image. This is 
partly due to the higher sensitivity of the ProteinChip system compared with the 
gel technique. In addition the gel view of the spectra is linear, while a 1 D-gel
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image is not. Of the 70 protein peaks found to be significantly different with 
SELDI, only 14 (20%) could be isolated on a 1 D-gel. Thanks to excellent MALDI- 
TOF results, all of those that could be isolated were identified.
A complication specific to neuroproteomics is the requirement for often 
large amounts of sample for experiments, which is invariably limited with brain 
tissue from mouse. In addition, the temptation to turn out larger amounts of 
sample by using whole brain must be weighed against the wish for regional 
specificity. This was certainly the case with the Hdh092 and Hdh0150 mouse 
models in this study. The decision to analyse microdissected caudate-putamen 
made the issue of total protein available in each sample even more pressing. 
Here, SELDI had an advantage by using only 20 pg of protein per sample, which 
is considerably less than other gel-based techniques.
The choice of timepoints for the different mouse models in this study was 
based on previous research conducted in these models by other methods. The 
R6/1 was the first model screened with SELDI-TOF. To maximize the chance of 
detecting differences in the brain proteomes of transgenic R6/1 compared with 
wild type littermates, the timepoint was selected after the age of onset of overt 
phenotypic changes in these animals. In transgenic R6/1, explicit behavioural 
changes were detected only from about 4 months of age (Mangiarini et al. 1996; 
Hansson et al. 1999; Clifford et al. 2002; Naver et al. 2003; Hodges et al. 2008). 
Research into the neuropathology of transgenic R6/1 confirmed this overall age of 
onset: neuronal intranuclear inclusions of the transgene, abnormal nuclear 
morphology and neurodegeneration were observed in transgenic R6/1 from 5 
months (Davies et al. 1997; lannicola et al. 2000; Turmaine et al. 2000; Spires et 
al. 2004a; Lazic et al. 2007). Changes in the physiology of striatal neurons were
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present in transgenic mice of 18 weeks, but not in younger animals (Hansson et 
al. 1999; Hansson etal. 2001a). Histological examination demonstrated weight 
reduction of the whole brain as well as reduced striatal volume in 15 week old 
transgenic R6/1 (Hansson et al. 1999; Lazic et al. 2007) and RNA microarray 
analysis revealed alterations in brain gene expression from 18 weeks (lannicola et 
al. 2000; Desplats et al. 2006; Hodges et al. 2008). All these studies substantiated 
an age of onset of 4 months. Some studies, however, reported changes in the 
transgenic mice a good deal earlier than 4 months, indicating the development of 
a mild disease phenotype at a much younger age: more sensitive tests recorded 
motor deficits from 7 weeks (Van Dellen et al. 2000; Hansson et al. 2001b; Van 
Dellen et al. 2008), the survival of neural precursor cells in the dentate gyrus was 
found to be compromised by the age of 10 weeks (Lazic et al. 2006) and, 
although neuronal inclusions were present in the majority of cells only by the 16th 
week, a small fraction of brain cells were found to contain them already at 8 
weeks (Hansson et al. 2001b; Naver et al. 2003). One experiment even found 
differences in exploratory behaviour as early as 4 weeks (Bolivar et al. 2004).
Previous proteomic research identified several dysregulated proteins in 
transgenic R6/1: a loss in dopamine receptors in the striatum at 43 weeks (Clifford 
et al. 2002), a reduction of BDNF protein in the striatum and the hippocampus as 
well as a downregulation of DARPP-32 in the striatum at 5 months (Spires et al. 
2004b), alterations in the release of striatal amino acid neurotransmitters at 16 
weeks (NicNiocaill et al. 2001) and the reduction of the synaptic vesicle protein 
rabphilin 3A in the cerebral cortex and the striatum from 16 weeks (Smith et al. 
2006). The Smith study also investigated the level of rabphilin 3A in 4 and 9 week 
old R6/1 and found no change, suggesting that protein changes coincide with
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other phenotypic changes, and that the majority of changes probably take place 
after the 16th week in these animals. But again an earlier change was detected in 
8 week transgenic R6/1 with the downregulation of the cannabinoid receptor 1 
(Naver et al. 2003), clearly showing the beginning of alteration several months 
before other changes were noted. Based on all these findings, 18 week old 
animals were chosen for SELDI-TOF analysis, a timepoint at which they were 
expected to present with significant differences, but before the animals became so 
ill that the alterations might no longer be HD specific but rather the effect of a 
more widespread deterioration.
As this was the first model investigated and previous research suggested a 
widespread pathology in the R6 mouse models (Li et al. 1999), homogenate of 
half cerebra was used, keeping in mind that only the largest changes in 
expression would be observed, and that less significant changes or alterations in 
specific brain regions or in subpopulations of neurons would not be found. On the 
CM 10 ProteinChip array, 11% of the peaks were significantly different, with 60% 
of the changes increased and 40% decreased. These results were consistent with 
the brain gene expression data previously obtained with 18 week R6/1 half 
cerebra (Hodges etal. 2008), where 15% of the probesets were dysregulated, 
with 60% upregulated and 40% downregulated.
Choosing the timepoint to analyse the Hdh092 brain proteome was less 
easy than it was with the R6/1, as there was no evidence of an overt behavioural 
phenotype in these animals at the time of the experiments (Wheeler et al. 1999). 
However, the existence of nuclear inclusions by the age of 14 months (Wheeler et 
al. 2000) and even as early as 5 months in the caudate and the olfactory tubercle 
in the colony used in this study (Bayman-Weston, unpublished), indicated that
134
changes consistent with HD pathology were certainly taking place in the older 
animals. As this model was considered a more accurate representation of the 
adult onset form of the human disease (Menalled 2005) and these animals were 
living a normal lifespan, an 18 month timepoint was expected to present with 
many differentially expressed proteins. Subsequent studies endorsed this choice: 
although there were no overt motor deficits, a mild behavioural phenotype was 
detected from as early as 4 months (Trueman et al. 2007; Trueman et al. 2008), 
molecular and neuropathological changes from 5 months (Brustovetsky et al. 
2005; Lynch et al. 2007) and gene expression changes in the striatum at 18 
months (Kuhn et al. 2007). In contrast to the initial experiments with the R6/1 
model where half cerebra was used, the more specific pathology in the Hdh092 
model (Wheeler etal. 2000; Trueman et al. 2007; Trueman etal. and 2008) was 
investigated using microdissected brain regions. At the outset, the caudate- 
putamen was examined as this is known to be the earliest and most affected brain 
region in HD, both in this mouse model (Wheeler etal. 2000; Brustovetsky etal. 
2005; Kuhn et al. 2007; Trueman et al. 2008) and others (Laforet et al. 2001; 
Kennedy et al. 2003; Menalled et al. 2003; Slow et al. 2003, Freeman et al. 2004; 
Van Raamsdonk et al. 2005), as well as in humans (Vonsattel et al. 1985; Myers 
etal. 1988; Heinsen etal. 1994; Kennedy etal. 2003; Hodges et al. 2006). 
However, various degrees of pathology have been shown in other brain areas in 
the Hdh092 (Lynch et al. 2007; Trueman et al. 2008) and other mouse models 
(Reddy et al. 1998; Slow et al. 2003; Van Raamsdonk et al. 2005), and in humans 
(Spargo etal. 1993; Heinsen etal. 1994; Macdonald etal. 1997; Halliday et al. 
1998). To assess whether this more limited pathology in the other regions was 
reflected in fewer protein changes in these areas, a comparison was made
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between the caudate-putamen, the hippocampus, the cerebellum and the 
prefrontal and motor cortex combined, all taken from 18 month old littermates.
The analysis on the CM 10 ProteinChip arrays detected a relatively high proportion 
of differentially expressed proteins in the caudate-putamen of HdhQ92/Q92. This 
high level of differential expression was not observed in the other regions, with 
few changes in the hippocampus and the cortex and almost none in the 
cerebellum. These results agree with the picture of HD as a disease affecting 
predominantly the caudate, to a lesser degree the cortex (Sotrel et al. 1991; 
Ruocco et al. 2008 and section 1.4) and the hippocampus (Spargo et al. 1993; 
Jech et al. 2007 and section 1.4) and with very little pathology in the cerebellum 
(Gutekunst et al. 2002 and section 1.4). Moreover, the large fold changes in the 
caudate-putamen were not found in the other regions. Our results also correspond 
with the findings obtained by mRNA microarray analysis on human tissue, which 
showed changes in 21% of the probe sets in the caudate, 3% in the BA4 motor 
cortex and only 1% in the cerebellum. This gene expression study also observed 
that the magnitude of the changes was smaller in the cerebellum than in the 
caudate (Hodges et al. 2006).
Earlier studies both in humans (Weeks et al. 1996; Augood et al. 1997) and 
in mouse models (Cha et al. 1998; Cha et al. 1999; Denovan-Wright & Robertson 
2000; Luthi-Carter et al. 2000) have shown alterations in gene expression as an 
early event in the disease process, often prior to the development of other 
behavioural or molecular phenotypes. To investigate whether animals 
representing stages of minimal deterioration would show alterations in their 
proteomes, the caudate-putamen of 10 and 12 month HdhQ92/Q92 were analysed 
and compared with Hdh+/+ littermates. Surprisingly, the younger animals showed
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only marginally fewer differences than the 18 month old ones, but the magnitude 
of the changes was significantly smaller. Seven significant peaks at 18 months 
were also significant at either 12 or 10 months. Although some changes were 
expected in the younger animals, this relatively high level of differential expression 
was unexpected. On the other hand, the behavioural study performed on 
littermates of these animals showed an early impairment at 4 months, which was 
present through to 14 months without being progressive, not even with the 
appearance of neuronal nuclear inclusions during this period (Trueman et al. 
2008). This would seem to indicate that widespread molecular changes take place 
early on without developing a severe phenotype and that, as the disease 
progresses, some of these changes might be compensated for, some might 
increase in magnitude to intensify the disease characteristics, whilst new 
alterations develop and cause further damage. A high level of differential 
expression early on might also be evidence of compensatory mechanisms at work 
which keep the disorder temporarily under control, despite the early expression of 
the genetic mutation.
Even though the CAG repeat in the Hdh0150 mouse model is about 60% 
longer than in the Hdh092 model, both lines have a normal lifespan and there is 
some parallel in the development of the disorder in these mice (section 1.8.4). 
Hence, the first time point chosen for investigation in the Hdh0150 was 18 months, 
as with the Hdh092, to allow comparison between the models. HdhQ150/Q15° brain 
was expected to present with many differentially expressed proteins at this age, 
given that previous studies reported a succession of behavioural, molecular, 
neuropathological and transcriptional changes prior to this (Lin et al. 2001; Yu et 
al. 2003; Strand etal. 2005; Tallaksen-Greene etal. 2005; Brooks et al. 2006;
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Woodman et al. 2007; Heng et al. 2007; Kuhn et al. 2007). As with the Hdh092, 
microdissected caudate-putamen was examined, as this brain region presented 
an earlier neuropathology, with nuclear inclusions, reactive gliosis and neuronal 
death, than the rest of the brain in this mouse model (Lin et al. 2001; Yu et al. 
2003; Heng et al. 2007; Woodman et al. 2007; Kuhn et al. 2007). The SELDI-TOF 
results were largely consistent with these reports. The 18 month HdhQ150/Q15° 
showed a substantial proportion of differentially expressed proteins and nearly 
twice as many as were found in the 18 month HdhQ92/Q92. The magnitude of the 
changes was somewhat lower in the f-fdhQ150/0150 though, with only a third 
showing a change > 40%, compared with more than half in the HdhQ92/Q92.
Because HdhQ150/Q150 developed various disease characteristics a good 
deal earlier than 18 months, caudate-putamen of 15 month Hdh0150/0150 was 
screened as well. There were significantly fewer differences at 15 than at 18 
months and the magnitude of the changes was considerably smaller in the 
younger animals. These results agree with earlier gene expression results, which 
showed an increasing number of gene expression changes with mounting severity 
of the disease phenotype (Woodman et al. 2007; Kuhn et al. 2007).
Several studies have explored the differences and similarities of the HD 
genetic mouse models (Luthi-Carter et al. 2000; Chan et al. 2002; Menalled 2005; 
Woodman et al. 2007; Kuhn et al. 2007). In the present study, nearly half of the 
differentially expressed proteins were changed in more than one of the mouse 
models tested. The majority of these were found in the two knock-in models. This 
might be due partly to the fact that the assays in these models were performed on 
microdissected tissue, while half cerebra were used for the R6/1. It might also 
point towards a stronger similarity between the Hdh092 and Hdh0150 mouse
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models, which would not be surprising bearing in mind that they were generated 
following similar strategies, even though they have different constructs inserted in 
their Hdh gene (section 1.8.4). One unexpected outcome however, was that more 
than half of the changes detected in both Hdh092 and Hdh0150 displayed a change 
in the opposite direction. This could indicate that, despite being of the same age, 
the animals were in another phase of the disease, and the discrepancy in the 
direction of the changes could be the outcome of compensatory mechanisms at 
work at different stages of the disease process. However, it is also possible that 
some of these discrepancies are due to technical artifacts.
By and large, the results obtained with SELDI-TOF correlated with the 
individual behavioural phenotypes of the different mouse models as well as with 
the findings of the majority of previous research. SELDI-TOF certainly has a 
number of advantages over other proteomic techniques, but some key 
disadvantages too. Several reports have also questioned the reproducibility of the 
system (Diamandis 2004b; Diamandis 2004a; Veenstra et al. 2004; Bons et al. 
2006; De Boer et al. 2006; Harezlak et al. 2007), an issue that was highlighted 
when a group of prostate cancer studies using SELDI failed to reproduce previous 
results (Adam et al. 2002; Qu et al. 2002; Semmes et al. 2005; McLerran et al. 
2008a; McLerran et al. 2008b).
To complement the results obtained by SELDI-TOF, DIGE was used for 
further investigation of the caudate-putamen proteome of the Hdh0150 mouse 
model. The biological significance in HD of the proteins already identified will be 
discussed in Chapter 6.
139
Chapter 4. Comparison of the proteome in the caudate-putamen of the 
Hdh0150 mouse model using 2-D Fluorescence Difference Gel
Electrophoresis (DIGE)
4.1 Introduction to DIGE
The SELDI approach, reported in chapter 3, has some shortcomings. To 
complement the SELDI findings, it was decided to investigate further one of the 
mouse models using a different technique. As the SELDI results showed that the 
caudate-putamen of 18 month HdhQ150/Q150 (Lin etal. 2001 and section 1.8.4) 
displayed the most protein changes, this model, brain region and timepoint were 
chosen for analysis with 2-D fluorescence difference gel electrophoresis (DIGE), 
the Ettan DIGE system of GE Healthcare. The caudate-putamen proteome of 18 
month Hdh0150/0150 was compared with that of their littermates. Protein spots 
found to be differentially expressed by DIGE were identified using matrix assisted 
laser desorption ionisation time-of-flight tandem (MALDI TOF/TOF) mass 
spectrometry.
4.2 Identification of differentially expressed proteins in the HdhQ150/Q1S0 
caudate-putamen using DIGE
4.2.1 The DIGE procedure
2-D electrophoresis (Klose 1975; O'Farrell 1975) is a widely used method 
for separating proteins on a polyacrylamide gel. Proteins are first separated 
according to their isoelectric point (pi) during isoelectric focusing. Isoelectric
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focusing is a technique for separating proteins by their electric charge. The total 
electric charge of a protein will change with the pH of its environment: a protein in 
a solution with a pH lower or higher than its pi will have a positive or negative 
charge respectively. During isoelectric focusing, protein samples are applied to 
the anode end of a gel strip with an immobilised pH gradient. An electric current is 
passed through the gel and proteins will migrate towards the cathode until they 
reach the pH at which the total electric charge of the protein is zero, the pi. This 
procedure concentrates the proteins into well-defined bands, at a point in the pH 
gradient corresponding to the pi of the proteins. To resolve the second dimension, 
the focused gel strip is placed at the top of a polyacrylamide gel and the proteins 
are separated with SDS-PAGE according to their molecular weight, at an angle of 
90° to the first dimension separation.
The DIGE system is a modification of traditional 2-DE (Unlu et al. 1997) 
that has been commercialised by GE Healthcare. It has been successfully used in 
protein profiling (Gade et al. 2003, Apraiz et al. 2006), to screen for biomarkers 
(Huang et al. 2006; Hye et al. 2006; Wu et al. 2007) and to study various types of 
cancer (Somiari et al. 2003; Liang et al. 2005; Yu et al. 2005; Nishimori et al.
2006) and other diseases, such as schizophrenia (Swatton et al. 2004) and 
severe acute respiratory syndrome (Wan et al. 2006).
DIGE is an improvement of 2-DE because it allows multiplexing of up to 
three samples on a single 2-D gel by labelling the samples prior to 2-DE with one 
of three spectrally resolvable fluorescent cyanine dyes (Cy2 , Cy3 and Cy5). The 
dyes attach to the e-amino groups of lysine side-chains and are designed to 
match in terms of charge and molecular weight (~450 Da), so that proteins will 
keep the same mobility in the gel. Initial experiments showed, however, that
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adding too much label could cause precipitation of the proteins due to the 
hydrophobicity of the dyes. Minimal labelling, a protocol in which only 3% of the 
lysine side-chains are labelled, was found to be optimal, as there was still 
sufficient dye present for detection, but it no longer had an effect on the solubility 
of the proteins. As a rule, only one dye molecule attaches per protein in this 
approach. The few proteins with more than one dye molecule attached would be 
in such small numbers that they would not be visible.
Multiplexing with DIGE limits the number of gels used and allows for direct 
comparison between the samples on a single gel. However, the most powerful 
tool in this approach is the option to use one of the dyes for labelling a standard. 
When comparing numerous samples on multiple gels, two samples, one test 
sample and one control, are usually labelled with Cy3 and Cy5 and separated on 
the same gel. The third dye, Cy2, is used to label an internal standard, made up of 
an equal amount of all the samples to be compared in the experiment. An aliquot 
of this standard is applied to each of the gels. Instead of comparing the Cy3 and 
Cy5 samples directly, a ratio is calculated between the measurements of the 
samples and those of the standard. Figure 4.1 shows how these ratios are 
normalised across all the gels involved, based on the Cy2 signal for each gel. The 
option of using an internal standard is one of the key benefits of DIGE. The pooled 
internal standard should also ensure that every protein in each sample appears 
on all the gels. All the experimental samples are then quantified against the same 
standard. This method compensates for gel to gel variation, assists in inter-gel 
matching and significantly increases the accuracy of spot comparison and 
statistics (Alban et al. 2003).
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The 2D-gels are scanned on the Typhoon Trio Variable Mode Imager from 
GE Healthcare. A coloured image is obtained with a different false colour overlay 
for each of the Cy dyes. This is for illustrative purposes only, as quantitative 
measurements are obtained with greyscale pixel intensities. The ensuing images 
are analysed with the DeCyder 2D Software, Version 6.5, from GE Healthcare.
Cy2- standard C y3-sam p le  1 C y5-sam ple 2
Cy3:Cy2 = 1 
Cy5:Cy2 = 1
Gel 1
Cy2- standard C y3-sam p le  3 C y 5 - sample 4
Cy3:Cy2 = 1 
Cy5:Cy2 = 1.5
Gel 2
Cy2-standard C y3-sam p le  5 C y5-sam ple  6
Gel 3 Cy3:Cy2 = 0.5 
Cy5:Cy2 = 0.5
1.6
1.4
1.2
0.8 
0.6 
0 4
0.2
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6
Figure 4.1 Multi-gel DIGE experiment using an internal standard. When comparing the 
spots circled in orange in samples 1-6 visually, the conclusion would be that only the 
protein in sample 3 is differentially expressed and decreased. The measurements 
normalised with the Cy2 signal are listed in the grey boxes next to the gels and 
assembled in the graph below. It shows that, contrary to the first conclusion, sample 3 is 
not differentially expressed but samples 4-6 are, with sample 4 increased and samples 5- 
6 decreased.
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4.2.2 Mouse brain samples
The experiment compared the caudate-putamen of six 18 month 
Hdh0150/0150 (Lin et al. 2001), two female and four male, with six Hdh+/+, three 
female and three male, on six gels. All were littermates from the same colony. 
Each gel ran one test and one control sample. The distribution of the samples 
over the six gels was random, based on a randomised set-up generated by 
Microsoft Excel.
4.2.3 Preparation of samples for DIGE
Sample homogenates in 1.5 ml Eppendorf tubes at the recommended 
protein concentration of 5 mg/ml in a total volume of 10 pi of urea-thiourea lysis 
buffer were labelled with 400 pmol dye (Cy3 or Cy5), according to the 
manufacturer’s instructions. Dilute solutions (< 1 mg/ml) do not label efficiently 
and high protein concentrations ( > 1 0  mg/ml) may cause streaking in the gel due 
to aggregation and precipitation of the proteins (Gorg et al. 2000). Protein sample 
and dye were mixed thoroughly by pipetting and vortexing. The solution was 
microcentrifuged briefly and left on ice for 30 min in the dark. Processing the 
labelled samples and DIGE gels must be carried out in the dark as far as possible, 
to avoid photobleaching of the fluorescent dyes upon exposure to light. The 
reaction was stopped with 1 pi of 10 mM lysine. The solution was mixed and spun 
briefly again and left on ice in the dark for 10-15 min. To compensate for possible 
differences brought about by the dyes, three of the test samples and three 
controls were labelled with Cy3, while the remaining six were labelled with Cy5.
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Parallel to labelling the samples, the internal standard was made up and 
labelled. For this six-gel experiment with 12 samples, the standard was made up 
of a 5 jul aliquot of each caudate-putamen homogenate containing 25 jug of protein 
in urea-thiourea lysis buffer. The 60 pi total volume of standard was labelled with
2.4 nmol Cy2 dye following the protocol described earlier. Before loading the 
samples on to the focusing strips, one Cy3 sample, one Cy5 sample and 10 pi of 
the Cy2 standard were combined in a 1.5 ml Eppendorf tube and mixed. An equal 
volume of 2 x sample buffer (7 M Urea, 2 M Thiourea, 4% w/v CHAPS, 0.01 w/v 
Bromophenol blue, 1% strip specific IPG buffer and 40 mM DTT) was added to 
the mix and incubated on ice in the dark for 15 min. The combined samples were 
subjected to isoelectric focusing (section 2.2.5) and separated on polyacrylamide 
gels (section 2.1.3) by SDS-PAGE (section 2.2.6).
4.2.4 Analysis on the Typhoon Imager: scanning gels
The DIGE gels were scanned on the Typhoon Trio Variable Mode Imager 
while still held between the glass casting plates. This approach is an improvement 
from traditional 2-DE. One of the difficulties in identifying protein spots on, and 
computing matches between, several 2-DE images arises from various degrees of 
distortion of the 2-DE gels during fixing and staining. With DIGE, the gels are kept 
between the casting plates for scanning, which avoids gel distortion and thus 
prevents the introduction of further technical variation.
The three different Cy dyes on a single gel were scanned successively, 
producing three different images, with the default setup specifications. Cy3 was 
scanned with a 532 nm laser and a 580 band pass (BP) 30 emission filter, Cy5
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with a 633 nm laser and a 670 BP 30 emission filter and Cy2 with a 488 nm laser 
and a 580 BP 30 emission filter.
4.2.5 Image analysis bv the DeCvder software: identifying soots
The DeCyder 2D Software, Version 6.5, is a fully automated approach for 
analysing DIGE images obtained with the Typhoon scanner. The software 
detects, matches and quantitates the protein spots and performs statistical 
analysis on the measurements.
Figure 4.2 shows the software start-up screen with the different modules 
and workflow. The Typhoon images are imported into the software by the Image 
Loader module and stored in an Oracle database. There are two possible 
pathways for further analysis. The first uses the Differential In-gel Analysis (DIA), 
followed by the Biological Variation Analysis (BVA) for multiple gels. The second 
uses the Batch Processor.
Differential In-gel Analysis (DIA)
The DIA module analyses up to three images from a single gel, performing 
automated spot detection, background subtraction, quantitation, normalisation and 
within-gel matching. The internal standard is specified as the primary image, while 
the samples to be compared are the secondary and tertiary images. A merged 
image is created from the three individual ones, integrating all the spot details in 
one image. Spot detection and boundary designation are carried out based on the 
pixel data from the individual images in combination with the merged image. The 
sensitivity of the spot detection process is determined by manually specifying the 
total number of spots to be detected. The number recommended in the GE
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Healthcare software manual is 2,500. This should include practically all the protein 
spots present on most 2D gels. Specifying a higher number of spots for detection 
will give more spots, although the majority of the additional spots usually prove to 
be artifacts. An exclusion filter, applied after spot detection, eliminates artifacts 
from the final analysis, by removing spots corresponding to a set of chosen 
parameters from the final spot list. The parameters used in these experiments 
were suggested by the company: maximum slope > 1.1, area < 100, maximum 
volume < 10,000 and maximum peak < 80 and > 65,000. These were somewhat 
lenient and failed to take out all the artifacts, but more rigorous settings risked 
removing real spots as well. The resulting spot map is superimposed on the three 
separate images. As explained in section 4.2.1, protein abundance for the 
secondary and tertiary image is expressed as a ratio of the corresponding spots 
on the primary image. Information on all the protein spots on a gel is saved as an 
XML file, which can be used for inter-gel analysis in other DeCyder modules. 
Figure 4.3 shows the DIA user interface, which offers four types of display: the gel 
image, a three dimensional view of a selected spot, a histogram of all the spots in 
that gel image and a table with information on all these spots.
Biological Variation Analysis (BVA)
The BVA module carries out inter-gel statistical analysis using the 
information held on the XML files. All spot maps are matched to a master image, 
which is generally the one with the highest number of spots. Spot matching is 
done through pattern recognition based on the neighbouring spots. Similar to the 
DIA, the BVA user interface, shown in Figure 4.4, links the gel image, the three 
dimensional view of selected spots and the spot table, but the histogram is
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replaced by a dot plot showing the selected spot in all the samples clustered in 
sample groups. The BVA also has the option to display the gel view of up to 48 
images at once as shown in Figure 4.5, making it easier to verify that a spot has 
been identified correctly in the different images.
Batch Processor
The Batch Processor module links the DIA and BVA module in an 
automated process, which allows analysis of multiple gels without manual 
intervention. Subsequent manual verification of the results is done in the BVA 
module.
The twelve sample experiment of Hdh0150 on six gels was analysed with 
the Batch Processor. All the spots identified as significantly different between the 
two sample groups were manually checked in the BVA module and corrected 
where the matching was found deficient.
4.2.6 Statistical analysis of identified spots
The BVA module offers different statistical tests, but this project only used 
the average ratio calculation and the Student’s t-test. The average ratio specifies 
the fold change: a value of 1.0 represents an unchanged spot, 2.0 indicates a two­
fold increase and -2.0 a two-fold decrease. The Student’s t-test was performed 
between the sample groups HdhQ150/Q150 and Hdh+/+. The threshold for statistical 
significance was set at 0.05. Only spots with p < 0.05 and an average ratio >1.20 
or <-1.20 were followed up.
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D eC yd er” 2D
Differential In-gel Analysis Biological Variation Analysis
XML Too box
Batch Processor
DeCyder
Differential Analysis Software specifically developed as a key element o f the 
0 I6 E  system.
Figure 4.2 Decyder 2D software start-up screen showing the different modules and 
workflow. (1) Images are imported into the software by the Image Loader module. (2) The 
individual images are analysed in the Differential In-gel Analysis (DIA) module and (3) the 
data obtained is stored as an XML file in the XML Toolbox. (4) Multiple gels analysed by 
the DIA can be matched and compared in the Biological Variation Analysis (BVA) 
module. (5) An alternative approach is the automated analysis performed by the Batch 
Processor, which integrates the DIA and the BVA for the analysis of multiple gels without 
manual intervention.
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Figure 4.3 DIA user interface, presenting four types of display linked together.
(1) Gel image with the internal control on the primary gel on the left being compared with 
one of the samples on the secondary or tertiary gel on the right. (2) Three dimensional 
view of a selected spot. (3) Histogram of all the spots on the secondary or tertiary gel 
image. (4) Table with information on all the spots.
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Figure 4.4 BVA user interface, presenting four types of display linked together.
(1) Gel image with the master gel on the left compared to another gel image on the right.
(2) Three dimensional view of selected spots. (3) Dot plot of the selected spot in all the 
samples clustered in sample groups. (4) Spot table.
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Figure 4.5 Gel view of up to 48 images simultaneously in the BVA module.
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4.3 Optimisation of DIGE technique for mouse brain samples
4.3.1 Sample quality and amount of protein on mini gels
To check the quality of the samples and the optimal amount of protein for 
gel loading, two 2DE experiments were performed with 18 month HdhQ150/0150 
caudate-putamen on NuPAGE 4-12% Bis-Tris Zoom mini gels. Focusing was 
carried out on 7 cm 3-1ONL IPG strips (section 2.2.5), followed by SDS-PAGE 
(section 2.2.6). On the first gel 5 jug of protein in 5 pi of homogenate was 
separated and 10 ^g of protein in 10 pi of homogenate on the second gel. Both 
gels were silver stained (section 2.2.7). The two scanned gels in Figure 4.6 show 
a clean image with numerous distinct spots and only a small amount of streaking. 
It was decided that the samples were dean enough to be run without 2D-clean up. 
This prevented the introduction of further technical variation into the sample 
groups during the 2D-clean up step. The gel with 10 jig of protein presented not 
only with more pronounced spots, but also with spots that were hardly or not at all 
visible when using only 5 jxg of protein.
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Figure 4.6 2DE separation of 18 month HdhQ150/Q150 caudate-putamen homogenate on 
NuPAGE 4-12% Bis-Tris Zoom mini gels. Both gels were silver stained. Gel A separated 
5 |ig of protein in 5 pi of homogenate. Gel B separated 10 pg of protein in 10 pi of 
homogenate.
4.3.2 Amount of protein on large gel format
To determine the optimal amount of protein on large format gels, two 2DE 
experiments were performed with 18 month HdhQ150/+ caudate-putamen 
homogenate on in-house large format gels (section 2.1.3). Focusing was carried 
out on 24 cm 3-1ONL IPG strips (section 2.2.5) and SDS-PAGE was performed as 
a batch (section 2.2.6). On the first gel 35 pg of protein in 25 pi of homogenate 
was separated. On the second gel 50 pg of protein in 25 pi of homogenate was 
separated. A third gel separated 75 pg of protein in 25 pi of homogenate, but this 
was carried out in a separate batch on a different day. All gels were silver stained 
(section 2.2.7).
Figure 4.7 shows the scanned images of the silver stained gels. While the 
gels with 35 pg (A) and 50 pg of protein (B) presented a clear image with little 
streaking, the gel with 75 pg of protein (C) had an area with distinct tear formation. 
However, this was believed to be caused not by the higher amount of protein
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present, but in all probability by a leak between the lower and the upper buffer 
chamber during electrophoresis. This notion was corroborated by the presence of 
a matching region on a DIGE gel, pictured in Figure 4.8, which was processed in 
the same electrophoresis batch as gel C.
Although the gel with 35 jug of protein presented a clear image with a 
reasonable number of well defined spots, many of the spots were weak. Using a 
higher volume of protein gave more and stronger spots. It was therefore decided 
to use 50 pg of protein per sample in future DIGE experiments.
pi 3.0 -----------------------------------------► pi 10.0 pi 3.0  ► pi 10.0
Figure 4.7 Silver stained 2D-gels of 18 month HdhQ150/+ caudate-putamen homogenate. 
Gel A separated 35 pg of protein, gel B 50 pg of protein and gel C 75 pg of protein. SDS- 
PAGE was performed on gel A and B in the same batch, while gel C was processed 
separately. While A and B present a clear image with little streaking and well defined 
spots, gel C has an area, highlighted by the red circle, with distinct tear formation, 
possibly due to a leak between the lower and the upper buffer chamber.
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4.3.3 DIGE trials
A DIGE experiment was performed with 18 month Hdh+/+ and HdhQ150/Q15° 
caudate-putamen homogenate on an in-house large format gel (section 2.1.3) 
with 50 jug of protein for each sample. The HdhQ150/0150 sample was labelled with 
Cy5 and the Hdh+/+ sample with Cy3 (section 4.2.3). Focusing was carried out on 
24 cm 3-1ONL IPG strips (section 2.2.5), followed by SDS-PAGE (section 2.2.6) 
and silver staining (section 2.2.7). Figure 4.8 shows the coloured overlaid DIGE 
image and the silver stained image. SDS-PAGE was performed in the same batch 
as gel C in Figure 4.7. Both gels have a corresponding distorted area, highlighted 
by the red circle, which is in all probability due to a leak between the lower and the 
upper buffer chamber. The region is on opposite sides of the gels because they 
were inserted back to back in the electrophoresis unit.
pi 3.0 ---------------------------------------------- ► p| 10.0 pi 3.0  ► p| 10.0
Figure 4.8 DIGE gel of 18 month Hdh+/+ and HdhQ150/Q15° caudate-putamen homogenate. 
The gel separated 50 jig of protein of each sample. The Hdh+/+ sample was labelled with 
Cy3 and the HdhQ150/Q150 sample with Cy5. A shows the coloured image obtained with 
false overlays for each of the Cy dyes. Green spots represent Cy3 and red spots Cy5 
labelled proteins and yellow spots are proteins that are present in both samples. B shows 
the silver stained gel. The red circle highlights a distorted area, probably caused by a leak 
between the lower and the upper buffer chamber.
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A different DIGE experiment was performed with the same samples and 
protocols as in the previous trial. Figure 4.9 shows the silver stained gel and the 
coloured DIGE images. The gel presented a clear image with a large number of 
well defined spots and little streaking, indicating that both the Cy dye labelling and 
the 2DE had worked well. The gel was analysed with the DeCyder DIA module. 
The number of spots to be detected was set at 2,500. An exclusion filter was 
applied with the parameters set out in section 4.2.5. After automated spot 
detection, background subtraction, quantitation, normalisation, artifact exclusion 
and within gel matching, the volume ratio of HdhQ15Q/Q150 over Hdh+/+ was 
calculated. All the spots which showed a fold change > 1.5, indicating a 50% 
increase or decrease, were manually checked for accuracy and corrected where 
matching was found to be inadequate. A total of 2084 spots were detected. The 
exclusion filter removed 362 (=17%) of these. Of the 1722 spots left, 62 (=4%) 
were decreased > 1.5-fold and 53 (=3%) were increased > 1.5-fold. When 
selecting only changes > 2-fold, these numbers dropped to 18 (=1%) decreased 
and 20 (=1%) increased spots.
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Figure 4.9 DIGE gel of 18 month Hdh+/* and Hdh0150/0150 caudate-putamen homogenate. 
The gel separated 50 jig of protein of each sample. A shows the silver stained gel. B is 
the coloured image obtained with false overlays for each of the Cy dyes. Green spots 
represent Cy3 and red spots Cy5 labelled proteins. Yellow spots are proteins that are 
present in both samples. C is the individual coloured image of the Cy3 labelled Hdh+/+ 
sample and D of the Cy5 labelled HdhQ150/Q150 sample.
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4.4 Comparison of H(jhQ1S0/QiS0 and Hdh+/* caudate-putamen proteome
The caudate-putamen proteome of six 18 month HdhQ150/Q150 was 
compared with six Hdh+/+ littermates using DIGE. The samples were run on six 
gels, each with a HdhQ150/0150 and a Hdh+/+ sample and an internal standard. The 
internal standard was labelled with Cy2 , while Cy3 and Cy5 were alternated 
between the sample groups. Table 4.1 gives an overview of the experimental 
design. After the gels were scanned on the Typhoon Imager, they were removed 
from the glass plates and silver stained to visualise the spots for picking. Spots 
cannot be picked directly from the fluor labelled proteins on the gels because the 
Cy dyes increase the molecular weight of the proteins, which causes a shift 
between the minimal amount of labelled protein and the bulk of still unlabelled 
protein. Because of this shift, the fluorescent spots do not correspond to the peak 
of unlabelled protein, which is essential to maximise identification. Figure 4.10 
shows the scanned images of the six silver stained gels.
The six gels were analysed in the DeCyder batch module. Gel matching 
was manually checked and corrected where necessary. Table 4.2 shows the 
number of spots included in the analysis after applying the exclusion filter for each 
of the gels in Figure 4.10, and the number of these that were matched to the 
master gel. Because gel 1 had the highest number of spots, it was designated the 
master gel. Table 4.3 shows what proportion of the spots was present on various 
numbers of gels. Although only 23% of the spots were matched over all the gels, 
almost half of the spots were matched on at least five gels and 82% of them on 
three gels or more. The Student’s t-test took only the results of the gels on which
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a particular spot was detected into the analysis. Gels where the spot was absent 
were excluded for that particular spot.
Of the 2760 spots on the master gel, 47 were differentially expressed with 
an average ratio > 1.20 or < -1.20 and p < 0.05. All 47 spots were checked 
manually for accurate matching and rematched where needed, with a new 
average ratio and p-value calculated for the modified spots. On two occasions, 
this rematching altered the statistical results for a spot so it was no longer 
significantly different. Of the 45 spots left, 10 were gel artifacts and 14 were not 
considered real peaks. Figure 4.11 shows a comparison between a real peak and 
spots which are rejected. A further three spots were too difficult to identify on the 
silver stained gels. This left 18 spots, of which 15 were decreased and 3 
increased. These spots were picked and analysed by MALDI TOF for protein 
identification.
To ensure that no significant spots were missed, all the spots with a p- 
value between 0.05-0.1, 100 in total, were manually checked, rematched where 
necessary and the p-value and average ratio recalculated. For two of the spots, 
this approach moved p < 0.05. These were also picked and analysed by MALDI 
TOF.
Table 4.4 shows the details of the 47 spots with p < 0.05 that were checked 
and the two with initially 0.05 < p < 0.1, which were added after rematching. 
Although not all gel plugs were taken from the same gel, the gel plug numbers 
given in Table 4.4 are all marked on the image of gel 6 in Figure 4.12 for easier 
presentation.
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Figure 4.10 Six silver stained DIGE gels, comparing the caudate-putamen proteome of 
six 18 month HdhQ150/Q150 with six Hdh+/+ littermates. On each gel there was one 
HdhQi5o/Qi5o samp|e one Hdh+/+ sample and an internal standard. The internal standard 
was labelled with Cy2, while Cy3 and Cy5 were alternated between the sample groups 
(ref. Table 4.1). The circles in the top right hand corner and in the lower half of gel 6 are 
air bubbles trapped under the gel during scanning of the silver stain image.
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Table 4.1 Experimental design of a six gel DIGE experiment comparing the caudate-
putamen proteome of six 18 month HdhQ150/Q150 with six Hdh+/+ littermates.
Gel Cy2 Cy3 Cy5
1 Standard Hdh+/+ sample 1 H d h Q150/Q150  s a m p |e  1
2 Standard Hdh +/+ sample 2 H d h ° i 5 m i 5 o  sam p|e2
3 Standard Hdh +/+ sample 3 H d h Q150/Q150  samp|e 3
4 Standard H d h Q 1 5 0 ^ 1 5 0  s a m p | e 4 Hdh+/+ sample 4
5 Standard Hdh 0150/0150 sample 5 Hdh+/+ sample 5
6 Standard Hdh 0150/0150 sample 6 Hdh+/+ sample 6
Table 4.2 Number of spots on six DIGE gels comparing the caudate-putamen proteome 
of six 18 month i-jdhQ150/Q150 with six Hdh+/+ littermates.
gel
Number of spots 1 
spots Included
or all gels 
spots matched 
to master gel
gel 1 2760 = master 2760
gel 2 2741 1821
gel 3 2479 1659
gel 4 2474 1775
gel 5 2528 1811
gel 6 2334 1641
The first column lists the number of spots included after applying the exclusion filter and 
the second column shows the number of spots in each gel that were matched to the 
master gel, in this case gel 1. Gel 1 served as master gel because it generated the 
highest number of spots.
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Table 4.3 Number and proportion of spots matched on six DIGE gels comparing the
caudate-putamen proteome of six 18 month HdhQ150/Q150 with six Hdh+/+ littermates.
Number and % of spots matched over number o f gels
number gels number spots % of total number accumulated %
6/6 gels 644 23 23
5/6 gels 664 24 47
4/6 gels 561 20 68
3/6 gels 406 15 82
2/6 gels 331 12 94
1/6 gels 154 6 100
The first column shows the number of gels. Columns two and three give the number of 
spots matched and the proportion of the total number of spots. The last column gives the 
accumulated percentage of the spots matched.
Figure 4.11 Difference between a real peak and a spot not considered a real peak.
A shows a real peak. B shows a peak caused by a dust particle on the gel. Although the 
pattern in C is generated by proteins present in the gel, they fail to present as individual 
peaks, which makes them impossible to isolate.
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Table 4.4 Spots with a significant difference in the caudate-putamen of HdhQ150/Q150 
compared with Hdh** littermates.
The caudate-putamen proteomes of six 18 month HdhQ150/Q1S0 were compared with six 
Hdhv+ littermates on six DIGE gels. The spots listed have an average ratio > 1.20 or < - 
1.20 and p < 0.05. The spot number was allocated by the DeCyder software for the spots 
on the master gel. The initial p-value and average ratio are listed, as well as the new p- 
value and average ratio for spots that were rematched. The comments indicate which 
spots were picked for MALDI/TOF identification and the reason why others were not. The 
plug numbers can be cross-referenced with the numbers on Figure 4.12 and the gel 
numbers are the reference given to the gels in Figure 4.10. The last two rows show the 
spots which initially had 0.05 < p < 0.1 but acquired p < 0.05 after rematching.
spot number 
on master 
gel
p-value averageratio
p-value
after
rematch
average 
ratio after 
rematch
comment
plug
number
n
gel for 
picking
n
2327 2.80E-05 -1.75 picked for identification 1 5
1597 3.40E-05 -1.31 picked for identification 2 6
1537 8.90E-05 -1.32 7.90E-05 -1.32 picked for identification 3 5
2326 0.00026 -1.63 picked for identification 4 2
2282 0.00033 -1.74 not real peak
1556 0.0004 -1.29 0.00074 -1.30 picked for identification 5 1
2051 0.0013 1.22 gel artifact
862 0.0017 1.21 gel artifact
1119 0.002 -1.26 picked for identification 6 1
2188 0.0031 -1.29 picked for identification 7 4
2439 0.0036 1.35 not real peak
2324 0.0042 -1.22 picked for identification 8 5
2180 0.0049 1.20 picked for identification 9 4
1741 0.0051 -1.33 picked for identification 10 1
2302 0.0055 -1.20 0.039 -1.32 picked for identification 11 6
2760 0.0057 -1.21 0.0089 -1.21 picked for identification 12 1
2050 0.008 1.24 not real peak
2380 0.0086 1.58 not real peak
2036 0.0096 1.35 0.0056 1.31 picked for identification 13 5
2564 0.011 -1.43 0.0017 -1.52 picked for identification 14 1
1116 0.011 1.21 gel artifact
2062 0.014 1.63 gel artifact
1120 0.015 -1.27 0.016 -1.23 picked for identification 15 5
2171 0.02 1.22 not real peak
1109 0.021 1.25 gel artifact
700 0.022 -1.25 gel artifact
1050 0.022 -1.20 not real peak
2325 0.025 1.35 0.006 1.34 picked for identification 16 4
2718 0.029 -1.61 not real peak
2279 0.032 -1.29 not real peak
846 0.032 1.22 0.026 1.19 rematched out
2177 0.034 -1.36 not real peak
1581 0.034 -1.23 0.046 -1.23 picked for identification 17 1
2502 0.037 1.41 not real peak
1108 0.038 1.27 difficult to identify on gel
2228 0.04 -1.28 not real peak
1803 0.04 1.27 0.05 1.20 rematched out
53 0.042 -1.50 not real peak
2170 0.042 -1.31 not real peak
61 0.042 -1.20 gel artifact
216 0.043 1.23 gel artifact
937 0.047 -1.40 not real peak
1857 0.047 -1.27 0.043 -1.21 picked for identification 18 4
1577 0.047 -1.20 difficult to identify on gel
2501 0.048 1.23 gel artifact
763 0.049 -1.54 difficult to identify on gel
1111 0.049 1.39 gel artifact
Spots with initial p-value between 0.05-0.1 but rematched to < 0.05
1082 0.061 -1.29 0.021 -1.29 picked for identification 19 4
1570 0.061 -1.16 0.016 -1.22 picked for identification 20 5
;*) number of spot plug picked can be found on Figure 4.12
(**) gel number refers to the numbers given in Figure 4.10
163
Figure 4.12 Spots picked for MALDI TOF/TOF analysis. Gel 6 shows the spots circled in 
red. The numbers of the spots refer to the plug numbers in Table 4.4.
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4.5 Identification of proteins from DIGE by MALDI TOF/TOF
Trypsin digestion was carried out by Mrs S.H.V. Nixon and MALDI 
TOF/TOF analysis by Dr. I. Brewis at the Proteomics Unit of the Central 
Biotechnology Services at Cardiff University. Of the 20 spots picked, 11 were 
identified, detailed in Table 4.5. The MALDI TOF/TOF identification categories are 
listed in section 3.8.4.
Of the 11 identifications, five were a category 1 and six a category 3. 
Because some proteins were identified from several spots, only six different 
proteins were isolated in total: serine/threonine protein phosphatase 2B (generally 
known as calcineurin) a-isoform (CaN-A) and creatine kinase B chain (CKB) were 
both identified from three spots each, glutamine synthetase (GS) was isolated 
from two different spots and carbonic anhydrase II (CA2), superoxide dismutase 
(SODM) and apolipoprotein E precursor (APOE) were found in single spots.
Figure 4.13 shows the identified spots with the protein match. The proteins that 
were isolated from multiple spots were in most cases a category 1 identification. 
Interestingly, the magnitudes of the changes for the different spots of one 
particular protein were nearly identical. The protein showing the largest change 
was CA2, with an average ratio of -1.75.
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Table 4.5 MALDI TOF/TOF identifications of DIGE spots.
The left section of the table gives the DIGE result for the 20 gel plugs picked fc 
identification. The right section shows the MALDI TOF/TOF identifications, with 
protein match and name, the gene name and the amino acid code for each pe| 
match. The criteria for identification use the expectation value (E.), both for the 
identification and for the peptide matches. The four MALDI TOF/TOF identifica 
categories are: (Cat.1) Conclusive identification with excellent tandem MS date 
more peptides, each peptide with E < 0.05; (Cat.2) Conclusive identification wil 
tandem MS data for one peptide with E < 0.0001; (Cat.3) Probable/possible ide 
with tandem MS data for one or more peptides with 0.05 < overall E < 0.05-0.0 
(Cat.4) Probable/possible identification with MS (not tandem MS) with E < 0.01
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DIGE RESULTS MALDI TOF/TOF identification
Plug p-value Ratio Match Protein Gene name Cat. E. overall Peptide match E. peptide
1 2.80E -05 -1 .75 C A H 2_M O  USE Carbonic anhydrase II C a2 3 2.30E -13
D FP IA N G D R
G G P LS D S Y R
1.80E-01
9 .30E -03
2 3.40E -05 -1.31 G LNA M O U SE Glutamine synthetase G lul 3 5 .10E -04 D IVE A H YR 2 .90E -02
3 7.90E -05 -1.32 no match
4 0.00026 -1.63 no match
5 0.00074 -1.3 G LN A _M O U SE Glutamine synthetase Glut 1 7.20E -44
V Q  AM Y IW V D G T G  EG LR
D IVE A H YR
M G D H LW IA R
L TG FH E TS N IN D FS A G V A N R
R PS A N C D P YA V TEA IV R
H Q Y H IR
1.30E -03  
1.30E-03  
4 .80E -02  
8 .50E -02  
1.20E-01  
1.30E-01
6 0.002 -1.26 PP 2B A _M O U S E Serine/threonine protein phosphatase 2B, catalytic subunit,alpha isoform (Calcineurin A) P p p 3ca 4 1.80E-05
A V P FP P S H R
YLFLG D Y V D R
3.20E-01
5.00E-01
7 0.0031 -1.29 A P O E _M O U S E Apolipoprotein E precursor A p o e 3 6.00E -05 LQ A EIFQ AR 2.60E -02
8 0.0042 -1.22 no match
9 0.0049 1.2 no match
10 0.0051 -1.33 no match
11 0.039 -1.32 no match
12 0.0089 -1.21 K C R B _M O U SE Creatine kinase, B chain C kb 1 8.60E -79
G T  GG VD TA A V G G  V FD V S N A D R
D LFD P IIE E R
VLTPELYAELR
G FC LP P H C S R
TFLV W IN E E D H LR
LAVEALSSLDG DLSG R
LLIEM EQ R
LLIEM EQ R
9.10E -13  
3 .50E -06  
3.70E -06  
4.50E -06  
8 .00E -05  
9 .20E -04  
1 20E-03  
3 .50E -02
13 0.0056 1.31 no match
14 0.0017 -1.52 S O D M _M O U S E Superoxide dismutase (Mn) - mitochondrial precursor
S od 2 3 2.30E -08
G D V TT  Q VALQ PALK
G ELLEAIKR
N VR PDYLK
1 40E-01  
2.90E-01  
5.20E-01
15 0.016 -1.23 PP 2B A _M O U S E Serine/threonine protein phosphatase 2B, catalytic subunit, alpha isoform (Calcineurin A) P pp 3ca 1 9.10E -16
LFE V G G S P A N TR
Y LFLG D YV D R
4.40E -05
2.00E -03
16 0.006 1.34 no match
17 0.046 -1.23 KCRB M O U SE Creatine kinase, B chain C kb 3 7.60E -05 VLTP ELYA E LR 5.20E -04
18 0.043 -1.21 no match
19 0.021 -1.29 PP 2B A _M O U S E Serine/threonine protein phosphatase 2B, catalytic subunit,alpha isoform (Calcineurin A) P p p 3ca 1 9 .10E -11
LFE V G G S P A N TR  
EVF DNDG KPR
2.70E -03
4 .70E -02
20 0.016 -1.22 KCR B _M O U SE Creatine kinase, B chain Ckb 1 4.30E -13
G TG G V D TA A V G G V FD V S N A D R
VLTPELYAELR
D LFD P IIE E R
8.50E -05  
6 .50E -03  
1.40E-02
CaN-A
s o d M . «
'  ^
Figure 4.13 Spots with identifications. The spots that were identified are circled in red 
and the corresponding protein matches are specified. The numbers of the spots and 
details of the protein matches can be found in Table 4.5.
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4.6 Discussion
The work reported in this chapter was carried out using DIGE, a variation of 
two-dimensional gel electrophoresis, which allows multiplexing of samples on the 
same gel by using fluorescent dyes. This technique was chosen to complement 
the SELDI analysis since some of the limitations of SELDI are not an issue or are 
less of an issue with DIGE. While the molecular weight range available to SELDI 
is limited to proteins below 20 kDa, the 2-DE approach with DIGE can 
theoretically visualise proteins of any size, although in actual fact high and low 
molecular weight proteins are still difficult to detect (Corthals et al. 2000; Oh-lshi 
et al. 2000). This was obvious in the present study where the sizes of the 
identified proteins were all between 25-59 kDa even though the corresponding 
spots were distributed over the larger part of the gels, from high to low molecular 
weight. This demonstrated that the main separation happened between 
approximately 20-100 kDa and that few proteins were detected outside this 
molecular weight range.
2-DE has other limitations which restrict the number of proteins within 
reach. Very acidic and very basic proteins are difficult to detect (Bae et al. 2003). 
This was evident on the experimental gels, where the extreme left (low pi) and 
extreme right (high pi) of the gels showed a substantial amount of streaking, with 
few clearly defined individual spots. The proteins that were identified ranged 
between pi 5.3-8.8 and the areas to the left and to the right of these became 
increasingly streaky and indistinct. Due to poor solubilisation, membrane bound 
proteins also prove hard to capture on a gel (Molloy 2000; Santoni et al. 2000a;
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Santoni et al. 2000b) and lower abundance proteins are notoriously difficult to 
isolate (Fountoulakis etal. 1999a; Fountoulakis etal. 1999b; Gygi etal. 2000a).
Another concern with DIGE is the numerous steps in the protocol which 
can introduce a substantial degree of technical variation, perhaps limiting the 
value of the quantitative outcome. Therefore, being able to avoid the 2D-clean up 
certainly limited the degree of error in this study. The cost of the dyes used in 
DIGE can definitely be a restricting factor for any large scale experiments too.
Despite a number of limitations, DIGE does have some key advantages 
over SELDI. One discussed earlier is the wider molecular weight range 
accessible with DIGE. Another is the number of proteins resolved simultaneously. 
Although one study reported 10,000 proteins on a single large format 2-DE gel 
(Klose 1999), gels routinely resolve around 2,000  spots (Ong & Pandey 2001), a 
number which was exceeded in this study. This is about twenty times as many 
proteins as with SELDI, even though it is still only a fraction of the mouse brain 
proteome. The 2DE approach of DIGE also provides some basic information on 
the captured proteins, such as their approximate molecular weight and isoelectric 
point, and it allows the study of protein isoforms and post-translational 
modifications. Still, the main advantage of DIGE over SELDI is undoubtedly the 
straightforward access to the proteins of interest for isolation and identification. 
With DIGE, only 6% of the significantly different spots were not picked because 
they were too difficult to identify on the gels. This is in stark contrast to SELDI, 
where 80% of the significantly altered proteins could not be isolated. This direct 
way of processing also compensates for the larger amount of sample 2-DE 
requires.
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The SELDI analysis of the R6/ 1, Hdh092 and Hdh0150 mouse models 
established 18 month Hdh0150 caudate-putamen as the model, brain region and 
time point with the highest number of differentially expressed proteins. As this was 
the first time the DIGE technique was used to screen and compare a large 
number of samples within one experiment in this laboratory, the 18 month Hdh0150 
caudate-putamen samples were chosen as they were expected to show a 
substantial number of differences. Since the DIGE equipment can process only 
six gels simultaneously, six HdhQ150/Q15° were compared with six Hdh+/+. All six 
gels were of sufficient quality to be included in the analysis and more than 80% of 
the spots were matched on at least half of the gels, which was a high rate of 
matching (Freeman & Hemby 2004). The HdhQ150/Q15° displayed a little less than 
5% differentially expressed proteins, about half increased and half decreased.
This measure of change was significantly lower than that detected by SELDI, 
which found 18% differentially expressed proteins, when only changes with p < 
0.05 are considered. The magnitude of the changes detected with SELDI and 
DIGE was comparable. The discrepancy in the levels of dysregulation between 
the two techniques may be a technical difference introduced by the individual 
procedures. On the other hand, it may correspond to a true variation, with a higher 
proportion of small proteins being dysregulated.
MALDI-TOF analysis identified only 11 of the 20 spots picked. It was 
recognised that five of the spots without identification were weak spots (Figure 
4.12: spots number 4, 9, 11, 16 and 18), which most likely did not contain enough 
protein for the analysis. A way to avoid this obstacle in future would be to use a 
preparative spot picking gel with a higher protein load of the sample mix, thus 
maximising the amount of protein extracted from each spot. This gel would be
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matched to the data obtained from the analytical gels so that spots of interest 
could be accurately picked. The failure to identify the remaining four spots could 
be due to some technical shortcoming of the MALDI process, possibly caused by 
co-migrating proteins, which MALDI may not be able to distinguish. It is also 
possible that the proteins in the samples have not yet been entered in the 
reference databases.
Three of the six proteins identified were isolated from more than one spot 
on the gel. Because of this, the category 4 identification for plug number 6 was 
accepted as a true identification. Different spots for one protein on a gel could 
correspond to different isoforms of this protein or may represent post-translational 
modifications such as phosphorylation, glycosylation or proteolytic cleavage. All 
these alterations could adjust the molecular weight of the protein or its charge, 
and therefore the isoelectric point, or both, and affect how the protein travels in 
the gel. This behaviour has been noted repeatedly in the past (Gygi et al. 2000b; 
Johnston-Wilson et al. 2000; Zabel et al. 2002; Welin et al. 2004; Brigulla et al. 
2006; McDonald et al. 2006; Selicharova et al. 2007).
Previous studies have reported behavioural, molecular, neurological and 
transcriptional changes by 18 months in Hdh0150, with many changes happening 
earlier in the striatum than in the other brain regions (section 1.8.4 and Lin et al. 
2001; Yu etal. 2003; Strand etal. 2005; Tallaksen-Greene etal. 2005; Brooks et 
al. 2006; Woodman et al. 2007; Heng et al. 2007; Kuhn et al. 2007). Therefore, 
^ ^ 0150/0150 caudate-putamen was expected to show a significant number of 
differentially expressed proteins by this age. Although DIGE did not identify as 
high a proportion of changes as SELDI did, the outcome was still consistent with 
previous results.
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DIGE certainly offers some clear advantages over SELDI and other 
proteomic techniques, despite certain limitations. One of these shortcomings is 
the difficulty in capturing certain groups of proteins. This can, to some degree, be 
matched by enriching samples for certain proteins, either by pre-fractionation or 
by separation through multiple narrow-range isoelectric focusing steps (Gorg et al. 
2000). The DIGE approach can also be complemented by peptide-based shotgun 
proteomics, which identifies proteins in complex mixtures using a combination of 
high performance liquid chromatography combined with mass spectrometry (Hu et 
al. 2007). This method is no longer limited by the molecular weight or isoelectric 
point of proteins.
As with many high throughput biological research tools, the statistical and 
experimental management of research projects is paramount. This is also the 
case with DIGE and has been examined by various groups (Fodor et al. 2005; 
Karp & Lilley 2005; Karp et al. 2007). Despite some drawbacks, DIGE certainly 
has potential in biological and medical research, although thorough experimental 
design and the right statistical analysis are essential.
To confirm the results obtained by SELDI-TOF and DIGE and to investigate 
further the proteins identified, western blot analysis was performed on several of 
the proteins. The biological significance of the proteins discovered will be 
discussed in Chapter 6 .
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Chapter 5. Confirmation of SELDI-TOF and DIGE results by western
blot analysis
5.1 Introduction to western blot
Some of the proteins identified by MALDI TOF/TOF from the SELDI-TOF 
and DIGE results were further investigated by western blot analysis. The 
quantities of these proteins in brain samples of HdhQ92/Q92 and Hdh0150/0150 were 
compared with those of their wild type littermates. The samples matched the 
mouse models, ages and brain regions in which the differential expression of 
these proteins was detected by SELDI-TOF and DIGE. To complete the picture, 
some western blot analysis was performed on samples in which no significant 
difference had been detected by SELDI-TOF or DIGE previously. Samples were 
probed with antibodies against Cytochrome c oxidase polypeptide Vlb (COX-Vlb), 
10 kDa heat shock protein (HSP10), 60 kDa heat shock protein (HSP60), Myelin 
Basic Protein (MBP), Calcineurin A (CaN-A), Creatine Kinase BB (CKB), 
Glutamine Synthetase (GS) and Superoxide Dismutase (SODM).
5.2 Optimisation of antibodies
All antibody optimisation experiments were performed with 10 month 
HdhQ92/+ homogenate of half cerebra on 10% and 12% Bis-Tris NuPage gels, 
testing two or three primary antibody dilutions for each, based on the 
recommendations of the suppliers (section 2.2.9). The primary antibodies chosen 
for optimisation were raised against COX-Vlb, HSP10, MBP, CaN-A, CKB, GS,
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SODM, Calmodulin (CaM) and Apolipoprotein (APOE). The primary antibodies 
against HSP60 and a-tubulin and the secondary antibodies had previously been 
optimised in this laboratory. Only one dilution was tried for CKB to avoid using too 
much of the antibody. The blots were scanned on the LiCor Odyssey infrared 
detection system (LI-COR Biosciences).
The antibodies against COX-Vlb, HSP10, CaN-A, CKB, GS and SODM 
presented a clear discrete band of the expected size. The antibody against MBP 
was expected to detect the four isoforms of MBP (14 kDa, 17.2 kDa, 18.5 kDa and 
21.5 kDa), which was the case. The antibodies against CaM and APOE failed to 
produce bands and were not used for further screening. Table 5.1 summarises 
the optimisation particulars, with images of the bands and the antibody dilutions 
used for further screening.
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Table 5.1 Antibody optimisation experiments.
Antibody Gel Sample Protein/lane Results
Dilution for 
screening
Mouse monoclonal 
anti-COX 
(cytochrome c 
oxidase) Vlb 
(COX-Vlb)
12%
Bis-Tris
HdhP92/* 
10 months 
Vi cerebra
50 ng
J-lO kD a  
1/2,000 1/1,000 1/500
1/1,000
Rabbit polyclonal 
anti-Cnp10 
(HSP10)
12%
Bis-Tris
HdhP92/t 
10 months 
Vi cerebra
50 pg J^lOkDa
1/10,000 1/5,000 1/1,000
1/1,000
Rabbit polyclonal 
anti-Myelin Basic 
Protein 
(MBP)
12%
Bis-Tris
HdhP92'* 
10 months 
Vi cerebra
50 pg
l l l l l l l i l B I B I l l l l l H S » l § 8 ^ 14 kDa
1/6,000 1/3,000 1/1,000
1/2,000
Rabbit polyclonal 
anti-Calmodulin 
(CaM)
12%
Bis-Tris
HdhP92/* 
10 months 
Vi cerebra
20 pg 
50 pg 
100 pg
[1] 20 pg protein in 1/2,000 -1/1,000 -1/500 — no bands
[2] 100 pg protein in 1/500 and 50 pg in 1/500 -1/100 —*• no bands
[3] 50 pg protein in 1/1,000 -1/500 -1/100 (no tween) -> no bands
[4] 50 pg protein in 1/1,000 -1/200 (overnight) —► no bands
not used for 
screening
Rabbit polyclonal 
anti-Calcineurin A 
(CaN-A)
10%
Bis-Tris
Hdtfi92* 
10 months 
% cerebra
20 pg
J J -6 2 k D a  
1/5,000 1/2,000
1/2,000
Rabbit polyclonal 
anti-Creatine 
Kinase BB 
(CKB)
12%
Bis-Tris
HdhPa2/* 
10 months 
Vi cerebra
50 pg = J J - 4 3  kDa
1/100
1/200
Rabbit polyclonal 
anti-Glutamine 
Synthetase
(GS)
10%
Bis-Tris
Hdfrp9v*
10 months 
Vi cerebra
20 pg
J J -4 2 k D a  
1/10,000 1/5,000
1/10,000
Mouse monoclonal 
[2A1 ] arrti- 
Superoxide 
Dismutase2 
(SODM)
10%
Bis-Tris
Hdtp™* 
10 months 
Vi cerebra
20 pg
J  -2 5  kOa 
1/4,000 1/2,000
1/2,000
Rabbit monoclonal 
[EP1374Y]anti- 
Apolipoprotein E 
(APOE)
10%
Bis-Tris
HOP9**  
10 months 
Vi cerebra
50 pg 1/50,000 -1 /20 ,000- no bands
not used for 
screening
Summary of the optimisation of antibodies against proteins found to be differentially 
expressed in Hdh692/092 and HdhQ150/Q150 by SELDI-TOF and DIGE. The protein 
abbreviation between brackets under the name of the antibody in the first column will be 
used henceforth.
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5.3 Western blot procedure
Western blot analysis was carried out on 10% or 12% Bis-Tris NuPage 
gels, following procedures in sections 2.2.6 and 2.2.9. The blots were scanned 
and quantitated on the LiCor Odyssey infrared detection system, which can read 
multiple proteins on a single membrane. Primary antibodies raised in mouse were 
probed with secondary IR Dye 800 anti-mouse and scanned at wavelength 800 
nm, generating green bands. Primary antibodies raised in rabbit were probed with 
secondary Alexa Fluora 680 goat anti-rabbit IgG and scanned at wavelength 700 
nm, generating red bands. This made it possible to probe for two proteins on a 
single blot, even if these proteins were similar in size, provided that the primary 
antibodies were raised in different species. Every blot was at the same time 
probed with an antibody against a-tubulin, to control for variation in loading. 
Student’s T-test analysis was performed on the normalised fluorescence intensity 
values, generated by the LiCor Odyssey system. Table 5.2 gives a summary of 
the antibodies used for comparing HdhQ92/Q92 and f - j^ 0150/0150 caudate-putamen 
with WT littermates.
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Table 5.2 Antibodies for comparing HdhQ92/Q92 and HdhQ150/Q15° caudate-putamen with WT
littermates.
Protein Company Cat No. Production Dilution Secondary antibody
COX-Vlb Invitrogen A21366 mouse mono 1/1,000 IR Dye 800 anti-mouse
MBP Chemicon AB980 rabbit poly 1/1,000 Alexa Fluora 680 goat anti-rabbit IgG
HSP10 Abeam ab53106 rabbit poly 1/2,000 Alexa Fluora 680 goat anti-rabbit IgG
CaN-A Abeam ab3673 rabbit poly 1/2,000 Alexa Fluora 680 goat anti-rabbit IgG
CKB Abeam ab38211 rabbit poly 1/200 Alexa Fluora 680 goat anti-rabbit IgG
GS Abeam ab49873 rabbit poly 1/10,000 Alexa Fluora 680 goat anti-rabbit IgG
SODM Abeam ab16956 mouse mono 1/2,000 IR Dye 800 anti-mouse
HSP60 Abeam ab46798 rabbit poly 1/20,000 Alexa Fluora 680 goat anti-rabbit IgG
a-tubulin in-house mouse mono 1/50,000 IR Dye 800 anti-mouse
Summary of antibodies used in western blot analysis (section 5.4). All secondary 
antibodies are used at a 1/5,000 dilution. (Cat. No. = company catalogue number; mono 
= monoclonal; poly = polyclonal).
5.4 Comparison of HdhQ92/Q92 and HdhQ150/Q1S0 caudate-putamen with their
WT littermates by western blot analysis
COX-Vlb was identified as differentially expressed in 12 month HdhQ92/Q92 
and 15 and 18 month Hdh0150/0150 by SELDI -TOF. Western blot analysis 
confirmed these results in 12 month HdhQ92/Q92 and 18 month HdhQ150/Q15° with p < 
0.05 (Figure 5.1 and Table 5.3).
The 14 kDa isoform of MPB was identified as differentially expressed in 12 
and 18 month HdhQ92/Q92 by SELDI -TOF. Western blot analysis confirmed these 
results in 12 month HdhQ92/Q92, but only with a band of p < 0.1. To investigate 
whether a change in 14 kDa MPB could be detected in younger animals, western 
blot analysis was performed with 10 month HdhQ92/Q92. The result was not 
significant. To examine whether a change in 14 kDa MPB could be detected in
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HdhQ150/0150, western blot analysis was performed with 18 month Hdh0150/0150\ the 
result was not significant (Figure 5.2 and Table 5.3). Since the antibody against 
MPB also detects the 17.2, 18.5 and 21.5 kDa isoforms, quantitation was 
performed on these bands as well. None of these isoforms was significantly 
different in Hdh092/092 and Hdh0150/0150 (Table 5.4).
HSP10 was identified as differentially expressed in 15 and 18 month 
f-ldfrQismiso ^  SELDI-TOF. Western blot analysis showed the same directional 
change in the 18 month animals, although only with a band of p < 0 .1. To 
investigate whether a change in HSP10 could be detected in younger animals, 
western blot analysis was performed with 10 month old Hdh0150/0150 and a 
combination of 3 and 4 month old Hdh0150/0150. There was a decrease in the 10 
month Hdh0150/0150, but as there were only two samples of each genotype 
available, no statistical comparison was performed. The result in the 3 and 4 
month animals showed no significant difference. To investigate whether the 
changes of HSP10 shown in Hdh0150/0150 could also be detected in Hdh092/092, 
western blot analysis was performed with 18 month Hdh092/092. The result was 
highly significant and showed a substantial decrease in HdhQ92/092 (Figure 5.3 and 
Table 5.3).
Although HSP60 was not one of the proteins identified by SELDI-TOF or 
DIGE, its association with HSP10 (section 6 .2) made it a candidate for further 
examination. Unfortunately the protein bands visualised by the antibody were too 
weak for accurate statistical analysis. Increasing the antibody concentration or 
using more protein did not improve the intensity of the bands.
Using DIGE, a 23%-29% decrease of CaN-A was observed in 18 month 
f_l^Qi5o/Qi5o Aithi0Ughi the western blot result was not significant, it showed the
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same directional change of near identical magnitude. Hdh0150/0150 of 15 months 
showed a larger decrease with p < 0.1 (Figure 5.4 and Table 5.3).
A decrease of around 22% for CKB in 18 month Hdh0150/0150 was observed 
using DIGE. Western blot analysis showed a significant and more substantial 
decrease in the 18 month animals. This was also the case for 15 month 
HdftCHso/Qiso with p < 0 .1. f- jf j^ 150^ 150 of 10 months showed a substantial increase 
(Figure 5.5 and Table 5.3).
For GS, DIGE analysis showed a highly significant decrease of around 
31% in 18 month Hdh0150/0150. Western blot analysis confirmed this result. 
HcjhQi5o/Qi5o -j 5 months showed a more substantial decrease with p < 0 .1. The 
results in 18 month HdhQ92/Q92 were significant and showed a slight increase 
(Figure 5.6 and Table 5.3).
One of the highest expression differences detected by DIGE was a 52% 
decrease of SODM. However, western blot analysis was not significant (Figure 
5.7 and Table 5.3).
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COX-Vlb expression
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Figure 5.1 Differential expression of COX-Vlb in mouse caudate-putamen.
A. Bar chart showing the results of western blot analysis of caudate-putamen of
• 12 month Hdh092/092 compared with HdhQ+/+;
• 18 month HdhQ150/Q150 compared with HdhQ+/+\
• 15 month HdhQ150/Q150 compared with HdhQ+/+.
A significant difference in COX-Vlb expression is shown in 12 month Hdh092/092 and 18 
month HdhQ150/0150 caudate-putamen compared with HdhQ+/+ caudate-putamen. The 
number of samples in the wild type and homozygote sample groups are indicated inside 
the bars. Error bars indicate standard error of the mean. For details on antibodies and 
western blot procedures see section 5.3 and Table 5.2. Representative images are 
shown in Figure 5.1.B.
1. H dh092 -  12 months 
HOM HOM WT WT
2. Hdh 0150 -  18 months 
HOM HOM WT WT
n E E | a-tubulin
B B 3 E S S COX -VI b □ Q B B
a-tubulin  
COX -VI b
3. HdhQ1S0 -  15 months 
HOM HOM W T W T
a-tubulin
COX-Vlb
B. Representative greyscale images of western blot analysis presented in Figure 5.1.A:
(1) 12 month Hdh°®2; (2) 18 month HdhQ150\ (3) 15 month Hdh0150. (HOM = homozygote;
WT = wild type)
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Figure 5.2 Differential expression of the 14 kDa isoform of MBP in mouse caudate- 
putamen.
A. Bar chart showing the results of western blot analysis of caudate putamen of
• 18 month HdhQ92/Q92 compared with HdhQ+/+\
• 12 month Hdh092/092 compared with HdhQ+/+\
• 10 month Hdh092/092 compared with HdhQ+/+\
• 18 month HdhQ150/Q15° compared with H d tf**.
The lack of difference in the expression of the 14 kDa isoform of MBP is shown in 
HdhQ92/Q92 and Hdh0150/0150 caudate-putamen compared with Hdh<Q+/+ caudate-putamen. 
The number of samples in the wild type and homozygote sample groups are indicated 
inside the bars. Error bars indicate standard error of the mean. For details on antibodies 
and western blot procedures see section 5.3 and Table 5.2. Representative images are 
shown in Figure 5.2.B.
1. Hdh092 -  18 months 
HOM HOM WT WT
2. Hdh092 -  12 months 
HOM HOM WT WT
a-tubulin
MBP-14 kDa
a-tubulin 
MBP-14 kDa
3. HdhQ92 - 1 0  months 
HOM HOM WT WT
4. HdhQ15° -  18 months 
HOM HOM WT WT
a-tubulin |  a-tubulin
MBP-14 kDa |  MBP-14 kDa
B. Representative greyscale images of western blot analysis presented in Figure 5.2.A:
(1) 18 month Hdh092-,(2) 12 month Hdh092-,(3) 10 month (4) 18 month
(HOM = homozygote; WT = wild type)
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Figure 5.3 Differential expression of HSP10 in mouse caudate-putamen.
A. Bar chart showing the results of western blot analysis of caudate-putamen of
• 18 month Hdh0150/0150 compared with HdhQ+/+;
• 15 month HdhQ150/Q150 compared with Hc//?Q+/+;
• 10 month HdhQ150/0150 compared with HdhQ+/+\
• 3+4 month HdhQ150/Q15° compared with H dh°^\
• 18 month Hdh092/092 compared with HdhQ+/+.
A significant difference in HSP10 expression is shown in Hdh092/092 caudate-putamen, a 
difference in 10 month HdhQ150/Q15C caudate-putamen and the lack of difference in 18 and 
15 month H<jhQ150/Q150 caudate-putamen compared with HdhQ+/+ caudate-putamen. The 
number of samples in the wild type and homozygote sample groups are indicated inside 
the bars. Error bars indicate standard error of the mean. For details on antibodies and 
western blot procedures see section 5.3 and Table 5.2. Representative images are 
shown in Figure 5.3.B.
1. Hdh0150 -  18 months 
HOM HOM W T W T
a-tubulin
HSP10
2. HdhQ150-  15 months 
HOM HOM W T W T
a-tubulin
HSP10
3. Hdh0150-  10 months
HOM HOM W T  W T
a-tubulin
HSP10
4. HdhQ150 -  3+4 months
HOM HOM W T W T
H  a-tubulin
HSP10
5 . HdhQ92 -  18 months
a-tubulin 
HSP10
HOM HOM W T W T
B. Representative greyscale images of western blot analysis presented in Figure 5.3.A:
(1)18 month Hdh™50-, (2) 15 month Hdh0150; (3) 10 month HdhQ150\ (4) 3+4 month
Hdh0150-, (5) 18 month HdhQ92. (HOM = homozygote; WT = wild type)
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Figure 5.4 Differential expression of CaN-A in mouse caudate-putamen.
A. Bar chart showing the results of western blot analysis of caudate-putamen of
• 18 month HdhQ150/Q15° compared with HdhQ+/+\
• 15 month HdhQ150/Q150 compared with HdhQ+/+\
• 10 month HdhQ150/0150 compared with HdhQ+/+;
• 18 month HdhQ92/Q92 compared with HdhQ+/+.
The lack of difference in the expression of CaN-A is shown in Hdh0150/0150 and HdhQ92/Q92 
caudate-putamen compared with HcfhQ+/+ caudate-putamen. The number of samples in 
the wild type and homozygote sample groups are indicated inside the bars. Error bars 
indicate standard error of the mean. For details on antibodies and western blot 
procedures see section 5.3 and Table 5.2. Representative images are shown in Figure 
5.4.B.
2. HdtP150-  15 months1. HdtP150-  18 months
HOM HOM W T W T
a-tubulina-tubulin
CaN-ACaN-A
3. HdtP150-  1 0 months 
HOM HOM W T  W T
a-tubulin
CaN-A
4. HdhP92 -  18 months 
HOM HOM W T W T
a-tubulin
CaN-A
B. Representative greyscale images of western blot analysis presented in Figure 5.4.A:
(1) 18 month Hdh \(2) 15 month Hdh0150’,(3) 10 month (4) 18 month
(HOM = homozygote; WT = wild type)
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Figure 5.5 Differential expression of CKB in mouse caudate-putamen.
A. Bar chart showing the results of western blot analysis of caudate-putamen of
• 18 month HdhQ150/Q150 compared with HdhQ+/+\
• 15 month Hdh0150/0150 compared with Hd/?Q+/+;
• 10 month HdhQ150/Q150 compared with Hdh
• 18 month Hdh092/092 compared with HdhQ+/+.
A significant difference in CKB expression is shown in 18 month HdhQ150/Q1S0 caudate- 
putamen, a difference in 15 and 10 month HdhQ150/Q1S0 caudate-putamen, and the lack of 
difference in HdhQ92/Q92 caudate-putamen compared with Hcf/7Q+/+ caudate-putamen. The 
number of samples in the wild type and homozygote sample groups are indicated inside 
the bars. Error bars indicate standard error of the mean. For details on antibodies and 
western blot procedures see section 5.3 and Table 5.2. Representative images are 
shown in Figure 5.5.B.
1. HdhQ15° -  18 months 2. Hdh0150 -  15 months
HOM HOM W T W T  HOM HOM W T W T
a-tubulina-tubulin
3. Hdh0150-  10 months 4. Hdh092-  18 months
a-tubulin a-tubulin
B. Representative greyscale images of western blot analysis presented in Figure 5.5.A:
(1) 18 month Hdh0™-,(2) 15 month Hdh0'50; (3) 10 month (4) 18 month
(HOM = homozygote; WT = wild type)
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Figure 5.6 Differential expression of GS in mouse caudate-putamen.
A. Bar chart showing the results of western blot analysis of caudate-putamen of
• 18 month HdhQ150/Q150 compared with Hdh0**]
• 15 month HdhQ150/Q150 compared with Hdh0**,
• 10 month HdhQ150/Q150 compared with Hdh0**',
• 18 month Hdh092/092 compared with Hdh0**.
A significant difference in GS expression is shown in 18 month Hdh0150/0150 caudate- 
putamen and 18 month HdhQ92/092 caudate-putamen and a difference in 15 and 10 month 
HclhQi5(VQi5o caudate-putamen compared with Hdh°** caudate-putamen. The number of 
samples in the wild type and homozygote sample groups are indicated inside the bars. 
Error bars indicate standard error of the mean. For details on antibodies and western blot 
procedures see section 5.3 and Table 5.2. Representative images are shown in Figure
5.6.B.
1. Hdh0150-  1 8 months 2. Hdh0150-  1 5 months
HOM HOM WT WT H O ^ H O ^ W T WT- - | - L, r -
a-tubulin a-tubulin
GS II 1 1 J l ~ GS
3. Hdh0150 -  10 months 
HOM HOM W T W T
a-tubulin
GS
4. Hdh092 -  18 months 
HOM  HOM  W T W T
a-tubulin
B. Representative greyscale images of western blot analysis presented in Figure 5.6.A:
(1) 18 month Hdhof5°; (2) 15 month Hdh0150](3) 10 month (4) 18 month
(HOM = homozygote; WT = wild type)
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Figure 5.7 Differential expression of SODM in mouse caudate-putamen.
A. Representative greyscale images of western blot analysis of
• 18 month HdhQ150/0150 compared with HdhQ+/+\
• 10 month HdhQ150/Q150 compared with Hdh0+/+\
• 18 month HdhQ92/Q92 compared with HdhQ+/+.
The lack of difference in the expression of SODM is shown in HdhQ150/Q15° and HdhQ92/Q92 
caudate-putamen compared with HdhQ+/+ caudate-putamen. The number of samples in 
the wild type and homozygote sample groups are indicated inside the bars. Error bars 
indicate standard error of the mean. For details on antibodies and western blot 
procedures see section 5.3 and Table 5.2. Representative images are shown in Figure
5.7.B.
1. HdhQ1S0-  18 months 
HOM HOM WT WT
a-tubulin
SODM
2. Hdh0150-  1 0 months 
HOM HOM WT WT
a-tubulin 
3  SODM
3. Hdh092 -  18 months 
HOM HOM WT WT
a-tubulin
SODM
B. Representative greyscale images of western blot analysis presented in Figure 5.7.A:
(1) 18 month HdhQ?5°; (2) 10 month Hdh0150; (3) 18 month (HOM = homozygote;
WT = wild type)
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Table 5.3 Summary of western blot analysis in Hdh092/092 and Hdh0150/0150 mouse 
caudate-putamen compared to Hdh+/+ caudate-putamen.
Protein Mousemodel Age
SELDI-TOF results Western blot results
p-value Log2FC Samples p-value Log2FC Figure
COX-Vlb
Hdh092 12 months 0.0727 -0.30 5 WT x 5 HOM 0.0498 -0.28 5.1. A
Hdh Q15° 18 months 0.0620 0.32 5 WT x 5 HOM 0.0475 1.22 5.1.B0.0757 0.21
Hdh0150 15 months 0.0722 -0.23 3 WT x 5 HOM 0.0569 0.29 5.1.C
MBP- 
14 kDa
Hdh092 18 months 0.0871 0.24 6 WT x 6 HOM 0.4908 -0.08 5.2.A
Hdh092 12 months 0.0022 0.49 5 WT x 5 HOM 0.0749 0.21 5.2.B
Hdh092 10 months 3 WT x 6 HOM 0.3836 0.16 5.2.C
Hdh0150 18 months 6 WT x 6 HOM 0.2046 -0.21 5.2.D
HSP10
Hdh0150 18 months 0.0270 0.23 3 WT x 3 HOM 0.0948 1.35 5.3.A
Hdh0150 15 months 0.0181 0.43 3 WT x 3 HOM 0.5618 -0.45 5.3.B
Hdh0150 10 months 2 W T x 2  HOM -1.14 5.3.C
Hdh 0150 3+4 months 6 WT x 5 HOM 0.6961 0.11 5.3.D
Hdh092 18 months 6 W T x 6  HOM 0.0065 -0.84 5.3.E
DIGE results
p-value Ratio
CaN-B
Hdh0150 18 months
0.002 -1.26
4 W T x 5  HOM 0.1985 -0.22 5.4.A0.016 -1.23
0.021 -1.29
Hdh0150 15 months 3 WT x 5 HOM 0.0963 -0.64 5.4.B
Hdh0150 10 months 2 W T x 2  HOM 0.17 5.4.C
Hdh092 18 months 6 WT x 6 HOM 0.2171 0.11 5.4.D
CKB
Hdh0150 18 months
0.0089 -1.21
4 WT x 5 HOM 0.0079 -1.42 5.5.A0.016 -1.22
0.046 -1.23
Hdh Q150 15 months 3 WT x 3 HOM 0.051 -1.48 5.5.B
Hdh0150 10 months 2 WT x 2 HOM 1.15 5.5.C
Hdh092 18 months 6 WT x 3 HOM 0.188 -1.1 5.5.D
GS
Hdh0150 18 months 3.40E-05 -1.31 4 WT x 5 HOM 0.0101 -0.4 5.6.A0.00074 -1.30
Hdh0150 15 months 3 WT x 5 HOM 0.084 -0.74 5.6.B
Hdh0150 10 months 2 WT x 2 HOM 0.51 5.6.C
Hdh092 18 months 6 WT x 6 HOM 0.042 0.17 5.6.D
SODM
Hdh0150 18 months 0.0017 -1.52 6 WT x 6 HOM 0.4934 -0.08 5.7.A
Hdh0150 10 months 2 WT x 2 HOM 0.05 5.7.B
Hdh092 18 months 6 WT x 6 HOM 0.6262 -0.06 5.7.C
No statistical analysis was performed on 10 month Hdh°150 western blot results as this 
was a 2x2 analysis. The relevant western blot images are referred to in the last column. 
(WT = wild type; HOM = homozygote)
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Table 5.4 Analysis of the differential expression of the 17.2 kDa, 18.5 kDa and 21.5 kDa 
isoforms of MBP in Hdh092/092 and Hdhr150/Q150 mouse caudate-putamen compared to 
Hdh+/+ caudate-putamen.
Model Age Samples
17.2 kDa 18.5 kDa 21.5 kDa
p-value Log2FC p-value Log2FC p-value Log2FC
Hdh 092 18 months 6 W T x 6  HOM 0.5756 0.07 0.5022 -0.09 0.8263 -0.04
Hdh092 12 months 5 W T x 5  HOM 0.3871 0.12 0.2904 0.15 0.4499 0.15
Hdh 092 10 months 3 WT x 6  HOM 0.3373 0.24 0.4840 0.12 0.7085 -0.08
Hdh0150 18 months 6 WT x 6 HOM 0.9789 0.00 0.4712 -0.15 0.3994 0.18
(WT = wild type; HOM = homozygote)
5.5 Discussion
Western blotting is a critical tool in protein detection and analysis. The 
technique makes it possible to identify a protein in a complex protein mixture and 
to provide information on the protein size. Enhanced chemiluminescence, the use 
of an enzyme-conjugated antibody to cleave a chemiluminescent substrate, is 
probably the dominant technique for detecting proteins in western blot format 
today (Patton 2000). However, as this approach detects single proteins only, 
comparative studies generally involve stripping and re-probing of blots, which can 
introduce a degree of technical variation; stripping can result in uneven protein 
loss across the membrane and incomplete stripping of antibodies can give rise to 
interfering bands when the blot is re-probed (Kaufmann et al. 1987). Other 
western blot methods have attempted to avoid these problems by multiplexing, 
using direct fluorescence in the visible light region, but the reliability of quantitation 
with these techniques has been questioned, as membranes have a degree of 
autofluorescence that can affect the signal. This drawback is largely avoided by 
using fluorophores in the longer wavelength region of the spectrum, where
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membranes have a much lower autofluorescence (Sowell et al. 2002). The main 
advantage of near-infrared (NIR) fluorescence technology, however, is that the 
fluorescent signal provides a linear response to the amount of protein present 
over a much wider range than is the case with non-fluorescent methods (Picariello 
et al. 2006). The NIR detection system also simplifies the protocol as there is no 
longer need for the use of substrate or a dark room. In addition, the fluorescent 
blots are stable for months and can be re-scanned any number of times without a 
significant loss of signal. Despite all of this, western blot analysis is still a semi- 
quantitative methodology.
To minimize variation, all the samples that were compared in one 
experiment in this study were analysed on a single blot. Seven of the proteins 
identified as differentially expressed in HdhQ92/92 and HdhQ150/15° caudate-putamen 
compared with HdhQ+/+ caudate-putamen by SELDI-TOF or DIGE analysis were 
further examined by western blot analysis. The SELDI/DIGE results for three of 
these proteins (COX-Vlb, CKB and GS) were confirmed by western blot analysis 
with p < 0.05. Two more proteins (14 kDa MBP and HSP10) showed a change in 
the same direction, but only with p < 0.1. Western blot results for two of the 
proteins (SODM and CaN-A) were not significant, although a comparable change 
was detected (p < 0.1) for CaN-A at an earlier timepoint in the same mouse 
model. The lack of confirmation by western blot analysis of some of the significant 
SELDI-TOF and DIGE results could be a technical artifact owing to the variation 
between 1 D-gel and 2D-gel systems, the difference in sensitivity of the detection 
systems, inadequate specificity of the antibodies used in western blot analysis or 
the number of samples, which could have been too low to give sufficient power to 
detect any differences. Bearing in mind that all experiments were performed on
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biological replicates, the variation between the individuals within the same sample 
groups could have an effect on the outcome as well. Although the western blot 
analysis was performed on the same brain region, age and mouse model used in 
the SELDI-TOF and DIGE experiments, the samples were not always obtained 
from the same individuals. Further investigation into the expression of these 
proteins in HD transgenic mouse brain with different antibodies and more samples 
might give a better insight. Subsequent analysis of brain sections by 
immunohistochemistry could provide more detailed information on the localisation 
of specific changes. All the proteins identified in this study by SELDI-TOF and 
DIGE were detected in caudate-putamen samples, and it would be most 
interesting to see whether these changes can also be seen in other brain regions.
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Chapter 6. General discussion
The two complementary proteomic techniques used in this study, SELDI- 
TOF and DIGE, identified a total of 16 proteins that were differentially expressed 
in the caudate-putamen of Hdh092 and Hdh0150 mouse models of Huntington’s 
disease. As SELDI-TOF and DIGE select for proteins in different molecular weight 
ranges, the lack of overlap between the two sets of identifications was to be 
expected. Figure 6.1 gives a summary of the proteins with the molecular 
pathways they play a role in.
Energy metabolism
Cytochrome c oxidase Vlb isoform 1 
Cytochrome b-c1 complex subunit7 
Cytochrome c 
Creatine kinase, B chain
Cell Cycle 
• Stathmin HD
Liaand transport
Hemoglobin a-subunit 
Apolipoprotein E precursor
Cellular stress
Glutamine synthetase 
Superoxide dismutase (Mn) 
10 kDa heat shock protein
Signal processing and 
transduction
Calmodulin
Calcineurin, A subunit, a-isoform 
FK506-binding protein 1A 
Carbonic anhydrase II 
Ubiquitin
Myelin basic protein, 14 kDa
Figure 6.1 Proteins identified by SELDI-TOF or DIGE analysis to be differentially 
expressed in HD mouse brain, and the molecular pathways they are part of.
191
6.1 The correlation between proteome and global gene expression
studies in HD
Of the 16 proteins found to be changed in HD mouse brain in this study, 13 
were also significant in gene expression studies (Luthi-Carter et al. 2000; Morton 
etal. 2005; Hodges etal. 2006; Kuhn etal. 2007; Hodges etal. 2008). Table 6.1 
gives a summary of the proteins identified in this study, which were also 
significant in gene expression studies of HD mouse brain and human HD brain. In 
general, the protein and the gene expression data are consistent. Both data sets 
show a higher number of proteins/genes decreased rather than increased in 
expression. Particularly significant is the agreement between the protein and the 
gene data for the 18 month Hdh0150, which provides the only direct comparison 
where the equivalent tissue from the same mouse model was analysed (Kuhn et 
al. 2007). The Hdh0150 protein data also agrees with the gene expression data for 
the Hdh092 mouse model, although the gene results did not achieve statistical 
significance, probably due to the low number of samples used. With the exception 
of superoxide dismutase, the Hdh0150 protein data also agrees with the gene data 
for the R6 mouse models.
Studies that have compared proteome and transcriptome data do not agree 
about the level of correlation between the two techniques. Some studies find a 
high level of similarity (Mijalski et al. 2005; Hartl et al. 2008) and some very little 
correlation in expression between the two levels (Frey et al. 2007). Hartl et al. 
(2008) examined the mouse brain transcriptome and proteome during embryonic 
development and found 60-70% concordance between the two techniques. As a 
large part of the control of embryonic development is known to be at the 
transcriptional level it may be that the concordance is less in adult mouse brain,
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but the data reported here do show a level of concordance that is consistent with 
that reported by Hartl et al. (2008).
The fact that the human gene expression data are less consistent with the 
mouse model proteomic data than the gene expression in the mouse models can 
be attributed to several factors. Most fundamentally, the effects of the HD gene 
may be different in human and in mouse brain: an example of this is the alteration 
in the 14kDa isoform of MBP, which does not exist in humans, that is seen in 
mouse (section 6.2 and Boggs 2006). The human HD brain samples in Hodges et 
al. (2006) had shorter CAG repeats and much longer courses of disease than 
those seen in the animal models. The human brains were nearly all from clinically 
diagnosed HD cases and all will have had some level of neurodegeneration with 
cell loss. Most of these mouse models have no frank neurodegeneration at the 
times at which they were examined (sections 1.8.2 and 1.8.4). Finally, the fact 
that neurodegeneration is more advanced means that in the human brain, 
especially in the caudate, most of the effects on transcription are likely to be 
secondary, and some will be a result of retrograde or anterograde signalling from 
other degenerating brain areas. Nevertheless some of the proteomic changes 
seen in the mouse model striatum are also seen in human caudate.
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Table 6.1 Summary of proteins changed in mouse HD brain, which were also changed in gene expression studies in mouse and 
human HD brain.
Proteins Gene
Protein expression Gene expression
Hdh 092 Hdh Hdh092 ( 1 > Hdh0,50 (2> R6/1 <3) R6/2 Human HD caudate(4)
Cytochrome b-c1 complex Uqcrb
Cytochrome c Cycs (6)
Creatine kinase, B chain Ckb j a (5), (6)
Superoxide dismutase (Mn) Sod2
Glutamine synthetase Glul 1
10kDa heat shock protein Hspel (6)
Calmodulin Calm1,2,3 (6)
Calcineurin-A, a-isoform Ppp3ca |3-isoform B subunit(5)
FK506-binding protein Fkbpla (7)
Carbonic anhydrase II Ca2 I___________  . . . . | (5), (6) CA XI
Myelin basic protein Mbp 14kDa (6)
Apolipoprotein E precursor Apoe (5). (6) cortex
Stathmin Stmnl
co
(1) Kuhn et al.,2007
® Luthi-Carter et al.,unpublished findings
p) Hodges et al.,2008
<4) Hodges ef al.,2006
(S) Luthi-Carter ef al.,2000 
<6) Morton ef al.,2005 
P) increased (Luthi-Carter eta!.,2000); decreased (Morton ef , 2005)
Where the results refer to a different subunit, isoform or brain region, it is indicated in the table.
significant decrease
result not significant, but negative trend
significant increase
result not significant, but positive trend 
increased/decreased in different samples/experiments 
not detected or result not significant
6.2 The functional implications of the observed proteome changes
Some of the proteins identified in this study have been implicated in HD 
pathogenesis, and others are parts of molecular pathways previously recognised 
to play a role in the disorder. Five cellular pathways can be picked out from the 
data: cytochrome c oxidase, cytochrome b-c1, cytochrome c and creatine kinase 
B all contribute to cellular energy metabolism; glutamine synthetase, superoxide 
dismutase and the 10 kDa heat shock protein are associated with cellular stress; 
calmodulin, calcineurin-A, FK506-binding protein, carbonic anhydrase II, ubiquitin 
and myelin basic protein play a role in signal processing and transduction; 
haemoglobin and apolipoprotein E are ligand transporters, and stathmin plays a 
part in the cell cycle.
6.2.1 Proteins involved in energy metabolism changed in HD mouse brain
Mitochondrial dysfunction, energy deficiency and the generation of free 
radicals have been recognised as early events in HD pathology (section 1.7.2). 
Four of the proteins identified in this study are key players in the energy 
production pathway, and their dysregulation may cause some degree of disruption 
to this process.
Cytochrome c oxidase, cytochrome b-c1 and cytochrome c are members of 
the electron transport chain located in the inner mitochondrial membrane (Figure
6.2). The electron transport chain is the mechanism by which energy, in the form 
of adenosine triphosphate (ATP), is extracted from redox reactions by the 
transport of electrons through the chain. Significant changes have been found in
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the activity of the electron transport chain complexes in human HD brain (section
1.7.2).
Cytochrome bc1 complex is the third complex in the electron transport 
chain. Mutations in complex III are known to cause exercise intolerance as well as 
multisystem disorders (Bouzidi et al. 1993). Subunit 7 of this complex was found 
to be decreased in the 18 month HdhQ92/Q92. Changes in complex III have been 
detected in HD earlier (section 1.7.2). It was also demonstrated that it is possible 
to curb metabolic energy insufficiency in HD by promoting complex 111, through the 
administration of coenzyme Q10 supplements in HD patients (Koroshetz etal. 
1997; Andrich etal. 2004), in rats (Kasparova et al. 2005) and in R6/2 mice 
(section 1.7.2 and Smith et al. 2006; Stack et al. 2006).
Cytochrome c oxidase (COX), or complex IV, is the last enzyme in the 
electron transport chain and has been identified as a marker of neuronal 
metabolic activity (Wong-Riley 1989). Subunit Vlb of COX was decreased in 12 
month HdhQ92/Q92 and in 15 month /-/Cf/7Qf5£yQ*50j but then increased in 18 month 
Hdh0150/0150. Previous studies found COX activity significantly decreased in 
human HD caudate (Brennan et al. 1985; Browne et al. 1997; Gourfinkel-An et al. 
2002), and in the striatum, cortex and muscle mitochondria of transgenic R6/2 
mice (Tabrizi et al. 2000; Gizatullina et al. 2006). These reports are in agreement 
with our results in the younger animals, which show a decrease of COX Vlb, 
which may correspond to a deficiency in energy metabolism. Although the 
increase in the 18 month HdhQ150/Q15° might seem inconsistent, a similar outcome 
was found in a QA rat model of HD (Maksimovic et al. 2001).
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The reduction of subunits of complexes III and IV in the HdhQ92/Q92 and the 
15 month Hdh0150/0150 could be indicative of reduced levels of oxidative 
phosphorylation (OXPHOS) and metabolic energy deficiency. Transcriptional 
dysregulation has been suggested as the basis of mitochondrial dysfunction in 
HD, through the interference of mutant huntingtin with transcription factors 
involved with mitochondrial biogenesis and function, such as p53 (Bae et al. 2005 
and section 1.7.2) and the transcriptional coactivator PGC-1a (Cui et al. 2006; 
Weydt et al. 2006 and section 1.7.2), or through direct interaction of mutant 
huntingtin with mitochondria (Panov et al. 2002; Choo et al. 2004; Orr et al. 2008 
and section 1.7.2). It should be noted that the changes identified in complex III 
and IV relate to only one subunit of each of the complexes, and it is uncertain how 
critical an alteration in these would be for the complex as a whole. The increase in 
subunit Vlb of complex IV in 18 month h m 01 50/0150 could be the result of 
compensatory mechanisms at work trying to rescue a failing mitochondrial 
system.
Cytochrome c (cyt c) is not one of the four electron transport complexes, 
but a free floating small heme protein, associated with the mitochondrial 
membrane, that transfers electrons between complex III and complex IV of the 
chain. Cyt c was increased in 18 month Hdh0150/0150. Cyt c was also found to be 
increased in Hdh0111 mice, following the interaction of mutant huntingtin with the 
mitochondrial membrane (Choo et al. 2004 and section 1.7.2). The disintegration 
of the OXPHOS system may lead to increased levels of cyt c as a compensatory 
mechanism to keep OXPHOS running, which in turn could induce apoptosis 
through caspase activation (section 1.7.4). The increase in cyt c in the older 
1-ldfrQi5miso QQy|g| be fl-,0 result of advanced mitochondrial dysfunction. In support
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of this, increased cyt c, in conjunction with elevated caspase 1 and caspase 3 
activity, eventually leading to neuronal dysfunction and cell death, has been 
observed in both mouse and human brain (section 1.7.4).
Electron transport chain
Space between 
inner and outer 
mitochondrial 
membranes
;©©
Inner mitochondrial 
membranee e
Succinate Mitochondrial matrixwaterNADH
Figure 6.2 The electron transport chain. Schematic of the different complexes in the 
electron transport chain and the production of ATP. NADH carries protons (+) and 
electrons (-) to the electron transport chain located in the inner mitochondrial membrane. 
The transfer of electrons along the chain provides the energy to transport protons across 
the membrane, which generates an electrochemical gradient. The accumulating protons 
follow the electrochemical gradient back across the membrane through an ATP synthase 
complex, thus providing the energy to synthetase ATP. The components identified in this 
study are shown in red: III = the cytochrome b-c1 complex; IV = the cytochrome c oxidase 
complex; Cyt c = cytochrome c.
Creatine kinase (CK) is an enzyme which also plays a part in the energy 
housekeeping of the cell by catalysing the conversion of creatine and ATP to 
phosphocreatine and adenosine diphosphate (ADP). This reaction is reversible 
and phosphocreatine, in turn, serves as an energy reservoir for the regeneration 
of ATP, especially in tissues with rapid ATP consumption, such as skeletal 
muscle, smooth muscle and brain. The presence of this energy buffer system
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keeps the ATP/ADP ratio high at subcellular locations where ATP is needed, and 
the breakdown of this system could bring about cellular dysfunction. CK consists 
of two subunits, a muscle (CKM) and a brain (CKB) type. The CKB form was 
found to be decreased in the 18 month Hdh0150/0150in HD, it was demonstrated 
that a decrease in the phosphocreatine ratio (Koroshetz et al. 1997; Lodi et al. 
2000) and a reduction in creatine levels (Sanchez-Pernaute et al. 1999) can result 
in general energy deficiency. Phosphocreatine levels were decreased in human 
HD muscle, reducing the rate of mitochondrial ATP production in symptomatic HD 
patients, and only marginally less so in presymptomatic carriers. Reduced levels 
of creatine in HD patients, and to a lesser degree in presymptomatic carriers, 
correlated with motor and cognitive performance. Creatine supplements are 
widely used to enhance athletic performance and have also been shown to 
enhance brain performance (Rae et al. 2003). In R6/2 mice too, dietary creatine 
supplements were found to exert a neuroprotective effect by increasing 
phosphocreatine levels (Ferrante et al. 2000).
6.2.2 Proteins involved in cellular stress changed in HD mouse brain
Excitotoxicity and oxidative stress have been strongly implicated as 
mechanisms leading to cell death in HD (section 1.7.1 and 1.7.3). Excitotoxicity is 
initiated by pathologically high levels of neurotransmitters, such as glutamate, in 
the brain. A possible contributor to this process is glutamine synthetase (GS). GS 
is an enzyme that is essential in the metabolism of nitrogen by catalysing the 
condensation of glutamate and ammonia to form glutamine. A consequence of 
this process is that GS has an impact on the level of glutamate in the cell and a 
reduction of GS can allow glutamate to accumulate to potentially toxic levels. GS
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was decreased in three samples of 18 month Hdh0150/0150. GS activity was also 
reduced in post-mortem brain from patients with HD and it has been suggested 
that a reduction in its activity may well contribute to HD neuronal pathology 
(Carter 1982; Butterworth 1986). In transgenic R6/1 and R6/2 mice, mRNA levels 
of GS were decreased, prior to any evidence of neurodegeneration (Lievens et al. 
2001; Behrens etal. 2002).
A protein involved in restricting oxidative stress in the cell is mitochondrial 
superoxide dismutase (SODM). SODM, or SOD2, serves a key antioxidant role by 
binding to the superoxide by-products of the electron transport chain and 
converting them to oxygen and hydrogen peroxide. SODM is one of the three 
forms of superoxide dismutase in humans, each with a different cellular location. 
Mice lacking SODM die shortly after birth, displaying massive oxidative stress, 
which illustrates its vital function (Li et al. 1995). SOD has been investigated 
extensively in HD, not always with consistent results. SOD1 and SOD2 were 
found to be expressed at only low levels in MSN, which could explain their 
selective vulnerability in HD to some extent (Medina et al. 1996). Striatal SOD1, 
but not SOD2, was found to be increased in young and decreased in older 
transgenic R6/1 mice. It is possible that this is the result of an early compensatory 
mechanism at work to protect cells from free radical-induced damage, followed by 
a failure of the system in the older animals. In a 3-NP rat model of HD, both SOD1 
and SOD2 were reduced (Santamaria et al. 2001). In HD patients, neither form of 
SOD showed a significant difference in enzymatic activity in skin fibroblast 
cultures (del Hoyo et al. 2006), but SOD2 activity was reduced in peripheral blood 
(Chen et al. 2007). Overexpression of SOD1 reversed the HD phenotype in cells 
expressing mutant huntingtin (Goswami et al. 2006). In this study, SODM was
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found decreased in 18 month HdhQ150/0150. Although there is little conclusive 
evidence from previous studies with respect to the role of SODM in HD, the 
analogy with its family member SOD1 suggests that a decreased SODM in HD 
brain may add to oxidative damage and accelerate neuronal death.
Another group of proteins involved in cell stress and stress responses are 
heat shock proteins (HSPs), or molecular chaperones. When cells are exposed to 
elevated temperatures or other forms of cellular stress, the expression of HSPs is 
increased. HSPs help to establish proper protein conformation, to stabilise 
partially unfolded proteins and to break down old or malfunctioning proteins. In our 
study, the 10 kDa heat shock protein (HSP10) was increased in 15 and 18 month 
old Hdh0150/0150. HSP10 is the human homologue of the bacterial GroES and 
works in conjunction with the 60 kDa heat shock protein, homologue of the 
bacterial GroEL, which is required for the correct folding of many proteins. To 
function, the two HSPs need to work as a protein complex (Monzini et al. 1994; 
Hartl 1996). HSPs have been associated with insoluble polyglutamine protein 
aggregates, possibly in an attempt to remove them (Chai et al. 1999). This was 
also recognised in HD, where HSPs co-localised with perinuclear inclusions 
(Waelter et al. 2001). In addition, treating mammalian cells with geldanamycin 
induced the expression of several HSPs, whilst inhibiting HD exon 1 protein 
aggregation in a dose-dependent manner (Sittler et al. 2001). Subsequently, 
several studies recognised HSPs as aggregate-interacting proteins which 
suppress mutant huntingtin aggregation and neuronal cell death (Mitsui et al.
2002; Fujimoto et al. 2005; Cornett et al. 2006; Goswami et al. 2006; Kitamura et 
al. 2006). Others, however, could not detect this beneficial effect in R6/2 mice 
(Hansson et al. 2003; Zourlidou et al. 2007). Several proteins involved in the heat-
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shock response pathway were shown to be upregulated in cells expressing 
mutant huntingtin, one of which was GroEL (Fan et al. 2008). On the other hand 
HSP70 expression was reduced in transgenic R6/1 and R6/2 brain, and it has 
been suggested that this was caused by the sequestration of the transcription 
factor for HSP70 by mutant huntingtin (Yamanaka et al. 2008). Hay et al. (2004) 
also reported a progressive decrease in protein levels of HSPs in transgenic R6/2, 
but subsequent quantification of mRNA levels showed no changes, so it was 
suggested that the decrease in protein levels could be a consequence of the 
sequestration of HSPs in aggregates (Hay et al. 2004). However, repeated 
experiments confirmed the decreased HSP levels in the transgenic R6/2 and 
showed comparable reductions of HSPs in HdhQ15Q/Q150 (Woodman et al. 2007). 
Only a few studies discuss HSP10/groEL in particular, although they too indicate 
that HSP10/groEL reduces aggregate formation and cell death in mammalian cell 
models of HD, and that HSP10/groEL requires HSP60/groES to function efficiently 
(Carmichael et al. 2000 ; Carmichael et al. 2002). In the present study, the 
increased level of HSP10 in Hdh0150/0150 caudate-putamen may indicate an 
upregulation initiated by the cellular stress in the striatum.
6.2.3 Proteins involved in cell signalling changed in HD mouse brain
A number of proteins involved in calcium signalling were altered in HD 
mouse brain. Aberrant neuronal Ca2+ signalling has been connected with HD 
pathology, both in human patients and in HD mice, and is thought to occur early 
on in the disease process (Hodgson et al. 1999; Panov et al. 2002). Because of 
this, it has been suggested that Ca2+ dysregulation may be an initiating event in 
the pathogenesis of HD, and that high levels of Ca2+ could start the cascade of
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events involving caspase activation (Zeron et al. 2002) and the catalysis of 
huntingtin proteolysis with the generation of toxic huntingtin fragments (section 
1.7.4).
Calmodulin (CaM) was found to be decreased in 10 and 18 month 
HdhQ92/Q92, but increased in 18 month HdhQ150/Q15°. CaM is a calcium-binding 
protein, which in turn binds a number of different proteins, many of them unable to 
bind calcium themselves. In this way, CaM mediates various processes, such as 
inflammation, metabolism, apoptosis, memory, and the immune response. CaM 
was found to interact with huntingtin, and this reaction appeared to be stronger 
with mutant than with wild type huntingtin in human HD brain (Bao et al. 1996). 
Further data suggested that CaM regulates the stabilisation of monomeric and 
aggregated huntingtin through transglutaminase 2. Longer mutant huntingtin 
proteins may be a trigger for transglutaminase cross-linking (section 1.6.4) and as 
such the calmodulin-huntingtin-transglutaminase complex could play a role in the 
formation of insoluble aggregates. This was corroborated by the finding that 
disrupting the CaM-huntingtin interaction decreases cytotoxicity in HD (Zainelli et 
al. 2004; Dudek et al. 2008).
Another protein involved in calcium messaging is the serine/threonine 
protein phosphatase 2B, generally known as calcineurin (CaN). CaN plays an 
essential role in T cell activation and the immune response, and is involved in the 
transduction of calcium signals. It is dependent on calmodulin for its activation. 
CaN is a heterodimer of CaN-A, the catalytic calmodulin-binding subunit, and 
CaN-B, the regulatory calcium binding subunit (Klee et al. 1998). In this study, the 
catalytic subunit was decreased in 18 month Hdh0150/0150'. CaN has already been
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put forward as a player in the HD disease process, although some of the data 
reported are somewhat contradictory. In human post-mortem brain, CaN was 
detected only in neuronal cells and was highly concentrated in the striato-pa11idaI 
and striato-nigral pathways. This pattern of distribution was similar to the one 
found in rat brain (Goto et al. 1986). Some studies proposed a harmful effect of 
the downregulation of CaN. A decreased expression of CaN-B was found in R6/2 
mice, and it was suggested that a deficiency in CaN might contribute to the 
defective neurotransmission process in HD (Lievens et al. 2002). Suppression of 
CaN also dramatically accelerated the neurological phenotype in R6/2 mice, 
putting forward the idea that CaN may play a protective role in HD (Hernandez- 
Espinosa & Morton 2006). In conflict with these reports are two studies proposing 
that CaN is detrimental for striatal neurons. The findings of one suggested that 
inhibition of CaN prevents mutant huntingtin mediated cell death of striatal 
neurons in HD (Pardo et al. 2006), while the other proposed that high levels of 
CaN-A could account for the increased vulnerability of striatal cells expressing 
mutant huntingtin to excitotoxicity (Xifro et al. 2008). Nevertheless, gene 
expression studies support the hypothesis that the lack of CaN contributes to the 
disease process in HD (Table 6.2) The current study also found a decrease of the 
a-isoform of CaN-A in 18 month HdhQ15Q/Q150.
FK506-binding protein 1A (FKBP-1A), also called immunophilin (FKBP12), 
is associated with the calcium release channel, which provides the pathway for 
calcium efflux required for the excitation-contraction coupling in skeletal muscle. It 
is also the binding protein for the immunosuppressant drug FK506, and this 
FKBP-1A/FK506 complex interacts with and inhibits calcineurin, and in this way 
inhibits T cell activation (Liu etal. 1991; Jayaraman et al. 1992). FKBP-1A was
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decreased in.12 month HdhQ92/Q92. In the HD-74Q cell line, FKBP-1A was initially 
significantly reduced, but levels subsequently increased (Kita et al. 2002).
Research into the immunosuppressive drug FK506 demonstrated 
neuroprotective and neuroregenerative effects of the drug in animal models 
recapitulating a wide range of neurodegenerative diseases and conditions 
following brain injury (Gold 1997; Christner et al. 2001; Hamilton et al. 2002; 
Brecht et al. 2003). Initially, CaN inhibition was thought to lead not only to 
immunosuppression, but it was also the proposed basis for this FK506-mediated 
neuroprotection (Dawson et al. 1993). However, FK506-like inhibitors which had 
no influence on CaN activity kept their neuroprotective and neuroregenerative 
properties (Steiner et al. 1997). Although the neuroprotective effects of FKBP 
inhibitors imply an involvement of FKBP-1A in neuronal cell death, there is 
evidence that its inhibition does not affect neuronal protection and regeneration, 
as FK506 retained these properties in cell cultures from FKBP12 knock-out mice 
(Gold et al. 1999; Guo et al. 2001). It is evident that the full function of FKBP-1A 
and its involvement in neurodegenerative disease is still very uncertain and that, 
although a dysregulation of the protein may certainly have some harmful effect, 
the way in which the damage would be inflicted remains unclear.
The most substantial change detected in this study was a 75% decrease of 
carbonic anhydrase II (CA2 ) in 18 month HdhQ15<yQ150. Carbonic anhydrases 
catalyse the conversion of carbon dioxide to bicarbonate and protons, to maintain 
the acid-base balance in blood and other tissues, and to help transport carbon 
dioxide out of the tissues. In the brain, CA2 was found in oligodendrocytes and 
GABAergic neurons (Kida et al. 2006). CA2 is thought to play a crucial role in 
signal transduction, long-term synaptic transformation and memory storage, and
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CA dysfunction is associated with impaired cognition, mental retardation, 
Alzheimer's disease and ageing (Sun & Alkon 2002). There were conflicting 
reports on the level of CA2 in Alzheimer’s disease brain. While some studies 
showed a significant reduction (Meier-Ruge et al. 1984; Sultana et al. 2006), 
some found no change (Vlkolinsky et al. 2001) and others reported the protein 
levels to be significantly increased (Sultana et al. 2007). In Pick's disease, CA was 
decreased (Meier-Ruge et al. 1984) and ageing was also associated with a 
significant decline of CA (Meier-Ruge et al. 1980). A decrease in CA certainly 
features in various forms of neurodegeneration and perhaps it contributes to the 
cognitive decline seen in HD patients.
Ubiquitin attaches to other proteins to label them for proteasomal 
degradation, a process called ubiquitination. As a consequence, ubiquitination 
has some control over the stability, function, and intracellular localisation of a wide 
variety of proteins. Ubiquitination also regulates DNA repair and endocytosis. 
Because of this, the ubiquitin proteasome pathway has been linked to diseases 
involving various types of cellular activity, and it has been suggested that the UPS 
is impaired in HD and contributes to HD pathology, although this is highly 
controversial (section 1.7.6). In the present study, ubiquitin was decreased in 15 
month HdhQ150/Q150.
The last protein involved in signal processing and transduction, which has 
been identified in this study, is myelin basic protein (MBP). MBP is the second 
most abundant protein in myelin in the central nervous system, and it is essential 
in the myelination of nerves. In addition, it may be involved in cell signalling by 
regulating intracellular Ca2+ levels and by binding various proteins, one of which is
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calmodulin. There are several splice variants of MBP, as well as a large number 
of post-translational modifications. Differential splicing generates a 21.5, 20 .2 , 
18.5, 17.24, 17.22, and 14 kDa MBP in mouse, and a 21.5, 20.2, 18.5, and 17.2 
kDa MBP in humans. The main isoform in the adult human central nervous 
system is 18.5 kDa MBP, whereas in adult mice it is 14 kDa MBP (Boggs 2006). 
MBP-knockout mice show decreased levels of myelination and experience 
tremors, seizures, and early death (Popko et al. 1987). MBP has been 
investigated for its role in demyelinating diseases, particularly multiple sclerosis 
(Musse & Harauz 2007).
In HD, an MRI study found loss of cerebral white matter in HD patients 
(Fennema-Notestine et al. 2004), while another study hypothesised that myelin 
breaks down early on in HD, followed by an attempt to remyelinate affected areas 
(Bartzokis etal. 2007). The 14 kDa MBP isoform was found to be increased in the 
12 and 18 month HdhQ92/Q92. In the light of the Bartzokis study, this could agree 
with the remyelination theory. However, it is important to bear in mind that the 
alteration in the level of MBP in the HdhQ92/Q92 involves only the 14 kDa isoform, 
and that the other isoforms appeared to be unchanged. Although the 14 kDa MBP 
is the main isoform in mice, it is absent in humans, and as such this finding might 
well be mouse specific and not relevant to the human disease.
6.2.4 Proteins involved in liaand transport changed in HD mouse brain
The first ligand transporter changed in HD mouse caudate-putamen in this 
study is the a-subunit of haemoglobin (Hb). Hb is the iron-containing oxygen- 
transport metalloprotein in red blood cells, which carries oxygen from the lungs to
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the rest of the body. In adults, Hb consists of two a and two p subunits. In 
Alzheimer's disease, reports on the contribution of Hb to the pathology differed, 
with some showing elevated and others lower levels of Hb in patients (Slemmon 
etal. 1994; Pandav etal. 2004).
In HD, knock-down of huntingtin expression in zebrafish gave rise to 
hypochromic blood due to decreased Hb production. Based on this, it was 
suggested that polyglutamine expansion disrupts the normal role of huntingtin in 
the iron pathway, and in this way contributes to HD pathology (Lumsden et al. 
2007). In the present study, the a-subunit of Hb was decreased in 10 month 
HdhQ92/Q92 caudate-putamen, but increased in the 18 month HdhQ92/Q92 caudate- 
putamen. It is possible, however, that the increase observed in the older animals 
is the result of a relative increase of blood vessels in the sample, due to some 
degree of neuronal death in the striatum.
The apolipoprotein E (APOE) precursor was found to be decreased in the 
18 month HdhQ150/0150 in this study. APOE is an apoprotein found in the 
chylomicron, which transports exogenous lipids, fat-soluble vitamins and 
cholesterol from the intestines to other parts of the body. It is synthesised 
principally in the liver, but has also been found in other tissues, including the 
brain. It is essential for the normal catabolism of triglyceride-rich lipoproteins. 
APOE was initially recognised for its importance in lipoprotein metabolism and 
cardiovascular disease, but recently it has been studied for its role in Alzheimer's 
disease (AD), immunoregulation and cognition. The APOE-e4 isoform is the only 
confirmed risk factor for AD, but there is no conclusive theory to explain the 
mechanism by which APOE-Z4 increases the susceptibility to this disease 
(Cedazo-Minguez 2007). In addition, APOE-e4 has been implicated in other
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neurological disorders, including multiple sclerosis (Masterman & Hillert 2004) and 
Parkinson’s disease (Martinez et al. 2005).
In parallel with these findings, several studies have looked into a possible 
effect of APOE-z4 on the age of onset in HD, with conflicting conclusions. APOE- 
e4 seemed to be a significant factor influencing the age of onset of HD in one 
study, but with the e4 allele raising the age of onset rather than lowering it (Panas 
et al. 1999). In another, the APOE-e2Iz3 genotype was associated with 
significantly earlier age of onset in males than in females (Kehoe et al. 1999). 
However, further investigation failed to detect an association between the APOE 
genotypes and the age of onset in HD (Harrington et al. 1994; Rubinsztein et al. 
1997; Kalman et al. 2000; Saft et al. 2004; Panegyres et al. 2006; Andresen et al. 
2007).
6.2.5 A protein involved in the cell cvcle changed in HD mouse brain
The last protein identified in this study is stathmin (STMN), which was 
increased in 18 month Hdh0150/150. STMN, also known as oncoprotein 18, plays a 
critical role in the regulation of the microtubule cytoskeleton (Rubin & Atweh 
2004). When STMN is mutated or when it is not functioning properly, it can cause 
uncontrolled cell proliferation, characteristic of cancer cells (Cassimeris 2002 ). 
Disruption of the cytoskeleton and abnormal aggregation of cytoskeletal proteins 
often accompany neurodegenerative diseases (Richter-Landsberg 2008), and it 
has been suggested that the phosphorylation of STMN in the brain may be 
involved in neuropsychiatric and neurodegenerative disorders (Hayashi et al. 
2006). It is not however clear just how STMN causes this harmful effect.
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6.3 Comparison of the different mouse models
The SELDI-TOF study, reported in Chapter 3, showed that many of the 
protein changes were detected in more than one mouse model, the majority of 
which were found in the two knock-in models, Hdh092 and Hdh0150. However, 
Table 3.9 shows that about three quarters of these changes display a fold change 
in the opposite direction in the two models. Although it is possible that some of 
these apparent discrepancies are due to technical artifacts, subsequent western 
blot analysis, reported in Chapter 5, did overall not contradict the original SELDI 
results. This suggests that the differences between the Hdh092 and Hdh0150 may 
well be genuine, which could indicate that the disease progresses at a different 
rate in the two models and that animals of the same age of both models could 
nevertheless be in another phase of the disease. As such, the difference in the 
direction of the changes could be the outcome of compensatory mechanisms at 
work at different stages of the disease process. Previous behavioural and 
neuropathological research into these mouse models has already indicated that 
the disease characteristics in the Hdh0150, and particularly in the Hdh0150/0150, are 
more severe and present at a younger age than in the Hdh092, which could 
correlate with our findings. The divergence between these two models could be 
attributable to the difference in length of the CAG repeat.
It would certainly be interesting to confirm these findings. Additional 
western blot analysis may provide some of the missing results for the proteins 
already assayed and it would be interesting to obtain and assay more samples of 
earlier timepoints for both models as well as assay some of the proteins identified 
from the SELDI-TOF analysis which have not yet been screened by immunoblot.
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Analysis by immunohistochemistry of brain sections of both mouse models 
at different ages could provide further evidence of differences between the models 
as well as provide more detailed information on the localisation of specific 
changes.
Comparing the Hdh092 and Hdh0150 mouse models should certainly go 
beyond the scope of the present study. One way to identify differences and 
similarities in these mice could be done by studying the phosphorylation state of 
huntingtin isolated from the brains of both HdhQ92/Q92 and HdhQ150/Q15° mice at 
different ages. Changes in the phosphorylation of huntingtin have been 
demonstrated to be relevant to the conformation and pathogenicity of the protein 
(Humbert et al. 2002; Pardo et al. 2006).
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6.4 Conclusion
The majority of the proteins identified as differentially expressed in the 
brain of HD genetic mouse models in this study contribute to one of the 
pathological mechanisms recognised in HD, such as excitotoxicity, mitochondrial 
dysfunction, impaired cellular signalling, oxidative stress, impaired UPS and cell 
death. However, it is likely that the majority of the changes detected are 
secondary effects of an ongoing disease process, although in turn they may 
initiate the development of further disease characteristics.
By and large, the outcome of the SELDI-TOF and DIGE analysis suggests 
that the dysregulation at mRNA level correlates well with alterations at the protein 
level. However, analysis of the proteome, in addition to quantifying the levels of 
protein, can also reveal other more qualitative aspects of proteins. The post- 
translational alterations of proteins are important as they nearly always influence 
the actual function of proteins, which are the final effectors of events in cells and 
organisms. In this study, post-translational modifications were observed for three 
of the proteins detected by DIGE analysis. However, all the putative post- 
translationally modified versions of the same protein show very similar changes in 
expression. All of this suggests that it may be acceptable to concentrate on gene 
expression studies as a broad-based approach for the study of expression 
differences in disease, at any rate until more sophisticated proteomic techniques 
are available. Proteomics, as it stands, may be more suitable for conducting 
hypothesis-driven follow-up studies from gene expression results.
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